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Glutamate Imaging of Mouse Models of Neurodegeneration
Abstract
Malfunctions in the glutamatergic system of the central nervous system have been implicated in
neurodegenerative diseases such as Alzheimer’s disease (AD), tauopathies, and Parkinson’s disease (PD).
A non-invasive measurement of glutamate would enhance our understanding of neurodegenerative
processes and potentially facilitate early diagnosis. The current method for measuring glutamate in vivo
is proton magnetic resonance spectroscopy (1HMRS) although it has poor spatial resolution and weak
sensitivity to glutamate changes. The primary objective of this thesis was to measure pathology induced
changes in glutamate levels in mouse models of neurodegeneration using a novel magnetic resonance
imaging technique, glutamate chemical exchange saturation transfer (GluCEST) imaging.
Several studies were performed in three mouse models of neurodegeneration: the APP-PS1 transgenic
model of amyloid-beta pathology of AD, the PS19 transgenic model of tau pathology, and the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin model of PD. Glutamate levels derived
from GluCEST imaging were correlated with results from 1HMRS and immunohistochemistry (IHC). The
primary IHC antibodies that were investigated include markers of phosphorylated tau protein, synapse
density, neuron density, glial cell reactivity, a glutamate transporter, and an NMDA receptor.
GluCEST contrast correlated with 1HMRS-derived glutamate levels in the striatum of APP-PS1 mice
(R2=0.91) and the thalamus of PS19 mice (R2=0.64). However, GluCEST detected deficits in PS19 mice
four months earlier than 1HMRS, highlighting the method’s enhanced sensitivity to glutamate.
Demonstrating the advantage of high spatial resolution, GluCEST imaging measured sub-hippocampal
dynamics in glutamate levels in the aging PS19 mouse. A gradient in glutamate levels along the mouse
hippocampus was also measured in vivo using GluCEST. While hippocampal glutamate levels were
significantly decreased in early stages of PS19 tauopathy, glutamate levels in the dentate gyrus (DG) and
cornu ammonis (CA1) increased at 9-13 months. Decreased GluCEST was concurrent with synapse loss
and occurred before structural volume loss. Elevated GluCEST was associated with glial fibrillary acidic
protein (GFAP) immunostaining in late stages of the PS19 tauopathy model and in the striatum of the
MPTP PD model.
Results of this work demonstrate the use of GluCEST imaging to study regional and temporal variations in
glutamate in different pathologies associated with neurodegeneration.
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ABSTRACT
GLUTAMATE IMAGING OF MOUSE MODELS OF NEURODEGENERATION
Rachelle L. Crescenzi
Ravinder Reddy, Ph.D.
Malfunctions in the glutamatergic system of the central nervous system have been
implicated in neurodegenerative diseases such as Alzheimer’s disease (AD), tauopathies,
and Parkinson’s disease (PD). A non-invasive measurement of glutamate would enhance
our understanding of neurodegenerative processes and potentially facilitate early
diagnosis. The current method for measuring glutamate in vivo is proton magnetic
resonance spectroscopy (1HMRS) although it has poor spatial resolution and weak
sensitivity to glutamate changes. The primary objective of this thesis was to measure
pathology induced changes in glutamate levels in mouse models of neurodegeneration
using a novel magnetic resonance imaging technique, glutamate chemical exchange
saturation transfer (GluCEST) imaging.
Several studies were performed in three mouse models of neurodegeneration: the
APP-PS1 transgenic model of amyloid-beta pathology of AD, the PS19 transgenic model
of tau pathology, and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin
model of PD. Glutamate levels derived from GluCEST imaging were correlated with results
from 1HMRS and immunohistochemistry (IHC). The primary IHC antibodies that were
investigated include markers of phosphorylated tau protein, synapse density, neuron
density, glial cell reactivity, a glutamate transporter, and an NMDA receptor.
GluCEST contrast correlated with 1HMRS-derived glutamate levels in the striatum of
APP-PS1 mice (R2=0.91) and the thalamus of PS19 mice (R2=0.64). However, GluCEST
detected deficits in PS19 mice four months earlier than 1HMRS, highlighting the method’s
v

enhanced sensitivity to glutamate. Demonstrating the advantage of high spatial resolution,
GluCEST imaging measured sub-hippocampal dynamics in glutamate levels in the aging
PS19 mouse. A gradient in glutamate levels along the mouse hippocampus was also
measured in vivo using GluCEST. While hippocampal glutamate levels were significantly
decreased in early stages of PS19 tauopathy, glutamate levels in the dentate gyrus (DG)
and cornu ammonis (CA1) increased at 9-13 months. Decreased GluCEST was
concurrent with synapse loss and occurred before structural volume loss. Elevated
GluCEST was associated with glial fibrillary acidic protein (GFAP) immunostaining in late
stages of the PS19 tauopathy model and in the striatum of the MPTP PD model.
Results of this work demonstrate the use of GluCEST imaging to study regional and
temporal

variations

in

glutamate

in

different

pathologies

associated

with

neurodegeneration.
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CHAPTER 1: Glutamate as a biomarker of early neurodegeneration
I.

Review of Glutamate in the Central Nervous System (CNS)

Glutamate in the CNS resides in several compartments, both intracellular and
extracellular, in neurons and in glial cells. Firstly, there are two main sources of neuronal
glutamate: as an intermediate of the tricarboxylic acid (TCA cycle), and derived from
glutamine from astrocytes as part of the glutamine-glutamate cycle (Figure 1). The TCA
cycle uses glucose as an ultimate source of ATP energy for cells via oxidative metabolism.
Isotopic labeled carbon (C13) studies using nuclear magnetic resonance (NMR)
spectroscopy have investigated the metabolism of glutamate as an intermediate (Gruetter
et al., 1998). This technique has been used to directly measure oxidative metabolism of
glucose by isotopic labeling of glucose with C13. Glutamate is synthesized by
transamination of α-ketoglutarate (α-KG) with an amino acid such as alanine, and
glutamate can be converted back to α-KG via deamination.
Figure
1.
Glutamate-Glutamine
Cycle:
Glutamate is released from neurons
as a neurotransmitter, and is
transported into astrocytes to be
recycled as glutamine. Energy is
required by glutamine synthetase to
convert glutamate to glutamine in
astrocytes; however, glutamine is
passively converted to glutamate in
neurons. Glutamate metabolism is
altered
in
neurodegenerative
disorders, manifesting in higher or
lower concentrations of glutamate,
or its receptors, transporters, or
enzymes.
1

A portion of neuronal glutamate is packaged into neurotransmitter vesicles to be
transported to the pre-synapses via vesicular glutamate transporter (VGlut, Bellocchio,
2000). Once released into the synaptic cleft, post-synapses of other neurons will accept
some of the extracellular glutamate by glutamatergic receptors and transporters. There
are three main families of neuronal glutamate receptors: N-methyl D-aspartate (NMDA),
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainite receptors.
The remaining free glutamate doesn’t remain long in the extracellular space, or else it
would become excitotoxic (Hertz et al., 1999). Glutamate is actively transported into
astrocytes by the glutamate transporter GLT-1/EAAT2. Astrocytes are the location of the
glutamine-glutamate cycle, by which three quarters of glutamate is ultimately recycled and
stored in the form of glutamine (Benjamin and Quastel, 1975; Westergaard et al., 1995).
This process of amidation of glutamate into glutamine is facilitated by glutamine
synthetase (GS), which is only present in astrocytes and oligodendrocytes (D’Amelio et
al., 1990; Norenberg and Martinez-Hernandez, 1979; Tansey et al., 1991). Glutamine is
shuttled back into neurons, which would not be possible in the form of glutamate because
it would trigger an action potential (Hagberg et al., 1985). Subsequently, neurons as well
as astrocytes can form glutamate from glutamine; this reverse process requires no energy
(ATP independent) via phosphate-activated glutaminase (PAG) (Hogstad et al., 1988;
Kvamme et al., 1982; Schousboe et al., 1979). Current evidence supports the conclusion
that only astrocytes can produce glutamine, and without its synthesis in astrocytes the
production of neuronal glutamate would be stopped (Tansey et al., 1991).
The concentration of total glutamate by weight of brain tissue is 5-15mM per kg wet
weight, which varies with the region of the brain (Schousboe, 1981). While the greatest
concentration of glutamate occurs in neurons (10-15mM, 7x greater than that of other
2

metabolites), there is a substantial contribution from glial cells (6-10mM) (McKenna,
2007). Extracellular space can contain up to 100µM glutamate during neurotransmission
with typical resting levels of 3-4µM. CSF contains around 10µM glutamate (Hamberger
and Nyström, 1984; Lehmann et al., 1983).
II.

Glutamate is implicated in neurodegenerative disorders

Glutamate is implicated in many neurodegenerative disorders (Danbolt, 2001).
Glutamate plays a role in the pathogenesis of the three neurodegenerative disorders
which will be dealt with in this thesis: Alzheimer’s disease (AD), tauopathies, and
Parkinson’s disease (PD). Glutamate levels may therefore be a good candidate for a
biomarker of early neurodegeneration. The following section introduces these
neurodegenerative disorders, explains the evidence of altered glutamate metabolism and
function as a neurotransmitter in their early stages, and highlights the current radiology
techniques for in vivo diagnosis.
a. Glutamate is implicated in AD and tauopathies
Alzheimer’s disease is the most common neurodegenerative disorder and the sixth
leading cause of death in the USA (James et al., 2014; Murphy et al., 2013). AD is
characterized by two hallmark proteins which accumulate in aggregates in brain tissue
that are detected at autopsy: extracellular amyloid-beta “plaques” and intracellular
neurofibrillary tangles (NFTs). Although AD is the most well-known tauopathy, a variety of
neurodegenerative disorders are classified as tauopathies due to the presence of
intracellular aggregates of tau protein. Other diseases in which tau pathology is the most
dominant feature include frontotemporal dementia with parkinsonism linked to
3

chromosome 17 (FTDP-17), corticobasal degeneration (CBD), progressive supranuclear
palsy (PSP), and Pick’s disease (PiD) (Lee et al., 2001; Thibodeau et al., 2009). Recently,
research interest in tauopathies has further intensified with the discovery that chronic
traumatic encephalopathy (CTE), which particularly affects athletes engaged in contact
sports and military personnel exposed to repeated explosions, is a progressive tauopathy
(Lakis et al., 2013; McKee et al., 2009).
The major component of NFTs is hyper-phosphorylated tau (h-p-tau) protein (Lee et
al., 2001). Tau protein is naturally phosphorylated to regulate its binding to microtubules
(Cleveland et al., 1977); in its phosphorylated state, tau dissociates from microtubules,
promoting their denucleation (Drechsel et al., 1992). When tau is hyperphosphorylated,
tau aggregates into paired helical filaments (PHFs) and straight filaments (together
referred to as NFTs) in vitro (Alonso et al., 2001). Presumably, when h-p-tau is unbound
from microtubules in vivo, it has a propensity to aggregate into NFTs due to the increased
concentration of tau in the cytoplasm.
The presence of NFTs is
required for the diagnosis of AD
and

tauopathies

(Dubois

et

al.,

at

autopsy

2007).

NFT

formation occurs in stages that are
determined semi-quantitatively at
autopsy using the Braak scale
(Braak and Braak, 1991) and
Figure 2. NFT pathology of AD.

which

correlate

with

the

progression of neuropathologic symptoms of tau pathology. Microgliosis is reported in
4

frontotemporal dementias (FTDs), and glial fibrillary tangles may be present in the same
regions where neuron loss and NFT inclusions occur (Komori, 1999). Additionally,
synapse loss is the closest histologic correlate to cognitive deficits (Terry et al., 1991) and
to the severity of cognitive deficits (DeKosky and Scheff, 1990).
Pathologic tau aggregates accumulate in the dendritic spines of hippocampal neurons
and, among other consequences, disrupt the function of neurotransmitters (Drechsel et
al., 1992). For instance, VGlut1 (vesicular glutamate transporter protein) is reduced in AD
cortical tissue (Kirvell et al., 2006) and correlates with cognitive impairment scores
(Kashani et al., 2008). VGlut1 is also reduced in the perforant pathway of patients with
cognitive impairment (Robinson et al., 2014); however, in patients a decade younger
(mean age 88.8 yrs) with cognitive impairment, VGlut1 is elevated over healthy controls
in the mid-frontal gyrus (Bell et al., 2007). The hippocampus and mid-frontal gyrus also
show reduced expression and protein levels of another excitatory amino acid transporter
protein (EAAT1, EAAT2, Jacob et al., 2007). This may be due to their association with
phosphorylated tau localized to NFTs in AD, PSP, and CBD patients (EAAT2, Sasaki et
al., 2009).
Glutamate receptors, namely NMDA and AMPA, are also implicated in
tauoapthies. Early autoradiography and immunohistochemistry (IHC) studies in AD tissue
have shown reduced NMDA binding in the cortex (Greenamyre and Young, 1989; Jansen,
1990; Penney et al., 1990), reduced AMPA binding in the hippocampus (Dewar et al.,
1991), and reduced AMPA receptors in the entorhinal cortex (Yasuda et al., 1995) and
hippocampus (Aronica et al., 1997). Reduced expression levels of genes encoding NMDA
and AMPA receptors were measured in the AD hippocampus (Jacob et al., 2007). Direct
evidence in cultured cortical neurons shows that NMDA receptor activation is required for
5

tau-induced cell death, and that reduced expression of NMDA receptors may be protective
(Amadoro et al., 2006). In a tauopathy mouse model, reduced levels of AMPA receptor
GluR1 were found in post-synaptic dendritic spines where pathologic tau accumulates
preferentially over the pre-synapse (Hoover et al., 2010). This occurred at 4.5mo of age
before loss of the spine structure itself. Dysfunction of the post-synaptic glutamate
pathway may indicate an earlier stage of pathology than synapse loss of dendritic spines

6

b. Current challenges and strategies for the diagnosis of AD and tauopathies
The National Institute of Neurological and Communicative Disorders and Stroke and
the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
recognizes several non-invasive diagnostic methods for a probable diagnosis of AD:
volume changes measured by MRI and cerebral glucose metabolism measured by FDGPET (Dubois et al., 2007). New biomarkers of earlier stages of AD are being actively
sought in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) trials (Weiner et al.,
2012). The ADNI I and ADNI II studies are two phases of a multi-center trial which aims
to test various novel imaging techniques for their potential as early correlates of AD. This
highlights the advanced stage of biomarker research for AD.
The variable clinical symptoms of tauopathies, however, present distinct challenges
for diagnosis. While AD is the most prevalent cause of dementia in people over 65 years
old, early onset dementia is just as likely to be caused by FTD (Ratnavalli et al., 2002).
Diagnosis at such early stages (<65yrs. old) is uniquely difficult for FTD. One study
reported that 71% of patients eventually diagnosed as FTD were originally mis-diagnosed
as non-dementia (Rosness et al., 2008). This is because early symptoms of FTDs can
often be mistaken for other disorders related to semantic difficulties, subtle psychiatric and
behavioral changes, and poor motor control (Jicha and Nelson, 2011; Rosness et al.,
2008).
Jicha and colleagues concluded that if we could identify the specific neurotransmitter
pathways and locations which are affected in an individual, it would be a key step towards
personalized medicine for FTD patients, as modulators of these pathways are already
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FDA approved (Jicha and Nelson, 2011). There is a vital need for biomarkers that can
accurately diagnose early stages of tauopathies.
Proton magnetic resonance spectroscopy (1H MRS) is a non-invasive tool that is
regularly used to study metabolic changes in neurodegenerative disorders such as AD.
While 1H MRS studies typically report reduced N-acetyl-aspartate (NAA) and elevated
myo-Inositol (MI) levels in patients with AD (Guevara et al., 2010; Kantarci et al., 2010,
2004; Vion-Dury et al., 2004), few studies report glutamate (Glu) levels. This is likely due
to the fact that the glutamate peak is more difficult to measure than NAA or MI because of
its low signal-to-noise ratio (SNR). For instance, patients with microtubule-associated
protein (MAPT) mutations (including P301L) have increased ratios of MI to creatine (Cr)
and decreased NAA/MI ratios while still pre-symptomatic; glutamate ratios were not
reported likely because the MRS protocol was not optimized for the SNR of smaller
metabolites (Kantarci et al., 2010).
Glu changes have been reported
by MRS at higher field strength in a few
AD studies. In a study performed at 3T
in the posterior cingulate gyrus of AD
patients, the Glu and glutamine (Gln)
Figure 3. Reproduced from Rupsingh et al. 2011.

ratio to Cr significantly decreased
(Hattori et al., 2002). Using a 4T

system, Glu/Cr and NAA/Cr concentration ratios were found to decrease significantly in
the hippocampus of AD patients (Rupsingh et al., 2011).
However, the ratio of Glu+Gln to total Cr was not statistically significantly different in
an AD population with mild cognitive impairment scores (Kantarci and Jack Jr., 2003).
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Only NAA/MI was significantly different in a converter MCI population which develops AD
(Kantarci et al., 2007). These early stages of pathology may be detectable using a more
sensitive measurement tool of glutamate levels.
The 1H MRS signatures of various mouse models of neurodegeneration have also
been reported. Longitudinal 1H MRS studies in a variety of mouse models of AD have
been reviewed (Mlynárik et al., 2012). These models reported significant reductions in Glu
and NAA roughly 6-10 months after initial amyloid deposition and later elevation of MI
(Mlynárik et al., 2012). A longitudinal study in the APP-PS1 mouse model of amyloid-beta
plaques reported a significant decrease in Glu/Cr and NAA/Cr with age, as well as
between control and transgenic mice (Marjanska et al., 2005). Transgenic mouse models
of tauopathy have been only sparsely studied using 1H MRS. An inducible model with the
P301L mutation has shown decreased glutamate levels in the hippocampus (Yang et al.,
2011) and in hippocampal extracts (Nilsen et al., 2013) by 1H MRS. This evidence from
1

H MRS in mouse models supports the occurrence of reduced glutamate in AD and tau

pathologies and demonstrates the promise of using pre-clinical models for the
development of more sensitive biomarkers.
Another imaging modality for early detection of tauopathies is positron emission
tomography (PET). Several PET radiotracers for tau imaging are under development.
Radiotracers for pathologic tau primarily target PHF tau, the pathologic structure found in
AD brains (Fodero-Tavoletti et al., 2014). However, PHF tau is not specific for the form of
aggregated tau found in pure tauopathies (Ballatore et al., 2007). For instance, the
radiotracer 18F-THK523 demonstrated specificity for PHF tau in AD patients but not in
other tauopathies; 18F-T807 for PHF tau likewise was only demonstrated in the AD brain
(Villemagne et al., 2008). Another tracer is nonspecific for NFT and amyloid-beta plaques,
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18F-FDDNP (Agdeppa et al., 2001). A promising agent is 11C-PBB3, which binds to
aggregated tau in AD and non-AD brains (Maruyama et al., 2013). Despite its high
specificity, the major shortcomings of PET include radiation exposure, low resolution,
imaging logistics as a result of the short half-lives of radioligands, and limited applicability
to functional studies. These findings underscore the critical need for development of noninvasive and high-resolution imaging techniques for the detection of tau pathology.
c. Glutamate is implicated in PD
Parkinson’s disease (PD) is the second highest diagnosed neurodegenerative
disorder after AD (de Lau and Breteler, 2006). Only 10% of the cases are caused by
genetic mutation while the majority are idiopathic. However, the common pathogenesis of
PD ends with the degeneration of the nigrostriatal dopaminergic pathway, which connects
the substantia nigra to the striatum as part of the basal ganglia motor loop (Alexander,
1994). Due to unknown causes, dopaminergic neuron loss is found in the substantia nigra
pars compacta (SNc) of PD patients (Alexander, 1994; Obeso et al., 2000). The
nigrostriatal dopaminergic pathway breaks down causing a dopamine deficiency in the
striatum (see pathways in Figure 4). As dopamine is depleted from the striatum in PD, the
motor cortex is unregulated and over-stimulated. Therefore, the primary symptom of PD
is poor motor control including tremors while resting, slow voluntary movement or freezing
when attempting voluntary movements (Vercruysse et al., 2014), rigidity and altered gait,
and eventually difficulty walking and performing normal tasks (Gazewood et al., 2013;
Obeso et al., 2000).
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Figure 4. Cortico-striatal pathway.
Glutamatergic pathways are shown in green, dopaminergic pathways in blue, and
GABAergic pathways in red. (+) and (-) symbols indicate excitatory and inhibitory
pathways. With the loss of dopaminergic input to the striatum from the substatia
nigra pars compacta in PD pathology, excessive excitatory inputs to the striatum
cause excitotoxic damage. Illustration created by Mikael Häggström, based on
images by Andrew Gillies/User:Anaru and Patrick J. Lynch [CC BY-SA 3.0
(http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons.

Our primary knowledge of early PD before excessive neuron loss is derived from in
vitro studies and key animal models. In particular, 1-methyl-4-phenyl1,2,3,6tetrahydropyridin (MPTP) is a well characterized neurotoxin that selectively targets
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dopaminergic neurons in the SNc (Blesa et al., 2012; Meredith and Rademacher, 2011).
When delivered in mice by specific dosing regimens (Jackson-Lewis and Przedborski,
2007), it quickly produces deficits in motor control which resemble those of PD patients.
MPTP crosses the blood-brain-barrier through the MAO-B, and is transported into
astrocytes (Marini et al., 1992). Astrocytes metabolize MPTP into methyl-4phenylpyridinium (MPP+) before it is released. MPP+ is a potent inhibitor of complex I in
mitochondria (Ramsay et al., 1986) and a specific substrate of the dopamine transporter.
Hence, MPTP toxicity is specific to dopaminergic neurons and particularly affects the SNc
and striatum of mice (Chan et al., 1991). This mimics the specific location of dopaminergic
neuron degeneration found in PD patients.
Glutamatergic excitotoxicity is a secondary effect of PD pathology (Ambrosi et al.,
2013; Beal, 2000, 1998). Excitotoxicity is induced when energy production of the
mitochondria is impaired (Novelli et al., 1988). As MPTP induces failure of the complex I
mechanism in the electron-transport chain of mitochondria, dopaminergic cells cannot
produce enough energy; the cell’s membrane potential becomes depolarized, opening
glutamatergic Ca2+ dependent NMDA receptor channels (Meredith and Rademacher,
2011; Meredith et al., 2009). This leads to a three-fold increase in extracellular glutamate
levels as measured by in vivo microdialysis (Meredith et al., 2009). Such high
concentrations of glutamate are toxic to neurons. When treated with NMDA antagonists,
MPTP toxicity is prevented in the SNc of rats (Turski et al., 1991) and primates (Lange et
al., 1993; Zuddas et al., 1992). Trials of NMDA antagonists in PD patients have likewise
shown benefits in motor control, lessening dyskinesia, and improved cognitive scores
(reviewed by Stayte and Vissel, 2014).
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Glial cells also play a role in glutamatergic excitotoxicity of PD. Impaired mitochondria
energy production further causes glutamate to accumulate in astrocytes in vitro
(McNaught and Jenner, 2000). This is likely due to the fact that as extracellular glutamate
levels are persistently elevated, reduced glutamine synthetase activity is detected, and
the clearing mechanism of astrocytes begins to fail (Morales and Rodriguez, 2012). The
response of neuroinflamation also causes microglia to become active and release higher
levels of glutamate (Barger et al., 2007).
Elevated glutamate levels are localized to the striatum of MPTP mice, which is
proposed to simulate early stages of PD before denervation of the striatum. Therefore, PD
pathology represents a neurodegenerative disorder that has localized excitotoxicity,
synapse loss, and eventual neuron loss. There is, therefore, a great need for a biomarker
with high spatial resolution to show specific changes during pre-symptomatic PD
pathology.
d. Current challenges and strategies for the diagnosis of PD
When the clinical symptoms of PD become apparent, up to 60% of neurons can
already be lost, causing an 80% deficiency in dopamine (DA) levels. Early, in vivo
diagnosis before the onset of motor symptoms is critical for the rescue of viable brain from
PD pathology.
The glutamate signal measured by 1H MRS has been reported to decrease in several
studies in the posterior cingulate gyrus (Griffith et al., 2008) and mildly in the substatia
niagra (Öz et al., 2006). This is contrary to the excitotoxicity hypothesis of PD
pathogenesis. However, it is important to note that the majority of patients recruited in
these studies are medicated with cholinesterase inhibitors or L-DOPA, a DA replacement
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molecule. Furthermore, research is not carried out on pre-symptomatic PD patients, who
may otherwise exhibit excitotoxicity. These confounds have made it difficult to measure
the anticipated excitotoxic effects of PD pathology in a patient population.
Several 1H MRS studies have reported glutamate changes in MPTP mouse models.
One study reported that glutamate concentration doubled in the dorsal striatum after the
onset of MPTP toxicity in mice (Chassain et al., 2010, 2008). When treated with L-DOPA,
glutamate concentration returned to baseline levels (Bagga et al., 2013; Chassain et al.,
2010). A study in the ventral striatum showed that glutamate levels increased in proportion
to the amount of dopamine denervation in the ventral tegmental area (VTA) and dorsal
striatum (Chassain et al., 2013).
A PET radiotracer called [11C]-MPEP was developed for an antagonist of the mGluR5
receptor. MGluR5 is a glutamate receptor specific to astrocytes which is active during
neuroinflammation and may be regulated by NMDA receptor activity (Ambrosi et al.,
2013). In a 6-hydroxydopamine (6-OHDA) neurotoxin rat model of PD, elevated
glutamatergic activity was measured using [11C]-MPEP in the striatum where neuron loss
had occurred (Pellegrino et al., 2007). In an MPTP model in rhesus macaques, [11C]MPEP binding increased 10-20% in the striatum, also indicating elevated glutamatergic
activity with the decrease in striatal dopamine levels (Sanchez-Pernaute et al., 2008).
Other radiotracers for mGluR5 activity are being developed and tested in MPTP models
of PD (Mu et al., 2010). A therapeutic effect has been achieved in 6-OHDA mouse models
by decreasing mGluR5 levels (Black et al., 2010), and in MPTP mouse models by
suppressing excitotoxicity (Aguirre et al., 2005; Battaglia et al., 2004). These studies
highlight the importance of monitoring glutamate levels, and the potential utility of a
biomarker for glutamate changes in PD pathology.
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III.

CEST MRI as a potential biomarker of neurodegeneration

Chemical exchange saturation transfer (CEST) MRI has been under development over
the last 15 years and provides several key advantages over spectroscopy, PET, and
conventional MRI techniques for monitoring specific biomolecular changes during
disease. The following section reviews CEST MRI theory, its current applications, and its
development for glutamate imaging. This thesis applies glutamate CEST imaging to
mouse models of neurodegeneration to demonstrate its utility as a biomarker.
a. CEST MRI theory and applications
The technique of “chemical exchange saturation transfer” MRI exploits the
phenomenon of proton exchange between substrate and water. Relevant substrates in
the body with exchangeable protons include hydroxyl, amide, and amine side-groups. As
protons exchange between substrate and bulk water, the magnetization state of protons
is transferred to the solvent (Figure 5). There are several mechanisms by which
magnetization is transferred: through chemical exchange and through dipolar crossrelaxation (Van Zijl and Yadav, 2011). The “CEST” experiment aims to measure the
chemical exchange mediated magnetization transfer.
The CEST effect is probed using MRI by first applying a radio frequency pulse with a
sufficiently narrow bandwidth at a known resonant frequency of the substrate protons (see
RF in Figure 5). The pulse acts to selectively saturate the magnetization of the substrate
protons. In practice, the duration of the saturation pulse is sufficient to allow for several
cycles of exchange to occur during the saturation pulse. When saturated protons
exchange with bulk water, their resonant frequency changes to that of their new chemical
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environment while maintaining their saturation state. The bulk water signal is effectively
decreased in proportion to the concentration of saturated, exchanged protons (depicted in
the last bulk water signal in Figure 5).

Figure 5. The principle phenomenon of CEST imaging.
The top schematic depicts the population of spins from each pool of protons and
their magnetization signal (adapted from Sherry and Woods, 2008. MRI measures
the net magnetization, which begins positive as protons are mostly aligned with
the applied magnetic field. Shown beneath are the amine protons of glutamate in
proximity to bulk water protons. When the frequency selective (∆ω) RF saturation
pulse begins, the amine protons of glutamate become saturated – in other words,
their net magnetization becomes zero as spins are flipped into the transverse
plane. As chemical exchange occurs during the duration of the RF pulse, amine
protons (blue) exchange chemical environments with bulk water protons (red).
Exchanged protons maintain their saturated magnetization state, which
effectively reduces the signal from bulk water, and then relax or undergo
additional exchange.
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Figure 6. Contributions to the signal from
Other cross-relaxation and direct
exchangeable protons and cross-relaxation.
saturation effects confound the CEST
Adapted from McVicar et al. 2014.
effect and must be dealt with in the
measurement of the CEST signal.
One competing effect is magnetization
transfer (MT) from protons on semisolid macromolecules to bulk-water.
The CEST effect from amine protons
is distinguished from MT from protons on large, slow moving macromolecules in several
aspects: chemical exchange occurs on a faster time scale, and the effect is narrow in
spectral width (green signal vs. yellow signal in Figure 6). Another competing effect is
dipolar

cross-relaxation,

producing

nuclear

Overhauser

enhancement

(NOE).

Intermolecular NOE exists especially in tissue, as compared to liquid solutions; the
mechanism describes the transfer of magnetization from aliphatic protons on the protein
backbone to water protons. This effect has been measured in rat brain tissue around
3.5ppm downfield from water (black signal in Figure 6, Jin et al., 2013; Van Zijl et al.,
2003). An additional confounding effect on the CEST signal is that of direct saturation (DS)
of protons that resonate close to water. This effect is symmetric with respect to the bulk
water resonance.
Therefore the so-called “asymmetry” analysis (Guivel-Scharen et al., 1998) has been
employed to measure the CEST effect without contributions from MT and DS. This method
relies on the fact that the DS component is symmetric about water, and the broad MT
effect can be assumed as a symmetric linear baseline. In practice, a narrow and symmetric
water line-width must be achieved through manual shimming (up to second-order shim
17

gradient directions) before a CEST pulse sequence is applied. CEST asymmetry is
calculated as the difference between the water signal after RF saturation at the resonant
frequency of exchanging protons (+∆ω, red signal in Figure 7), minus the water signal
measured after saturating equidistant downfield from water (-∆ω, blue signal in Figure 7).
A CEST asymmetry map is produced from the difference image, where images have been
acquired after RF saturation at ±∆ω (see blue and red outlined images in Figure 7). The
difference is reported as a percentage of the negative offset image (Liu et al., 2010).
Although NOE effects are asymmetric and exist in the -∆ω signal, the cross-relaxation
signal is slower to develop than chemical exchange so that this contribution is assumed
to be minimal (Van Zijl et al., 2003).

Figure 7. CEST asymmetry (%) calculation accounts for contributions to the
CEST signal from MT and DS.
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The first CEST experiment in the body was applied to diamide groups of urea and was
carried out on the healthy human kidney (Dagher et al., 2000). It is remarkable that the
CEST signal was obtainable at 1.5T in such a structure. Since this time, the non-invasive
CEST imaging technique has been applied in vivo without the use of external contrast
agents to an array of specific biological substrates.
CEST imaging of amide protons has been employed to measure pH changes in human
tissue. The first application of CEST imaging to detect pH changes utilized chemical
exchange of amide protons (APT CEST) at 3.5ppm in the ischemic rat brain (Zhou et al.,
2003a, 2003b). The first detection of pH changes in human brain tumors followed in 2006
(Jones et al., 2006). APT CEST may also be sensitive to tumor grade (Wen et al., 2010;
Zhou et al., 2008, 2003a).
CEST imaging of hydroxyl protons has been applied to glycogen in the mouse liver
(van Zijl et al., 2007) to glucose as a natural contrast agent for tumors (Chan et al., 2012;
Walker-Samuel et al., 2013), to glycosaminoglycans in cartilage tissue of the human knee
(Cai et al., 2012; Ling et al., 2008; Singh et al., 2012), to myo-inositol in the healthy human
brain (Haris et al., 2011) and in a mouse model of AD (Haris et al., 2013b).
CEST imaging of amine protons has been applied to creatine in skeletal muscle
(Kogan et al., 2014) and heart tissue (Haris et al., 2014a). Similarly, based on the amine
protons of glutamate, glutamate CEST (GluCEST) has been demonstrated (Cai et al.,
2012). The major focus of this thesis is concerned with GluCEST applications. Therefore,
the following section describes this method in detail.
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b. The development of Glutamate CEST (GluCEST) MRI
In order to observe the CEST effect, the exchange rate (k) of the solute protons should
be in the slow-intermediate exchange regime (

≤∆

), where ∆

is the chemical shift

difference between the water resonance and the resonance of exchanging protons on the
solute. The exchange rate for glutamate protons under physiologic conditions was
estimated using simulations based on Bloch-McConnell equations (McConnell 1958).
Amine protons on glutamate resonate 3ppm downfield from water (at 9.4T the glutamate
Δω ~ 7200 rad s−1), with an exchange rate (k ~ 3000 s−1) in the slow to intermediate
regime. In developing the GluCEST technique, it was shown that GluCEST asymmetry is
directly proportional to glutamate concentration (R2=0.97, Figure 8A-B), with a slope of
0.6% GluCEST per mM [Glu] (Cai et al., 2012).
The measurable CEST effect also depends on the amplitude and duration of the
saturation pulse (Figure 8C). For human subjects, the B1 power is limited by RF-specific
absorption rate (SAR). On the human scanner at 7T, GluCEST is achieved with a B1rms =
3.6µT for 1 second duration (Cai et al., 2012). For animal experiments at 9.4T, the B1rms =
6µT (250Hz) for 1 second duration is used (limited by the coil hardware).
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Figure 8. GluCEST development.
(A) These experiments were performed in glutamate phantoms immersed in PBS
at 7T. (B) GluCEST asymmetry is linearly proportional to glutamate concentration.
(C) The GluCEST signal also depends on the amplitude and duration of the
saturation pulse. Reproduced from Cai et al. 2012.

The CEST effect is also sensitive to changes in pH (Englander and Kallenbach,
1984). The exchange rate catalyzed by hydroxide and hydronium ions depends on pH in
a non-linear fashion (Figure 9A, Bai et al. 1993). Data is shown for glutamate dipeptides
in 0.5 M KCL and 50mM citric acid or succinic acid buffers, measured at 5⁰C in D20 at
11.7T; faster exchange from glutamate at higher pH was measured by solvent saturation
transfer in water (and 50mM phosphate buffer) and converted to pD scale. For glutamate
in solution at low temperature, the exchange rate measured by 1D-NMR is slowest around
pH 4, and increases as a parabola towards lower pH and up to physiologic pH. At
physiologic temperature, the CEST asymmetry was measured for glutamate using an
imaging sequence over a range of pH (Figure 9B-D). Experiments were performed at
37⁰C at 7T in 10mM glutamate in solutions with various pH using phosphate-buffered
saline (PBS). CEST asymmetry peaks around pH 4-5, where the exchange rate more
closely meets the slow-intermediate regime compared to pH 7. At physiologic pH from 621

7.4, the GluCEST effect is linear with a change of -9.5% GluCEST per unit of pH. In
Alzheimer’s disease a pH change of at most 0.25 is reported in the hippocampus (Mandal
et al. 2012). This would estimate a GluCEST variation of 2.4% CEST asymmetry, which
is roughly 10% noise in the typical measured signal in vivo for mice (25% CEST
asymmetry).

Figure 9. CEST effect dependence and sensitivity to pH.
A) Exchange rate dependence on pH. Reproduced from Bai et al., 1993. B) Zspectra analysis displays the bulk water signals with and without saturation at
various frequency offsets. The CEST effect of glutamate produces decreased
water signal at + 3ppm upfield from water, compared to saturation downfield 3ppm. C) CEST asymmetry curves. Dotted line reports simulated data. D)
GluCEST asymmetry at various pH reveals a linear dependence in the physiologic
range from 6.0-7.4. Reproduced from Cai et al., 2012.
Other metabolites with exchangeable protons are present in the brain. It is necessary,
therefore, to define the contribution to GluCEST from these extraneous metabolites. This
was achieved by applying the GluCEST protocol to phantoms of pure metabolites in
phosphate-buffered

saline

(PBS)

at

physiologic

concentrations,

pH=7,

and

temperature=37⁰C (Figure 10). NAA has an amide proton and showed no contribution to
GluCEST at 10mM concentration. Myo-inositol has 6 hydroxyl protons; however, their
CEST effect occurs at 0.6 ppm from water, and no GluCEST signal was observed from
10mM concentration. Creatine has amine protons with a CEST effect at 1.8ppm, and
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contributed <0.5% GluCEST asymmetry at 6mM concentration. Amine protons exist on
aspartate, glutamine, and taurine (sampled at 2mM each); however, no contribution was
measured from these metabolites. Gamma-aminobutyric acid (GABA) displayed 1%
GluCEST asymmetry at 2mM concentration. This is compared to 6% GluCEST from a
glutamate sample of 10mM. In total, ~25% of the GluCEST signal can be attributed to
other metabolites. Greater specificity is achieved in vivo due to the higher concentration
of glutamate compared to GABA and creatine in the brain.

Figure 10. Contribution to GluCEST asymmetry from other metabolites.
GluCEST asymmetry measures the total endogenous free Glu in the brain, with
minor contributions from Cr and GABA. To test the specificity of GluCEST,
experiments were performed in solutions immersed in PBS at 7T. Solutions
include glutamate (10mM), myo-inositol (MI, 10mM), creatine (Cr, 6mM), glutamine
(Gln, 2mM), GABA (2mM), NAA (10mM), aspartate (Asp, 2mM), and taurine (Tau,
2mM). Reproduced from Cai et al. 2012.

The novel GluCEST MRI technique is able to measure total glutamate levels in vivo in
the healthy human brain (Cai et al., 2012). Since its development and in addition to the
studies presented in this thesis, the technique has also shown increased glutamate levels
after inducing stroke and thereby producing hypoxic conditions in a rat model (Cai et al.,
2012), and in rat brain tumors after administration of glutamate (Cai et al., 2012; Haris et
al., 2014b).
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c. Thesis Design
This thesis sought to apply the GluCEST imaging technique to mouse models of
neurodegeneration in order to determine the potential of GluCEST MRI as a biomarker of
early stages of neurodegeneration. There are several advantages of using GluCEST MRI
to measure glutamate levels. GluCEST imaging is completely non-invasive as it produces
contrast based on endogenous free glutamate without the use of contrast agents. Also,
the GluCEST effect has a much larger sensitivity (~100 fold) to glutamate levels than in
vivo 1H MRS. In addition, exploiting the advantage of an MRI technique, GluCEST can
map glutamate levels at a high spatial resolution (156 um2 in-plane) compared to PET and
1

H MRS with voxels on the order of several mm3.
Chapter 2 of this thesis compares the application of GluCEST to 1H MRS in the APP-

PS1 mouse model of AD. Chapters 3-5 present GluCEST,

1

H MRS, and

immunohistochemistry studies on mouse models of tauopathy. The final chapter details
the application of GluCEST to a model with elevated glutamate levels, the MPTP based
mouse model of PD.
Several questions were investigated in this thesis regarding GluCEST: 1) to what
extent are glutamate levels measured by GluCEST MRI and 1H MRS correlated? 2) What
is the earliest stage of tauopathy that can be detected using GluCEST MRI? 3) What is
the

distribution

of

glutamate

changes

throughout

the

brain

of

mice

with

neurodegeneration? 4) Are changes in GluCEST merely reflective of structural changes
due to volume loss, or is GluCEST contrast associated with early molecular markers of
disease?
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Several studies were carried out in which GluCEST and 1H MRS were performed in
the following mouse models of neurodegeneration: the APP-PS1 transgenic model of the
amyloid-beta pathology of AD, the PS19 (P301S) transgenic model of tau pathology, and
the MPTP neurotoxin model of PD. Additionally, IHC was performed to determine the
pathologic events which accompany changes in glutamate levels. The primary antibodies
which were investigated include: AT8 for phosphorylated tau protein, synaptophysin for
synapse density, NeuN for neuron density, VGlut1 for vesicular glutamate transporter
protein, NR1 for NMDA glutamate receptors, and GFAP for glial cell reactivity.
Results of this work demonstrate the utility of GluCEST imaging to study regional and
temporal

variations

in

glutamate

in

different

pathologies

associated

with

neurodegeneration.
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CHAPTER 2: Imaging of glutamate changes in a mouse model of Alzheimer’s
disease
I.

Introduction

1

H MRS has been widely used in the study of biochemical changes in the AD brain

during disease progression (see Chapter 1, section II.b “Current challenges and strategies
for the diagnosis of AD and tauopathies” on page 7). Previous 1H MRS research has
depicted decreased hippocampal Glu concentration in AD patients compared to healthy
controls (Hattori et al., 2002; Rupsingh et al., 2011). However, the clinical utility of 1H MRS
is limited by poor spatial resolution and a long acquisition time.
This chapter reports the first application of GluCEST MRI in a mouse model of
neurodegeneration. Glutamate levels were mapped in the brain of a transgenic mouse
model of AD as well as in age-matched wild-type (WT) mice. The correlation between Glu
changes measured via GluCEST and 1H MRS was investigated. Finally, the potential for
GluCEST to detect early AD pathology is discussed.
II.

Methods

a. Mouse preparation and monitoring during MRI
Transgenic mice with mutated human amyloid precursor protein (APP) and presenilin1 (PS1) display amyloid-beta pathology in the hippocampus and spatial memory deficits
reminiscent of AD pathology (Puoliväli et al., 2002). Six APP-PS1 mice and six WT mice,
aged 18–20 months, were used in this study (from Wyeth Research, Collegeville,
Pennsylvania, USA). Mice were housed at the University Laboratory Animal Resources
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(ULAR) animal husbandry facility at the University of Pennsylvania. Mice were kept in
cages with littermates in a humidity controlled room ~22°C under a 12 hour light/ dark
cycle with ad libitum access to food and water.
All spectroscopy and imaging studies were performed on a 9.4T small-animal
spectrometer using a 30 cm horizontal bore magnet fitted with a 12 cm gradient insert and
interfaced to a Varian spectrometer (Agilent Technologies Inc., Santa Clara, CA, Figure
11C). Mice were anesthetized using isofluorane gas (1.5-2% isofluorane mixed with
oxygen at 2 L/min), and secured to a body-bed (Figure 11A) inside a 20mm diameter
volume coil (M2M Imaging Corp., Cleveland, OH, Figure 11B). Body temperature was
monitored using an anal temperature probe and maintained at 37 °C using hot air blown
inside the bore of the magnet (M2M Imaging Corp., S2PAM software). Breath rate was
monitored using a pressure-pillow underneath the chest connected to a fiber-optic readout
and maintained between 40-80bpm.
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Figure 11. Mouse imaging setup at 9.4T.
(A) Mouse loaded in a custom made holder constructed by Mr. Allen
Bonner at the CMROI to control motion during the MRI scan. (B) Mouse
volume coil for transmitting and receiving signal (M2M Imaging Corp.,
Cleveland, OH). (C) The 9.4T small-animal imaging spectrometer
(Agilent Technologies Inc., Santa Clara, CA) located on the ground
floor of John Morgan building in the Small Animal Imaging Facility
(SAIF). The mouse holder is inserted into the coil, which is inserted
into the magnet bore. The MRI scan can last up to 3 hours for a single
mouse, during which time they are kept warm using forced hot air and
monitored using an anal temperature probe and a respiration pillow.

b.

1

H MRS method and protocol

Protons exist in biological tissue primarily as a component of water (110M
concentration of water protons in the body multiplied by the hydration fraction of tissue,
typically 80-90%) but also on small molecules at lower concentrations than water (<120mM). Small molecule protons are MR-sensitive with a resonant frequency shifted from
water. Magnetic resonance spectroscopy seeks to measure the signal from these small
molecules. In order to detect signals from protons bound to small metabolites, the intense
water signal will be suppressed by applying a frequency selective saturation pulse (or train
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of pulses). Protons from the following metabolites can be detected by spectroscopy at the
approximate indicated chemical shifts in the mouse brain at 9.4T (Pfeuffer et al., 1999):
lactate (Lac, 1.3ppm), N-acetylaspartate (NAA, 2.0ppm), gamma-aminobutyric acid
(GABA) and glutamine (Glx, 2.2ppm), glutamate (Glu, 2.35ppm), glutamine (Gln,
2.45ppm), aspartate (Asp, 2.7ppm), creatine (Cr, 3.0ppm), choline (Cho, 3.2ppm), taurine
(TAU, 3.4ppm), and myo-inositol (MI, 3.5-3.6ppm).
Single-voxel spectroscopy is a technique that detects the metabolite signal from a
localized region of interest (ROI). These sequences employ gradients applied along 3
perpendicular directions in order to isolate signal from a chosen voxel. There are several
sequences developed which can perform single-voxel spectroscopy.
This study used the stimulated echo acquisition mode (STEAM) sequence (supplied
by vendor Varian) with the following parameters: voxel size: 3.5mm x 3.5mm x 2mm (voxel
volume = 24.5 mL); spectral width: 4 kHz; number of points: 4006; averages: 264; TE = 8
ms; TM = 7 ms; TR = 5 s. Water suppression was achieved using the variable pulse power
and optimized relaxation (VAPOR) delay method. Localized shimming was performed to
obtain water line widths of 20Hz or less. The unsuppressed water spectrum was also
acquired using the same parameters for the purpose of normalization to the water volume
in a given voxel. All spectra are displayed normalized to water.
In order to quantify the metabolite concentrations, a spectral range of 0-4.2 ppm was
used. Metabolite concentrations, including glutamate, were measured using LCModel
software (Provencher, 2001). Concentrations are reported relative to the total creatine
(tCr) concentration, which did not vary between genotypes. LC model quantifies data
through the recursive fitting of prior knowledge basis sets. During each iteration, a least-
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squares algorithm was used to optimize the fit. The quality of the final fit was determined
in terms of the Cramer–Rao lower bound (CRLB), a measure of the variance in the error.
c. GluCEST MRI protocol in mice
There are several important factors to consider when designing the GluCEST pulse
sequence for small animal imaging. Amine protons on glutamate resonate at 3ppm offset
downfield from water. A saturation pulse was implemented with 1 second duration (four
Hanning pulses at 250ms each with a 4μs inter-pulse-delay) with an amplitude B1rms of 5.9
uT, that had been optimized in order to adequately saturate the amine protons on
glutamate. A spoiled gradient echo (GRE) readout sequence was used. The time between
each saturation pulse was set to 8 s to allow for ample T1 recovery. The final image
parameters used in this study are: field of view: 20 x 20 mm2; slice thickness: 2 mm; flip
angle: 15°; TR = 6.2 ms; TE = 2.9 ms; matrix size: 128x128.
According to the motivation presented in Chapter 1, section III.a “CEST MRI theory
and applications” on page 15, the asymmetry analysis was used to measure the CEST
effect. GluCEST asymmetry was calculated as:
(∆

)

=

( ∆ )

−

( ∆ )

(∆ )

. (1)

where Msat (±∆ω) are the magnetizations obtained with saturation at a ‘+’ and ‘–‘ offset to
the water resonance; ∆ω is equivalent to the resonance offset of the exchanging spins.
In interpreting the CEST effect, other factors that play a role are B0 inhomogeneities
and the suboptimal amplitude and duration of the B1 saturation pulse (Cai et al., 2012).
Any local B0 inhomogeneity will cause the saturation pulse to miss the targeted glutamate
protons. To account for this, a B0 map is acquired based on differences in phase
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accumulation in GRE images acquired at successive TE = 3.5, 4.0, 4.5 ms (2 signal
averages each, Figure 12A). Additionally, several images are acquired with the saturation
pulse applied over a range of offset frequencies (Δω = ± 2.4-3.6ppm, steps of 0.2ppm)
that spans the variation in B0 (±0.6ppm) expected from the B0 map. B0 corrected CEST
weighted images at ± 3 ppm are calculated from the local B0 value and the acquired CEST
weighted images from different offset frequencies using polynomial interpolation.
In addition, B1 maps were acquired in order to correct for inefficiencies in the saturation
pulse. Specifically, B1 maps were calculated from two images acquired with a rectangular
preparation pulse with varying flip angles: 30° and 60° (2 signal averages each, Figure
12B). A linear correction for B1 was applied to the CEST map using a ratio of the actual
B1 value to the expected value (Singh et al., 2013).
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Figure 12. B0 and B1 inhomogeneity maps are acquired to correct GluCEST maps.
(A) When the resonant frequency of B0 is intentionally offset ±0.4ppm, B0 maps
reveal the proportional inhomogeneity. (B) B1 maps are relatively homogeneous,
indicating efficient saturation. (C) The final GluCEST maps are corrected for B0
and B1 inhomogeneities.

For this study, GluCEST, B0 and B1 maps were acquired from two successive brain
slices including the striatum (corresponding to the location of the voxel acquired using 1H
MRS) and the hippocampus. The total imaging acquisition time was around 30 minutes.
For MTR mapping, the same brain slices were imaged after saturation at 20 ppm with
a saturation power of 250 Hz and a saturation duration of 1 s. An image with saturation at
100 ppm was also collected and considered as the magnetization off image (M0).
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d. Image processing
All image processing and data analysis were performed using software routines written
in MATLAB (version 7.5, R2007b, MathWorks, Massachusetts, USA). Acquired images
were corrected for B0 and used to generate a GluCEST contrast map using equation
. (1

. (1. GluCEST contrast was further corrected for B1 and mapped as false colors

(Figure 12C). Z-spectra were obtained from the CEST images by plotting the normal
image intensity as a function of the resonance offset of the saturation pulse. CEST
asymmetry curves were generated by plotting the relative water signal difference at
frequency offsets from 0 to 4.8 ppm.
Similarly, MTR maps were computed by equation
"=

#

−

#

× 100%

. (2:

. (2)

where M0 is the equilibrium magnetization image and Msat is the magnetization with a
saturation pulse applied at 20 ppm.
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III.

Results

a. GluCEST mapping and 1H MRS of wild-type and transgenic mice
AD mice with amyloid-beta pathology display anatomical differences in brain structure
compared to WT mice. Dilated ventricles are clearly observable in the proton images
displayed in Figure 13A, D. The GluCEST maps illustrate the regional distribution of Glu
in the brain of both WT and AD mice (Figure 13B, E). Higher GluCEST contrast was
observed in gray matter relative to white matter, which reflects the difference in Glu
concentration. The mean GluCEST contrast from the representative WT and APP-PS1
brains over the chosen voxel was 26.41.6% and 19.11.9%, respectively.
To further confirm that the change in GluCEST contrast is a result of a change in Glu
concentration, 1H MRS was performed for the voxel shown on the anatomical images
(Figure 13A, D). This voxel was placed in an area devoid of cerebrospinal fluid. 1H MRS
spectra showed a decrease in the Glu peak amplitude of APP-PS1 relative to WT mice
(arrows, Figure 13C, F). Decreased N-acetyl-aspartate (NAA) peak amplitude and
increased myo-inositiol (mIns) peak amplitude can also be seen from the 1H MRS spectra,
which is characteristic of AD pathology.
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Figure 13. GluCEST mapping and 1H MRS of a representative WT and APP-PS1
mouse.
(A, D) The anatomical brain image from a WT and APP-PS1 mouse. (B, E) The
corresponding GluCEST maps. The WT GluCEST map shows the regional
distribution of Glu in the brain. Higher GluCEST contrast is observed in gray
matter relative to white matter. Lower GluCEST contrast is observed throughout
the APP-PS1 map. (C, F) The 1H MRS spectra from the voxel placed in (A) shows
the major brain metabolites. The Glu peaks are labeled at 2.3 and 3.75 ppm, where
arrows highlight the trend of decreased Glu observed in the spectra of the APPPS1 mouse compared to WT. tCr, total creatine; Lip, lipid. Figure adapted from
(Haris et al., 2013a).

b. Z-spectra and asymmetric magnetization transfer ratio curves
The z-spectra and MTRasymmetry curves obtained from WT and APP-PS1 mice are
shown in Figure 14A, B. The 3 ppm line on the MTRasymmetry curves corresponds to the
location of the GluCEST effect. MTRasymmetry is observed over a broad spectrum with a
maximum CEST contrast at ~2 ppm (Figure 14B). This may be a result of the broad
asymmetry of Glu due to its faster exchange rate. Another contribution to the broad
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MTRasymmetry is the chemical shift averaging effect, which shifts the line to a higher field
towards the water resonance. No significant change in MTR contrast was observed in AD
(48.3±1.5) relative to WT (48.0±1.1) mice.

Figure 14. Z-spectra and MTR curves from WT and APP-PS1 mice.
(A) Z-spectra analysis depicts the normalized magnetization after saturation over
a range of frequency offsets from water (∆ω = ±5ppm). (B) Asymmetric
magnetization transfer ratio (MTRasymmetry) curves from WT and APP-PS1 mice for
the voxels shown in Figure 13A, D. The dotted line at 3 ppm in the MTRasymmetry
curves reflects the GluCEST contrast.
c. Reproducibility of GluCEST maps in vivo
In order to evaluate the reproducibility of GluCEST contrast, the GluCEST protocol
was performed successively during the same scan session. The GluCEST images were
highly reproducible (Figure 15) with the intracovariance being less than 3%.

Figure 15. Reproducibility of GluCEST mapping in a WT mouse.
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d. Average GluCEST contrast in the hippocampus
The hippocampus is the primary structure associated with the early loss of pyramidal
neurons and their synapses in AD pathology, which control learning and cognitive function
(Mu and Gage, 2011). GluCEST maps of brain slices containing the hippocampus were
also obtained (Figure 16B, D). There was a significant reduction (31%) in GluCEST in the
hippocampus of APP-PS1 mice compared to WT (p<0.01, Figure 16E).

Figure 16. GluCEST maps in the hippocampus region of WT and APP-PS1
mice.
(A) Anatomical brain image from a WT mouse. (B) The corresponding GluCEST
map. (C, D) Anatomical image and corresponding GluCEST map from an agematched AD mouse. Significantly decreased GluCEST contrast in the
hippocampus was observed in APP-PS1 relative to WT mice. The hippocampus
regions are shown in the rectangular boxes in both WT and AD mice (arrows). (E)
Bar graph showing the mean hippocampus GluCEST contrast in WT and AD mice.
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e. Correlation of average GluCEST contrast and glutamate concentration
Comparative analysis showed a decrease of ~28% in GluCEST contrast (p<0.01,
Figure 17A) and a decrease of ~29% in Glu/tCr ratio (p<0.01, Figure 17B) in APP-PS1
relative to WT mouse brain over the chosen voxel displayed in Figure 13. The mean
Glu/tCr ratios and standard deviations in WT and APP-PS1 mice were 1.58 ± 0.13 and
1.12 ± 0.08, respectively. An excellent positive correlation (R2 = 0.91) was observed with
a slope of ~15% GluCEST per Glu/tCr ratio.

Figure 17. Correlation between GluCEST and 1H MRS data in WT and APP-PS1
mice.
(A, B) Bar graphs showing the mean GluCEST contrast (%) and spectroscopyderived glutamate/total creatine (Glu/tCr) ratio from WT and AD mice for the
voxels shown in Figure 13. (C) Graph showing the strong positive correlation
between GluCEST and Glu/tCr.
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IV.

Discussion

a. The neurochemical profile and GluCEST in the hippocampus mimics human AD
pathology
In the current study, we have shown that high-resolution imaging of Glu alterations in
a transgenic mouse model of AD is possible using the GluCEST MRI technique.
Significantly decreased GluCEST contrast in APP-PS1 relative to WT mice was observed
in the hippocampus and striatum, and the results were further validated through
demonstration of comparable changes of Glu/tCr on 1H MRS in the striatum.
The hippocampus is the primary region affected in early AD pathology and is
associated with learning and memory. A previous 1H MRS study reported a progressive
decrease in hippocampal Glu/tCr in APP-PS1 mice with advancing age (Marjanska et al.,
2005). However, 1H MRS can only measure Glu from a single voxel (8cm3), and thus a
heterogeneous distribution of Glu cannot be easily monitored. In the current study, a more
profound decrease in GluCEST contrast was observed in the hippocampus relative to
other regions clearly suggesting its involvement in the early disease process. In the current
study, a decrease in GluCEST contrast of 31% in the hippocampus of APP-PS1 relative
to WT mice was measured. This finding is consistent with human AD, for which a decrease
in hippocampal Glu of ~35% was observed by 1H MRS (Rupsingh et al., 2011). The same
study also showed a 15–20% change in the Glu concentration in MCI relative to controls.
As a result of the high reproducibility of GluCEST mapping, it may be feasible to image
the change in Glu concentration at high spatial resolution from control to MCI to the full
onset of AD. GluCEST MRI, therefore, has the potential to provide a diagnostic marker at
the early stage of AD.
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b. Glutamate levels measured by GluCEST correlate with 1H MRS
A strong positive correlation between GluCEST and spectroscopy-derived Glu levels
was observed (R2=0.91). This suggests that the observed change in GluCEST contrast is
caused by a change in Glu concentration. A contributing factor to GluCEST that does not
affect 1H MRS is the magnetization transfer effect from the bound pool of water. A
decrease in the magnetization transfer effect would overestimate the GluCEST contrast
from AD pathology. However, in the current study, no apparent change in the MTR
contrast was observed.
c. Technical considerations for applying GluCEST to mice in vivo
The precise saturation of exchangeable protons requires perfect B0 homogeneity. B0
inhomogeneity could interfere with the selective saturation frequency and make the two
selective frequencies asymmetric relative to the bulk water signal. In this case, the CEST
effect would reflect the difference between DS and MT effects. The CEST effect is also
highly dependent on the saturation B1 amplitude (Ward et al., 2000). With fixed saturation
duration, a higher B1 can induce a higher CEST effect (Winter et al., 2006). B1 homogeneity
is a critical requirement for quantitative CEST imaging. Artifacts induced by B0 and B1 field
inhomogeneity and the corresponding correction algorithms have been discussed
previously in detail (Sun et al., 2007). In the current study, we used the methods described
previously to correct the B1- and B0-induced artifacts caused by small B0 and B1 variations.
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V.

Summary
Using the GluCEST MRI technique, decreased Glu levels in the APP-PS1 transgenic

mouse model of AD were imaged at high spatial resolution. Compared with WT controls,
AD mice exhibited a notable reduction in GluCEST contrast (~30%) in all areas of the
brain. The change in Glu was further validated through 1H MRS. A positive correlation was
observed between GluCEST contrast and Glu/Cr ratio measured by 1H MRS. These
results demonstrate the potential of GluCEST as a novel noninvasive biomarker for the
diagnosis of early AD, and enable the development of disease-modifying therapies for AD.
•

GluCEST contrast is reduced by ~30% in the hippocampus and striatum of the
APP-PS1 mouse model of AD.

•

GluCEST contrast correlates with the glutamate signal measured by 1H MRS
in the striatum (R2=0.91) with a slope of 15% GluCEST asymmetry per ratio of
Glu/total creatine.
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CHAPTER 3: In vivo measurement of glutamate loss is associated with
synapse loss in a mouse model of tauopathy
I.

Introduction

The previous proof-of-principle study in mice with amyloid-beta pathology confirmed
that GluCEST MRI is decreased in the hippocampus with AD-like pathology which reflects
reduced glutamate concentration. However, many neurodegenerative disorders exist in
which tau pathology is the most dominant feature including FTDP-17, CBD, PSP, and PiD
(Lee et al., 2001; Thibodeau et al., 2009). This motivates the study of GluCEST as a
potential marker of glutamate alterations in the presence of isolated tau pathology.
The transgenic PS19 mouse with mutated human tau at P301S was developed by the
Center for Neurodegenerative Disease Research (CNDR) at the University of
Pennsylvania (Yasumasa Yoshiyama et al., 2007) and develops several histological
symptoms of tau pathology (Figure 18). In addition to NFT pathology, which mimics
human tauopathy, early symptoms of synapse loss are apparent in the hippocampus of
PS19 mice. Synapse loss is the closest histologic correlate to cognitive deficits (Terry et
al., 1991) and to the severity of cognitive deficits in AD patients (DeKosky and Scheff,
1990). Therefore, an in vivo surrogate marker of synapse loss would be highly valuable
as a potentially non-invasive correlate to dementia. As glutamate is the primary excitatory
neurotransmitter in the CNS and resides in high concentrations in the healthy synapse,
the following study hypothesized that GluCEST imaging would correlate with synapse
integrity in the PS19 mouse brain.
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Figure 18. Progressive pathologic symptoms of tau pathology in the PS19
transgenic mouse.
Histological sections from various brain regions are shown for PS19 (top row)
and WT mice (bottom row) at several ages. IHC methods displayed utilized
antibodies to the following proteins: synaptophysin for synapse density, glial
fibrillary acidic protein (GFAP) for glial cell reactivity, paired helical filament (PHF)
tau for h-p-tau, hemetoxylin and eosin (HE) for neuronal morphology, and
thioflavin S (thio s) and congo red for the beta-sheet structure of NFTs.
Reproduced from Yoshiyama et al. 2007.

In this study, GluCEST imaging as well as 1H MRS are employed to study the
consequence of tau pathology on glutamate in a P301S mouse model with tau pathology.
In vivo measures of glutamate are associated regionally with histological measurements
of tau burden including the severity of pathological tau, neuron loss, and synapse loss.
Given the translational opportunities of GluCEST, these findings in a pre-clinical model of
tauopathy have immediate potential application to clinical studies.
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II.

Methods

a. PS19 transgenic mouse model of tauopathy
The mouse model of tauopathy studied here was the PS19 line of the P301S
transgenic mouse overexpressing the human P301S mutant tau found in FTDP-17
patients (Yoshiyama et al., 2007). The first sign of tau pathology in this mouse model is
defective axonal transport followed by synapse loss and hyper-phosphorylated tau
accumulation at presynaptic terminals. As the animals age, pathological tau progresses
along the perforant pathway, from the entorhinal cortex into the hippocampus and prefrontal cortex, while severe neuron loss is apparent at later stages of disease (Hurtado et
al., 2010). Behavioral studies show decreased ability in spatial learning with the
progression of disease (Brunden et al., 2010). Note that the onset of pathology in this
generation of mice is later than originally published (see current generation in Zhang et
al., 2012).
This study was approved by the university’s IACUC. Mouse husbandry and
handling during imaging was identical to that stated in Chapter 2, section II.a “Mouse
preparation and monitoring during MRI” on page 26.
b.

1

H MRS acquisition in the hippocampus and custom processing

1

H MRS was performed on WT (n=8) and PS19 (n=7) mice. The point-resolved

spectroscopy (PRESS, Bottomley, 1987) pulse sequence was used with the following
parameters: TR/TE = 3000/14 ms, spectral width = 4 kHz, number of points = 4006. The
VAPOR water suppression technique was used to acquire a water-suppressed spectrum
(averages = 384). An additional spectrum was acquired without water suppression to
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obtain the water reference signal for normalization (averages = 16). Unsuppressed water
spectra had line widths of 20Hz or less after localized shimming. Total acquisition time for
spectroscopy was about 20 minutes. Spectra were acquired from a voxel localized in the
hippocampus (2x2.5x3mm3).
Spectra were processed using in-house software (developed in MATLAB v.7.9.0
R2009b). First, manual phasing was performed using the creatine peak (3.0ppm) as a
constant phase, and adjusting a variable phase component. Baseline correction was
performed to fit the global baseline and local baseline features while maintaining broad
macromolecule curves from 0.5-3ppm and from 3-4.2ppm. Metabolite peak locations and
widths were identified manually (centered at approximately 1.3 ppm for Lac, 2.0 NAA, 2.2
Glx, 2.35 Glu, 2.45 Gln, 2.7 Asp, 3.0 tCr, 3.2 Cho, 3.4 TAU, 3.5 MI, 3.6 MI-2, 3.75 Glu-2,
3.9 Cr-2, and 4.1 MI-3). A predetermined set of macromolecule peaks were also included
(0.9, 1.2, 1.4, 1.7, 1.9, 2.9, 3.9, and 4.3 ppm). The peak-fitting routine (MATLAB
“lsqcurvefit”) performs a nonlinear least squares fitting of Lorentzian peaks to the spectra
corrected for phase and baseline. The ratio of the integrals of metabolites to the internal
standard of total creatine (tCr) is reported.
c. GluCEST imaging and ROI segmentation
GluCEST imaging was performed on aged PS19 mice (n=9, mean age=20.7 months)
and their age-matched WT littermates (n=8, mean age=19.0 months). A customprogrammed RF spoiled GRE readout with a frequency selective saturation preparation
pulse sequence was used as described previously in Chapter 2, section II.c “GluCEST
MRI protocol in mice” on page 30. GluCEST maps were acquired from one slice through
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the mid-hippocampus with four signal averages for each saturation frequency. The total
scan time for GluCEST, B0, and B1 maps was under 12 minutes.
Regions of interest (ROIs) were segmented by hand from T2-weighted images
including the hippocampus, thalamus, and cortex. Sub-regions of the hippocampus cannot
be distinguished using the in vivo image. Instead, sub-regions were segmented based on
a threshold applied to the GluCEST maps:

above 30% GluCEST asymmetry was

considered the DG region, below 5% as cerebral spinal fluid (CSF) and surrounding voxels
with partial volume effects, and the mid-range values as the CA. For comparison, a highresolution ex vivo image of the mouse brain shows that this threshold segments the DG
from the CA region adequately (Figure 23a). The high-resolution image was acquired
based on the gadolinium enhanced protocol developed by Johnson et al., 2007. The
thalamus was segmented excluding the cerebral peduncle, and the cortex was segmented
excluding the superior sagittal sinus.
d. General tissue preparation and methods of immunohistochemistry
After imaging, mice were sacrificed using standard methods of transcardial
perfusion/fixation as approved by the IACUC of the University of Pennsylvania. The
transcardial perfusion procedure was as follows:
i. The mouse was deeply anesthetized to a surgical plane of anesthesia (non-responsive
to toe pinch or ear flick). The mouse was anesthetized with an intraperitoneal injection of
ketamine/xylazine/acepromazine (100:10:1 mg/kg) according to its weight.
ii. The mouse was restrained in a supine position on dissection block using tape to
secure fore and hind limbs.
iii. The thorax was opened to visualize the heart.
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iv. A small hole was opened in the right atrium as an exit port for the blood.
v. A small hole was opened in the left ventricle. A blunt needle, connected to a
perfusion pump, was inserted into the hole.
vi. Isotonic saline is pumped through the mouse to rinse out the blood. This is
necessary to help reduce the background in these tissues. Subsequently, the mouse
was perfused with 20mL of fixative solution of 4% paraformaldehyde (PFA) in PBS.
vii. The brain was removed from the skull and stored overnight at 4°C in 4% PFA.
The brain tissue was then prepared for histology. Each brain was bisected into two
hemispheres (for some mice both hemispheres were kept). One hemisphere was kept and
placed in a steel mold, and sliced into 2mm thick sections using razors (Figure 19). The
anatomical sections are described according to the following diagram:

Figure 19. Method of gross-slicing the brain.
The dissected brain is placed in a steel mold with grooves for razor blades. Seven
slices are made from rostral to caudal, producing 8 slices of tissue that are 2mm
thick each. The red lines indicate the edge of the brain slice that is placed on the
bottom of the embedding tray. The view from ventral to dorsal (V-D) shows the
shape of each slice lying flat in the embedding tray.
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The 8 slices were placed in a cassette and stored in a leaching buffer to remove excess
fixative for several hours. Cassettes were processed in a paraffin-infusing machine
(Shandon Excelsior by Thermo scientific) by the CNDR histology staff. Paraffin-infused
slices were placed in an embedding tray and sectioned at 6µm thick using a microtome
and hot-water bath (Figure 20). This procedure yields ~250 slices per mouse brain,
although typically only the first 150 slides were kept in order to obtain the anatomical
sections corresponding to the imaged sections by MRI.

Figure 20. Methods of embedding and sectioning tissue in preparation for IHC.
A. The brain slices in the embedding tray are covered in paraffin and set to harden
into a block. B. The paraffin block is sectioned using a microtome at 6µm thick.
C. Each tissue section is placed on a slide for use with IHC protocols.
Several protocols for IHC were performed using the following general procedure:
i. De-paraffinize slides in xylene and dehydrate in a series of ethanol concentrations.
ii. Block endogenous peroxidase activity by soaking slides in H202 and methanol.
iii. Apply an optional pre-treatment of boiling in citric acid (Vector Antigen Unmasking
Solution, Vector Laboratories) to create more permeable cell membranes.
iv. Apply primary antibody in a buffered TRIS (2-amino-2-hydroxymethyl-propane1,3-diol) fetal bovine serum (TRIS/FBS) and incubate overnight. This antibody
provides specificity for the protein of interest in the tissue.
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vi. Apply the secondary antibody, biotinylated anti-immunoglobulinG, which
recognizes the primary antibody and is specific for the species in which the primary
antibody was raised.
vii. Apply horseradish peroxidase-streptavidin developing system (†BioGenex,
Hyderabad, AP India) or (‡Vectastain ABC Kit, Vector Laboratories).
viii. DAB (3,3' diaminobenzidine) is a peroxidase substrate and was used as the
chromagen (Vector DAB, Vector Laboratories).
ix. Apply an optional counterstain of hemetoxylin to visualize the nuclei of cells.
x. Rehydrate and coverslip slides in the reverse series of ethanol concentrations.
e. Antibodies applied using IHC on aged PS19 mice
Three different primary monoclonal antibodies (MAbs) were used in this study. The
first MAb is AT8, an antibody specific for phosphorylated tau at residues Ser202 and
Thr205 (Goedert et al., 1995) (1:7500 dilution in PBS, Thermo Scientific). This MAb is
used to localize pathological tau protein, which is hyper-phosphorylated. Adjacent tissue
sections were immunostained with NeuN antibody for neuronal nuclei (1:200 dillution,
Millipore), and MAb SY38 for synaptophysin localized to the pre-synaptic terminals
(1:2000 dillution, Millipore). Quantification of synaptophysin (WT n=4, PS19 n=7) and
NeuN (WT n=5, PS19 n=6) immunostaining in the CA3 was performed on 20x images;
synaptophysin in the DG on 4x images, in the thalamus on 20x images, and in the
entorhinal cortex on 20x images, after setting an intensity threshold for all images.
Percentages reported reflect the area occupied by immunostaining, normalized to the area
of the ROI (Image J).
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f.

Statistical analyses
Statistical analyses were performed using MATLAB (7.9.0 R2009b). Boxplots were

generated in MATLAB and represent the median in red, upper and lower quartiles within
the box, and the extremes at the whiskers. Outliers were considered those data points
beyond one times the interquartile range. Mean and standard deviations of all measures
are reported in mean ± std format throughout. Student’s t-test was performed to determine
significance of differences between measures obtained in PS19 brains to that from WT
animals.
III.
a.

Results

1

H MRS from WT and PS19 mouse hippocampus

Representative metabolite spectra from the hippocampus of a WT and PS19 mouse
are shown in Figure 21A. Differences in metabolite profiles were evident between WT and
PS19 cohorts. The greatest difference was measured in glutamate at 2.35ppm, where the
average ratio of glutamate to total creatine [Glu]/[tCr] in PS19 mice was 1.0 ± 0.10 (mean
± std) compared to 1.3 ± 0.13 in the WT cohort (p=0.11). The average concentration of
tCr was not different between PS19 and WT mice. The metabolite NAA as a ratio to tCr
was also decreased in the PS19 mice (1.1 ± 0.10 vs. 1.2 ± 0.19, p=0.34).
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Figure 21. PS19 mice have decreased glutamate in the hippocampus
compared to WT according to 1H MRS.
(A) Example spectra from a PS19 mouse compared to WT shows diminished
peaks of N-acetyl-aspartate (NAA, 2.01ppm) and glutamate (Glu, 2.35ppm). (B) The
average ratio of glutamate to total creatine [Glu]/[tCr] was decreased in the
majority of PS19 mice compared to the WT cohort (n=7, 1.0 ± 0.10, mean ± std/2,
vs. 1.3 ± 0.13, p=0.11). There was also a slightly lower group average of NAA in
PS19 mice (1.1 ± 0.10 vs. 1.2 ± 0.19, p=0.34).

b. GluCEST maps of the whole brain and regions of interest
GluCEST asymmetry in WT mice was higher in grey matter as compared to white
matter with very low glutamate levels in the CSF (Figure 22ii). The GluCEST maps from
PS19 mice showed distinctively decreased glutamate across the majority of the brain slice
(Figure 22bii, Figure 22cii).
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Figure 22. GluCEST maps and corresponding IHC in WT vs. PS19 mice.
a-c i) Anatomical images corresponding to the GluCEST slice through the midhippocampus.
a-c ii) GluCEST maps in a WT and two PS19 mice reveal lower glutamate levels
throughout the brain of tauopathy mice.
a-c iii) Corresponding slices of brain tissue stained for hyper-phosphorylated
tau (AT8) reveal varying severity of pathological tau protein within the PS19
cohort.
a-c iv. & v.) Neuron (NeuN) and synapse (Syn) immunostaining in the CA3
pyramidal cell layer of the hippocampus. While neuron loss in this region is
inconsistent, synapse loss is apparent in PS19 mice, for which immunostaining
is fainter and reveals a thinning band of synapses.
d) Detailed hippocampal anatomy for reference. CA1-3: cornu ammonis , P:
pyramidal cell layer of CA, DG: dentate gyrus, G: granule cell layer of DG .
e) Quantified NeuN and Syn staining in the CA3 of the hippocampus. Synapse
density is significantly reduced in PS19 mice (24.6 ± 2.1 vs. 33.6 ± 2.6, p≤0.01).
Neuron density is less-severely reduced in PS19 mice (55.4 ± 4.4 vs. 61.2 ± 5.7,
p=0.18).
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Within the hippocampus, two sub-regions of GluCEST contrast are distinguishable
(Figure 23b-c). The first region includes the majority of the hippocampus, which has lower
GluCEST signal in PS19 mice (15.9% ± 0.76 , mean GluCEST asymmetry% ± std)
compared to 22.4% ± 1.1 for WT, p≤0.001). This region corresponds to the anatomical
sub-region of the hippocampus called the CA and the surrounding axonal layers. The
second region corresponds to the anatomical region of the DG, Figure 23c) and has
consistently high GluCEST signal in both WT (34.1% ± 0.84) and PS19 (33.0% ± 0.55,
p=0.19). Significantly reduced GluCEST levels were also measured in the thalamus region
of PS19 mice (23.5% ± 0.89 vs. 27.7% ± 1.4, p≤0.05, Figure 25c). Average GluCEST
asymmetry was not statistically different in the cortex of PS19 mice compared to WT
(22.8% ± 1.2 vs. 23.3% ± 1.1, p=0.72, Figure 26c).
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Figure 23. Average GluCEST asymmetry in sub-regions of the hippocampus.
a) For anatomical comparison, a high-resolution (42 µm isotropic) image of
the ex vivo brain was acquired after infusion with gadolinium (Gd) according to
the protocol by Johnson et al., 2007 for MR histology.
b-c) The hippocampus is a composite of two distinct sub-regions, the CA
and the DG. The DG was segmented based on a GluCEST threshold above 30%,
which corresponds to the correct anatomical location as compared to the Gdenhanced image.
d) In the CA sub-region of the PS19 hippocampus, GluCEST is significantly
decreased by 29% (p≤0.001). There is no significant difference between groups
in the DG sub-region of the hippocampus (p=0.19).
c. Histological measures of tau burden
We sought a neuropathological correlation to glutamate changes in the tauopathy
mouse brain. Brain tissue was processed by IHC for hyper-phosphorylated tau (AT8,
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Figure 22iii), for neuron density (NeuN, Figure 22iv), and for synapse density (Syn38,
Figure 22v). The severity of tau pathology varied among PS19 mice. An example of a
PS19 mouse with mild pathology is shown in Figure 22biii. The majority of PS19 mice
demonstrated tau immunostaining in the entire hippocampus and in several layers of
entorhinal cortex as in Figure 22ciii.
Neuron density in the CA3 region of the PS19 hippocampus appears to be decreased
in some PS19 mice (Figure 22civ) but not in others (Figure 22biv.) compared to the
consistently dense band of neurons that are seen in WT mice (Figure 22aiv). Quantified
neuron density reflects this inconsistency, whereas no significant difference was
measured between WT and PS19 NeuN immunostaining (Figure 22e).
Synapse density is diminished in the CA3 of PS19 mice as evidenced by fainter
staining and a thinning band of the pyramidal cell layer compared to WT mice (Figure
22bcv vs. Figure 22av). Quantification reveals significantly lower synapse density in the
CA3 of PS19 mice compared to WT (24.6 ± 2.1 vs. 33.6 ± 2.6, p≤0.01, Figure 22e). In the
DG, there is no significant difference in synapse immunostaining in PS19 mice relative to
WT (74.2 ± 7.5 vs. 79.6 ± 1.2, p=0.25, Figure 24c). The thalamus region has a lower
density of punctuate immunostaining under high magnification as depicted in the black
and white (BW) insets (Figure 25a-b). Quantification of the intensity in this region shows
an 8% lower area occupied in the PS19 thalamus (39.9 ± 2.2 vs. 43.3 ± 1.5, p=0.10, Figure
25d). There was no difference in synapse density in the entorhinal cortex of PS19 mice
(49.9 ± 1.5 vs. 50.5 ± 2.2, p=0.37, Figure 26d).
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Figure 24. Comparison of GluCEST with synapse immunostaining in subregions of the hippocampus.
a-b) Synapse immunostaining and corresponding GluCEST images of
the hippocampus region.
c) Quantification of IHC and GluCEST in the DG and CA show similar
trends. Synapses are maintained in the PS19 DG, where GluCEST was also
high. Both synapse density and GluCEST asymmetry are significantly
reduced by 27 and 29%, respectively, in PS19 mice relative to WT.
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Figure 25. Comparison of GluCEST with synapse immunostaining in the
thalamus.
a-b) Synapse immunostaining and corresponding GluCEST ROIs in the
thalamus. The black and white inset shows less punctate staining in the PS19
thalamus.
c) Average GluCEST asymmetry of the thalamus (Thal) region is significantly
decreased by 15% (p≤0.05) in PS19 mice compared to WT.
d) Synapse density shows a similar trend, decreasing 8%, although
significance was not reached.
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Figure 26. Comparison of GluCEST with synapse immunostaining in the
cortex.
a-b) GluCEST ROIs in the cortex and corresponding immunostaining in the
entorhinal cortex showing no difference in synapse density even though
pathological tau is present.
c) Average GluCEST asymmetry was not statistically different in the cortex of
PS19 mice (22.8% ± 1.2) compared to WT (23.3% ± 1.1), p=0.72.
d) Quantified synapse density in the entorhinal cortex was not different between
the two cohorts.
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IV.

Discussion

a. Advantages of GluCEST over 1H MRS for measuring the distribution of glutamate in
the hippocampus
1

H MRS measured a decrease in the [Glu]/[tCr] ratio in the hippocampus (Figure 21b).

This result is consistent with the trend in glutamate previously observed from APP-PS1
mice (Haris et al., 2013). Glutamate differences were not significant in the PS19
hippocampus likely due to the all-encompassing voxel over distinct sub-regions of the
hippocampus. The hippocampus can be divided into two sub-regions, the CA and the DG,
which have unique connectivity and function as well as distinct structural changes in AD
patients (Greene et al., 2012).
The GluCEST imaging technique was able to distinguish these two sub-regions
(Figure 23) as a result of higher spatial resolution compared to conventional 1H MRS, as
well as increased sensitivity to glutamate. Specifically, using the GluCEST method, the
amine protons of glutamate are saturated over a period of one second. During this time,
the saturated amine proton magnetization exchanges ~103 times and accumulates in the
water pool. In theory, this amplifies 1 mM glutamate signal to 1M signal, but in practice
other experimental parameters such as suboptimal saturation and back exchange
preclude the theoretical maximum amplification. As has been shown previously (Cai et al.,
2012), in practice GluCEST has at least two orders of magnitude sensitivity advantage
over 1H MRS.
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b. GluCEST deficits are associated with synapse loss in sub-regions of the hippocampus
The GluCEST signal in the CA of the hippocampus was significantly reduced by 29%,
which is associated with a significant reduction in synapse density by 27% (Figure 24c).
This is in contrast to the DG sub-region, where glutamate was maintained even in the
PS19 brain, whereas neurodegeneration occurs in the rest of the hippocampus (Figure
23d). Synapse integrity was also intact in the DG of PS19 mice with no significant
differences measured from immunostaining (Figure 24c). This is consistent with the fact
that there is a continuous turnover of neurons in the DG region compared to the other
regions of the brain (Eriksson et al., 1998; Jin et al., 2004a; Spampanato et al., 2012). In
the DG of AD patients (Jin et al., 2004b) and in a mouse model of AD (Jin et al., 2004a),
there is evidence that neurogenesis is actually increased. Therefore, it is important to
distinguish the DG from the rest of the hippocampus of tauopathy brains. To the best of
our knowledge, these are the first MRI results that potentially report neurogenesis in vivo.
Tau tangles are most abundant in the hippocampus of PS19 mice, which is where
reduced glutamate is expected. However, more widespread glutamate loss was found in
regions where pathological tau was not present as in the case of the thalamus (Figure
25a-b). Vice versa pathological tau was present in the entorhinal cortex of most PS19
mice, yet GluCEST was not decreased in this region (Figure 26a-b). Therefore, lower
glutamate cannot be attributed only to the occurrence of tau pathology.
Rather, synapse loss appears to be the closest neuropathological correlate to
GluCEST imaging in the PS19 mouse. A thinning band of synapses was consistently
observed in the CA3 region of the hippocampus of PS19 mice, unlike neuron loss which
occurred in only a few cases (Figure 22e). Similarly, neuronal dysfunction was only
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slightly indicated by a decrease in [NAA]/[tCr] in the PS19 hippocampus (Figure 21b).
Also, synapse loss was measured in the thalamus of PS19 mice, where GluCEST
decreases were significant and pathological tau was not yet present (Figure 25).
Therefore, synapse loss, and not neuron loss or pathological tau, correlates most closely
with the location of glutamate loss measured by GluCEST maps in both the CA and
thalamus.
Specifically, the mouse in Figure 22b has mild tau pathology and intact neurons,
however the synapse band is weak. This case supports the hypothesis that decreased
glutamate reflects early stages of neurodegeneration, before neuron loss. In a more
severe case in Figure 22c, the GluCEST map is greatly decreased from WT, and
associated with severe pathology, thinning neurons, and virtually no synapses in the CA3.
This example supports the hypothesis that GluCEST will be decreased further as the
severity of tau burden progresses beyond synapse loss.
Synapses are an important location of early neurologic dysfunction (Selkoe, 2002).
Synapse loss is also the closest correlate to cognitive deficits in AD patients rather than
the amount of tangles (Terry et al., 1991). Glutametergic synapse loss is among the
earliest symptoms of disease found in AD brain tissue (Selkoe, 2002). GluCEST imaging,
therefore, has the potential to monitor synapse loss in vivo as an early marker of dementia
symptoms.
V.

Summary
The effect of tau pathology on glutamate levels has been investigated in the brain of a

transgenic mouse model using both in vivo MR techniques and IHC. For the first time, in
vivo evidence is reported that glutamate is decreased in the CA sub-region of the
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hippocampus and in the thalamus where synapse loss also occurs. The DG sub-region
maintains glutamate levels in tauopathy mice. Future studies should consider using
GluCEST imaging to monitor the health of the DG as a potential region for neurogenic
therapy (Chohan et al., 2011). The further development of GluCEST MRI for preclinical
applications will be valuable as microtubule-stabilizing therapies are being tested in the
PS19 mouse model of tauopathy (Zhang et al., 2012). Highlights from these results are
as follows:
•

GluCEST imaging has been applied to a P301S mouse model of tauopathy, and
shown to significantly decrease in the CA sub-region of the hippocampus and the
thalamus.

•

Synapse loss is the closest histopathological correlate to GluCEST loss in these
regions.

•

Glutamate is maintained in the DG sub-region of the hippocampus where
neurogenesis is known to occur.
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CHAPTER 4: Longitudinal GluCEST imaging correlated with 1H MRS in the
thalamus of a mouse model of tauopathy
I.

Introduction

The following study continued to investigate glutamate deficits in PS19 mice with
tauopathy. A longitudinal study was designed to measure the temporal variation in
glutamate levels using 1H MRS and GluCEST imaging. 1H MRS was performed in the
thalamus due to the fact that the previous study showed insignificant spectroscopy results
in the hippocampus while GluCEST was significantly reduced in the thalamus. Therefore,
the thalamus provided a reliable region in which the two modalities could be compared
over repeated measures. The goals of this study were 1) to determine whether 1H MRS
or GluCEST MRI is more sensitive to early metabolic changes in tau pathology in a preclinical mouse model, and 2) to evaluate the extent of correlation of glutamate levels
measured by the two modalities. The hypothesis is that due to its inherent greater
sensitivity, GluCEST will be able to detect earlier changes in glutamate levels in PS19
mice than 1H MRS.
II.

Methods

a. Experimental design
This study examined the PS19 mouse model of tauopathy, which is a transgenic
model with the P301S mutation common in FTDP-17 patients (Yoshiyama et al., 2007).
The strain used in this study has been bred on a congenic BL6 background at the CNDR.
The effect of a congenic background is to produce a quicker and more consistent
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progression of pathology than that characterized on a bigenic background. Two cohorts
of PS19 mice and their WT littermates were studied: Cohort 1 including (n=6) WT and
(n=6) PS19, and Cohort 2 including (n=3) WT and (n=6) PS19. This study was approved
by the university’s IACUC. Mouse husbandry and handling during imaging was identical
to that stated in Chapter 2, section II.a. “Mouse preparation and monitoring during MRI”
on page 26.
b. GluCEST imaging
Imaging and spectroscopy were performed during the same scanning session at
several ages: Cohort 1 at 3, 7, and 13months, and Cohort 2 at 9 and 13 months. A customprogrammed RF spoiled GRE readout with a frequency selective saturation preparation
pulse sequence was used as described previously in Chapter 2, section II.c. “GluCEST
MRI protocol in mice” on page 30. The following sequence parameters were used in this
study: saturation preparation pulse power (B1rms = 6uT and duration of 1s as four pulses
of 250 ms duration each), and GRE readout (effective TR/TE = 6.6/3.3 ms). The entire
preparation/acquisition combination was repeated every 8s. GluCEST images were
collected with saturation frequencies from ± 2.5 – 3.5 ppm offset from water with a step
size of 0.25 ppm.
GluCEST, B0, and B1 maps were acquired from 3 consecutive slices (1mm thick each)
spanning the hippocampus from rostral to caudal (Figure 27). Due to changes in the
anatomy of PS19 brains as disease progresses, visual estimation of slice positions would
be inaccurate. Therefore, the central slice position was determined to be 2.3 mm from the
lambda marker viewed in a sagittal scout image. The adjacent slices were acquired 1mm
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rostral and caudal to this position. The total imaging time including GluCEST, B0 and B1
mapping for each slice was approximately 15 min.
ROIs were segmented from the T2-weighted anatomical image. The thalamus ROI was
segmented manually excluding the white matter region of the cerebral peduncle. The
average GluCEST asymmetry % was measured in the thalamus of each slice. Group
averages were determined for WT and PS19 mice at each age and for each slice
separately.
c.

1

H MRS acquisition in the thalamus

Spectroscopy was performed using a PRESS pulse sequence (TR/TE 3000/28ms,
256 averages, sw=4006) while gating to respiration. A voxel was chosen in the thalamus
of the right hemisphere of the brain (Figure 27, 2.5 x 2.5 x 3 mm3 = 18.75 mm3 volume).
Voxel shimming was performed manually until a water signal line width of at least 20Hz
was reached. Water suppression was applied using the WET technique: 4 pulses with
300Hz bandwidth and optimized flip angels of approximately 90° and an inter-pulse delay
of 60-80ms chosen in order to keep the acquisition time within a breath period. The water
reference peak was also acquired (TR/TE 3000/28ms, 16 averages, sw=4006) with
identical water suppression gradients but without RF pulses in order to account for eddy
current effects due to water suppression. The total acquisition time for spectroscopy was
19 minutes.
Spectra were processed using in-house software as described in Chapter 3, section
II.b. “1H MRS acquisition in the hippocampus and custom processing” on page 44. All
spectra shown are normalized to water. Metabolite concentrations are reported
normalized to creatine (3.0 ppm), which did not vary between genotypes or with age.
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Figure 27. In vivo
metabolic data was
acquired from a 3mm
section of the mouse brain.
(a) T2-weighted anatomical
images, outlining a voxel
(2.5 x 2.5 x 3 mm3) in the
thalamus
region
from
1
H
MRS
was
which
acquired.
(b)
GluCEST
maps
corresponding
to
the
anatomical
images,
spanning three slices (1
mm thick each) through the
hippocampus from rostral,
middle, to caudal.

d. Statistical analyses and data handling
Spectroscopy results are reported with error bars expressing the standard error of the
ratio of means (SERM) for ratios of PS19 to WT metabolite concentrations normalized to
total creatine concentration:
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where avgTG is the group average [metabolite]/[tCr], and stdTG is the group standard
deviation of [metabolite]/[Cr] for a given age. N is the number of data points in the group.
Pair-wise student’s one-tailed t-tests were applied to group averages of GluCEST at
each age for each slice, assuming unequal variances.
A statistical test for repeated measures was used to determine the significance of
longitudinal data. A linear mixed effect model (LMM) was chosen for its flexibility in
handling missing data because Cohort 2 was not imaged at 3 months. First-order auto
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regressive analysis was used as covariance structure based on Bayesian Information
Criterion (IBM SPSS version 22). The linear mixed effect model with time and genotype
was fitted for each of the outcome measures with Time, Group (genotype) and
Time*Group as fixed effects and intercepts as random effects. A significance level of
p≤0.05 was considered statistically significant, and F-values are reported wherever
necessary.
For all analyses, GluCEST and 1H MRS data from Cohort 1 acquired at 7 months and
Cohort 2 at 9 months were combined because the group average values varied less than
2%. Spectroscopy data that could not be accurately analyzed due to large line widths were
removed from the study. Due to poor SNR from Glx at 2.2ppm, integrals from 2.0-2.2ppm
were combined by a weighted average based on 3 protons from NAA at 2.0ppm and 2
protons from GABA and glutamine at 2.2ppm. GluCEST slices that were corrupted by
motion were also removed from the analysis.
In order to correlate GluCEST asymmetry values to [Glu]/[Cr] measured by 1H MRS,
strict inclusion criteria were applied: 1) the spectroscopy voxel must be located entirely
inside the thalamus/hypothalamus region, 2) all three GluCEST slices must have been
acquired, 3) each GluCEST slice must have the correct anatomy. This is to ensure that a
consistent region of tissue is compared between the two modalities. The exact
spectroscopy voxel location was mapped onto each slice and segmented from GluCEST
maps. The final dataset included at 3 months WT N=5, PS19 N=3; at 7-9 months WT N=9,
PS19 N=5; at 13 months WT N=7, PS19 N=3.

67

III.
a.

Results

1

H MRS reveals a changing neurochemical profile as PS19 mice age

At an early age of 3 months there are subtle differences observed in the neurochemical
profile between WT and PS19 mice (Figure 28). Quantification of metabolite
concentrations normalized to total creatine levels reveals elevated Glu in PS19 mice at 3
months (Figure 29), as shown in the representative spectrum in Figure 28. A trend in
lower levels of NAA, choline (Cho), and taurine (Tau), and elevated lactate (Lac) in PS19
mice is also observed as early as 3 months (Figure 29). By 7-9 months of age, Glu is
decreased below WT, and MI is increased above WT levels in PS19 mice. As tauopathy
progresses, Glu levels continue to decrease until a significant difference between group
averages occurs at 13 months (Table 1). NAA and Cho levels are also significantly lower
in PS19 mice compared to WT by 13 months. A significant effect of time was modeled for
Glu, Gln, and MI, all normalized to total Cr using an LMM analysis (Table 1). Metabolite
levels could not be modeled by genotype, nor the interaction between genotype and time
using a LMM analysis.
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Figure 28. The neurochemical profile changes as tauopathy progresses in
PS19 mice.
1
H MRS from the thalamus and corresponding GluCEST images at ages 3, 9, and
13 months. Glutamate levels are elevated in young PS19 mice compared to WT.
By 13 months, spectroscopy shows clear loss of NAA (2.0 ppm), and Glu (2.35
ppm) in PS19 mice compared to WT. The corresponding GluCEST maps support
the 1H MRS results, also showing a decreasing trend in glutamate levels. Group
average myo-inositol (MI 3.5-3.6 ppm) levels are increased in PS19 mice by 13
months.
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Figure 29. Quantification of 1H MRS metabolite levels.
Metabolite concentrations are reported as a ratio of PS19 to WT, each normalized
to total creatine. Error bars represent the standard error of the ratio of means.
Abbreviations: Lactate (Lac, 1.3ppm), N-acetyl-aspartate (NAA, 2.0-2.2ppm),
glutamate (Glu, 2.35ppm), glutamine (Gln, 2.45ppm), choline (Cho, 3.25ppm),
taurine (Tau, 3.4ppm), and myo-inositol (MI, 3.53ppm). Glu decreases with age in
PS19 mice compared to WT. Other decreasing trends were measured in NAA,
Cho, and Tau. A significant difference between group averages was measured at
13 months for NAA, Glu, and Cho (*p≤0.05). A trend in elevated levels of Lac and
MI was measured in PS19 mice throughout lifetime.
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Table 1. Statistical analysis for repeated measures on longitudinal
spectroscopy results in PS19 mice.
Metabolite concentrations normalized to total creatine (tCr) measured by 1H
MRS are listed at each age, mean ± SEM. The absolute concentration of Cr did not
vary with age or between genotype. The number of data points included in each
group average is listed under #. A linear mixed model (LMM) analysis for repeated
measures was applied in order to model the effects of group (genotype), time, and
group*time on metabolite levels. A significant effect of time was modeled for Glu,
Gln, and MI. Spectroscopy results do not show a significant group effect or
interaction between group and time. *p≤0.05
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b. Longitudinal GluCEST imaging in the thalamus
GluCEST asymmetry (%) maps from representative WT and PS19 mice, for all three
slices, are shown longitudinally in Figure 30. Trends in group-average GluCEST values
from the thalamus are graphed below for each slice. In WT mice, an increase in GluCEST
as mice age to 7-9 months is observed throughout the brain for all three slices. In PS19
mice, however, GluCEST decreases in the thalamus throughout lifetime. At 7-9 months,
GluCEST is significantly lower than WT values in the rostral (22.6 ± 1.7 vs. 27.6 ± 0.71,
18% difference, p≤0.01) and middle thalamus (22.3 ± 1.4 vs. 28.3 ± 1.1, 21% difference,
p≤0.01). By 13 months GluCEST is also significantly lower in the PS19 caudal thalamus
(22.4 ± 0.85 vs. 24.9 ± 1.2, 10% difference, p≤0.05).
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Figure 30. GluCEST asymmetry (%) maps from representative WT and PS19
mice.
GluCEST maps are shown for each slice at 3 months (mo.), 7-9mo., and 13mo.
Trends in group average GluCEST values from the thalamus are shown for each
slice a) rostral, b) middle, and c) caudal. Pair-wise student’s t-tests were
performed at each age between WT and PS19 mice (*p≤0.05, ** p≤0.01). In WT
mice, GluCEST increases from 3 to 7-9 months in all slices. By 7-9 months of age,
GluCEST is significantly reduced in the rostral and middle slices of PS19 mice.
The combination of these effects produces the greatest difference in the mid-slice
at 7-9 months (21% difference from WT).
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c. Correlation of average GluCEST asymmetry and glutamate concentration by 1H MRS
Comparatively, there is good agreement between the trends in glutamate levels
measured by GluCEST and 1H MRS (Figure 31). A linear correlation coefficient of R2=0.64
with a slope of ~25% GluCEST asymmetry per Glu/Cr ratio was measured.

Figure 31. Correlation of GluCEST and 1H MRS in the thalamus.
Correlation between group averages of GluCEST and 1H MRS results from the
same voxel in the thalamus for each time point. Error bars represent the standard
error of the mean. There is good agreement between the trends in glutamate
levels measured by GluCEST and 1H MRS. A linear correlation coefficient of
R2=0.64 with a slope of 25% was measured.

74

IV.

Discussion

a. Correlation of 1H MRS and GluCEST data
One goal of this study was to determine the extent to which the two modalities, 1H
MRS and GluCEST MRI, correlate in their measurements of neuronal glutamate levels in
vivo. Both modalities measured a significant decrease in glutamate levels with the
progression of tau pathology. A 21% difference in GluCEST asymmetry was measured in
the mid-thalamus of PS19 mice compared to WT at 7-9 months of age (Figure 30, p≤0.01).
A significant deficit was measured by spectroscopy at 13 months (p≤0.05, Table 1).
Although the two modalities measured the same trend in glutamate, GluCEST was able
to detect earlier deficits in PS19 mice.
Two more subtle trends in longitudinal glutamate levels were measured both by 1H
MRS and GluCEST. First, at 3 months of age there was a slight elevation in glutamate
levels in PS19 mice compared to WT: GluCEST measured a 3% elevation in the rostral
and middle slices (Figure 30), while 1H MRS measured a 2% elevation in the thalamus
overall (Figure 29). This effect is potentially an early sign of excitotoxicity. A recent study
investigated the excitotoxicity hypothesis in a P301L mouse model of tauopathy at 5
months of age, and found excess glutamate in the extracellular space as well as reduced
uptake of glutamate which can lead to excitotoxicity (Hunsberger et al., 2015).
Additionally, glutamate levels were found here to increase in the thalamus of WT mice
from 3 months to 7-9 months: GluCEST measured a 5-19% increase compared to 3 month
levels depending on slice position (Figure 30), and 1H MRS measured a 5% increase
(Figure 29). Group averages of Lac, Gln, Cho, and Tau also increased in WT mice from
3 months to 7-9 months, although the differences remained within the range of noise
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(Table 1). This is likely a developmental effect caused by enhanced energetics and
metabolism at this age. A complementary study in the cortex of healthy mice from postnatal day 10 up to 3 months of age showed that the trend in glutamate and choline
continually increased (Kulak et al., 2010).
The correlation of group average data from GluCEST and 1H MRS showed a positive
linear correlation coefficient of R2=0.64 (Figure 31). A slope of 25% GluCEST asymmetry
per Glu/tCr ratio, and an intercept of 1.6 was measured. A previous study also correlated
GluCEST asymmetry to Glu/tCr in the hippocampus region in the APP/PS1 mouse model
with amyloid-beta plaques characteristic of Alzheimer’s disease (Haris et al., 2013a). This
study reports a correlation coefficient of R2=0.91, a slope of 15%, and an intercept of 2.2.
Overall, the range of GluCEST and Glu/tCr values were narrower in the tauopathy mouse
model compared to the APP/PS1 model of amyloid pathology, reflected by a shallower
correlation slope.
Compared to histopathological events in the PS19 mouse model, hyperphosphorylated tau presents itself in the mid-thalamus region during the latest stages of
disease (Hurtado et al., 2010). We have shown here, however, that there are early
metabolic changes in the thalamus. In addition to dynamics in glutamate levels, 1H MRS
also measured an increasing trend in MI as early as 7-9 months. MI is an indicator of
gliosis, which is known to occur in the PS19 mouse model (Yoshiyama et al., 2007). In
this particular congenic mouse model, we have shown by IHC that enhanced GFAP, as a
marker of gliosis, is observed in the thalamus by 6 months (results not shown here).
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b. Longitudinal neurophysiologic changes in the PS19 mouse model of tauopathy
Currently, we are only aware of two reports of 1H MRS in a P301L mouse model. One
study at 4.7T on an inducible P301L mouse model at early stages of pathology reports
significantly increased MI/Cr ratio in a voxel containing both hippocampus and thalamus
(Yang et al., 2011). NAA/Cr and Glu/Cr ratios were also reduced although insignificant.
The second study was performed on the PS19 model in late stage pathology by the author
of this thesis (Crescenzi et al., 2014). In a smaller voxel including only hippocampus,
significantly lower Glu/Cr and reduced NAA/Cr were measured.
The 1H MRS signature of various APP/PS1 mouse models of AD has been reported
longitudinally and has been reviewed by (Mlynárik et al., 2012). These models report
significant reductions in Glu and NAA roughly 6-10 months after amyloid deposition and
later elevation of MI (Mlynárik et al., 2012). In one definitive longitudinal study of the
APP/PS1 mouse model (n=27) vs. controls (n=30), a significant decrease in NAA/Cr and
Glu/Cr was measured with age, as well as between control and transgenic mice
(Marjanska et al., 2005). A significant increase in MI/Cr was also measured, and a
significant interaction between group and time was reported based on ANOVA. Effects on
other metabolites were not reported. Comparatively, our methodology varied in that the
mice in our study were scanned repeatedly. Our findings show a similar significant effect
of time on ratios of Glu/Cr and MI/Cr, and significantly lower Glu/Cr in tauopathy mice by
13 months (Table 1). However our metabolite levels did not model a significant effect of
time or interaction between time and group by a repeated measures analysis.
Lactate also showed an elevated trend in PS19 mice at every age from 3-13 months
(Figure 29). This indicates a hypoxic condition in the brain tissue, perhaps causing
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oxidative stress. Increased levels of lactate can be caused by over-activation of NMDA
receptors (Retz and Coyle, 1982), i.e. excitotoxicity, which leads to oxidative stress (Coyle
and Puttfarcken, 2014). Acidic conditions in the brain have also been shown to induce
gliosis, likely in response to a calcium-dependent protease calpain I (Lee et al., 2000).
Calpain I, whose reaction yields reactive oxygen species (McCord, 1985), was discovered
to be a necessary mechanistic link between NMDA-excitotoxicity and pathologic tau
degradation leading to cell death (Amadoro et al., 2006). These results present in vivo
evidence of early excitotoxicity, by 1H MRS and GluCEST MRI, and oxidative stress by 1H
MRS.
c. Advantages of GluCEST over 1H MRS for earlier diagnosis
Although both 1H MRS and GluCEST-MRI monitor glutamate changes, there are
several important advantages of GluCEST highlighted here. For diagnostic purposes,
early glutamate elevation and subsequent deficits are the earliest markers of tauopathy
investigated here. GluCEST was able to measure glutamate deficits earlier than 1H MRS
by 4 months. For further applications of GluCEST to mouse models of tauopathy, only one
slice through the mid-hippocampus and thalamus would be necessary to measure a 21%
deficit in glutamate by 7-9 months of age (Figure 30). Also, a greater dynamic range is
available in the GluCEST measurement (Figure 31). Furthermore, GluCEST maps
measure glutamate levels at high-resolution (156 µm x 156 µm x 1mm pixel resolution vs.
2.5 x 2.5 x 3 mm3 voxel resolution). In roughly the same total scan time, glutamate levels
can be mapped in the whole brain slice rather than in a single voxel. The hippocampus,
thalamus, and cortex (Crescenzi et al., 2014), as well as a whole-brain ROI (not published)
display lower glutamate levels in mice with tauopathy detected by GluCEST. This is useful
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in order to show that glutamate deficits occur throughout the brain as an overall metabolic
effect.
V.

Summary
The goals of this study were to determine whether 1H MRS or GluCEST is more

sensitive to longitudinal glutamate changes as tau pathology progresses, and to what
extent the two modalities are correlated. 1H MRS and GluCEST were performed
longitudinally in the thalamus of WT (n=9) and PS19 (n=12) mice at ages 3, 7, 9, and 13
months old. The greatest glutamate deficit in PS19 mice compared to WT was measured
in the thalamus by GluCEST at 7-9 months of age (a 21% difference, p≤0.01). A significant
deficit was measured by 1H MRS at 13 months (p≤0.05). Increasing dynamics in glutamate
levels were also measured at 3 months of age when PS19 mice have slightly elevated
glutamate levels. An increasing trend in glutamate was measured in WT mice as they age
to 7-9 months of age. The following is a highlight of these results:
•

Both GluCEST and 1H MRS measured the same trend in glutamate levels and
are correlated (R2=0.64) in the thalamus of aging PS19 mice.

•

GluCEST was able to detect deficits in PS19 mice four months earlier than
H MRS.

1
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CHAPTER 5: Longitudinal imaging of sub-hippocampal dynamics in glutamate
levels in a mouse model of tauopathy
I.

Introduction

Thus far I have shown that GluCEST is reduced in the hippocampus of a mouse model
of AD and in locations of severe synapse loss in the hippocampus of a tauopathy mouse
model (Crescenzi et al., 2014). These findings were detected in the late stage of disease
when low levels of hippocampal glutamate were measured after synapse loss and volume
loss had already occurred.
Evidence from the literature supports a variable trend in glutamate levels during the
course of tau pathology and throughout different sub-regions of the hippocampus.
Glutamate is a necessary component of long-term potentiation (LTP), the measurable
process of learning and memory. Glutamate levels are an indicator of synaptic growth
during LTP (Dolphin et al., 1983) and may be an indicator of synaptic dysfunction in
neurodegenerative disease (Clare et al., 2011; Gong and Lippa, 2010). LTP is dependent
upon NMDA receptors in the hippocampal sub-field CA1 and the DG; however, synaptic
transmission does not depend on NMDA receptors in the mossy fiber-CA3 (Lynch et al.,
2004; Nicoll and Schmitz, 2005). LTP was found to be impaired in the CA1 and not the
CA3 of a mouse model of tauopathy exhibiting cognitive deficits (Chong et al., 2011). In
contrast, LTP was enhanced in the DG of young (2-3 months) tauopathy mice (Boekhoorn
et al., 2006; Pennanen et al., 2006). An effective in vivo surrogate biomarker of synapse
loss would correlate with the sub-hippocampal location and dynamics of synapse loss.
The primary goal of this study was to measure longitudinal changes in subhippocampal glutamate levels from early to late-stage pathology in order to determine
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when glutamate deficits are observed in relation to synapse and volume loss. Sub-regions
of the hippocampus were analyzed in order to associate location-specific deficits in MRI
and histological measures. This study was driven by two main hypotheses: 1) decreased
GluCEST signal will occur when synapse loss is measurable and before volume loss; and
2) glutamate levels will decrease in specific regions of the hippocampus as disease
progresses in PS19 mice compared to WT. Additionally, a histologic basis for changes in
glutamate levels was investigated by IHC of age-matched littermates. A variety of celltype specific antibodies (NeuN and GFAP) and pre-synaptic glutamate transporter
(VGlut1) and post-synaptic receptor (NMDA-NR1) antibodies were applied to tissue from
age-matched littermates in order to compare longitudinal MRI and histological measures.
II.

Methods

a. Experimental design
This study was performed in parallel with that presented in “CHAPTER 4: Longitudinal
GluCEST imaging correlated with 1H MRS in the thalamus of a mouse model of tauopathy”
(page 63). A separate analysis was performed on data from the hippocampus driven by
the aforementioned hypotheses. Refer to Chapter 4, section II.a. on page 63 for the
experimental design. Following imaging, 13 month old WT mice were sacrificed and their
brain tissue was processed for histology (n=7). PS19 tissue at 13 months was also
processed but not analyzed with histology due to the atrophic hippocampus in aged PS19
mice, so that ROI selection was not possible. In order to correlate histological measures
to in vivo imaging data at each age, mouse tissue at younger ages was obtained from
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littermates raised by the CNDR under the same housing conditions: 3months (n=4 WT,
n=4 PS19), 6 months (n=6 PS19), and 9 months (n=6 PS19).
This study was approved by the university’s IACUC. Mouse husbandry and handling
during imaging was identical to that stated in Chapter 2, section II.a. “Mouse preparation
and monitoring during MRI” on page 26.
b. GluCEST Imaging and segmentation by k-means cluster analysis
Refer to Chapter 4, section II.b. on page 64 for the “GluCEST imaging” methods. The
GluCEST signal was measured from four anatomical sub-regions of the hippocampus: the
DG, the CA1 and CA2,3, and the adjacent fourth ventricle containing CSF. It is not possible
to delineate these sub-regions from a T2-weighted in vivo MRI (Figure 32i). Although highresolution atlases exist, both for MRI (Johnson et al., 2010) and histology (Adler et al.,
2014), these methods require registration with exact ex vivo tissue, which cannot be
obtained in a longitudinal study.
In the present study, we first manually segmented the hippocampus proper from the
T2-weighted image (Figure 32i). The outline of the hippocampus can be adequately
delineated in each slice: rostral, middle (mid), and caudal. The hippocampal mask was
applied to the corresponding GluCEST map (Figure 32iii). A secondary segmentation was
then applied to each hippocampus using the k-means clustering algorithm (Matlab script
by Jose Vicente Manjon Herrera, 2005). The k-means method has been used to segment
gray matter, white matter, and CSF voxels from in vivo anatomical MRIs of the brain
(Leung et al., 2015; Vemuri et al., 2008). Likewise, we used this method to segment three
clusters from the hippocampus based on the GluCEST MRI contrast. This algorithm uses
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a statistical method to set a threshold between high, medium, and low GluCEST values
with respect to each hippocampus (Figure 32iv). The final segmented clusters from all
three slices of an example PS19 mouse are shown in Figure 32v.
In total, 9 clusters were segmented from the hippocampus of each mouse. The
hippocampus is a curved 3D structure, which was imaged in 2D coronal sections. This
presents a problem for labeling ROIs along the functional axis (Strange et al., 2014) or
“long” axis of the hippocampus (see (Snyder et al., 2011) for more discussion). Rather,
the cluster locations within each slice roughly fall along the dorsal-ventral axis. Therefore,
clusters are labeled within each slice: dorsal “D” in red, intermediate “I” in green, and
ventral “V” in blue. This nomenclature was motivated by the segmentation presented by
(Dong et al., 2009) based on gene-expression patterns within the hippocampus. From
each cluster the average GluCEST asymmetry value was measured. Additionally, the
volume of each cluster was measured as the number of pixels normalized to the total
hippocampus volume.
The cluster locations can be qualitatively compared to the location of hippocampal
sub-regions of interest, thereby extending the cluster-analysis of GluCEST to specific subregions of the hippocampus along the dorsal-ventral axis. In Figure 32vi the sub-regions
are outlined on hippocampus atlases and colored according to their corresponding cluster.
A final cluster model of hippocampal sub-regions is provided in Figure 32vii for reference.
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Figure 32. Image acquisition and segmentation pipeline
i. Anatomical T2-weighted MRI acquired from a live mouse brain. The example
images shown here are from a 3 month old PS19 mouse. Slice positions were
chosen relative to the Lambda marker (yellow) identified on the sagittal scout
image. The three slices (1mm thick each) span the hippocampus from rostral to
caudal.
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ii. GluCEST asymmetry maps represent glutamate levels in each slice. Gray
matter regions such as the thalamus have higher glutamate levels, compared to
white matter regions like the corpus callosum, where glutamate levels are low.
iii. Hippocampus proper segmented from the T2-weighted MRI and applied to
GluCEST maps from each slice.
iv. Histogram of GluCEST values in an example hippocampus. The k-means
clustering algorithm sets a threshold between high, medium, and low GluCEST
values.
v. Example cluster masks of the hippocampus for each slice. The 3 clusters
are anatomically correlated to the dorsal (D, red), intermediate (I, green), and
ventral (V, blue) hippocampus.
vi. Three slices of the hippocampus from the Allen Brain Atlas (Johnson et.
al., 2010). Hippocampal sub-regions of interest are outlined: dentate gyurs (DG),
cornu ammonus (CA1, and CA2-3), and the CSF. Each region is colored to indicate
their approximate cluster position. In younger mice the CA1 extends through the
caudal-ventral hippocampus, which later becomes CSF as mice age.
vii. Depicted here is an approximate model of the hippocampal sub-regions
which contribute to each cluster (dorsal, intermediate, ventral) in each slice
(rostral, middle, caudal). The average GluCEST asymmetry and volume were
computed for all nine clusters, and displayed in this grid format.

c. IHC protocols and quantification
Mouse brain tissue was prepared for histology following the methods outlined in
Chapter

3,

section

II.d.

“General

tissue

preparation

and

methods

of

immunohistochemistry” on page 46. Several antibodies were applied to sectioned brain
tissue. AT8 monoclonal antibody was utilized to depict phosphorylated tau at residues
Ser202/Thr205 (1:7500), developed with a horseradish peroxidase developing system
(BioGenex, India) and DAB (Vector DAB, Vector Laboratories), and counterstained using
hemetoxylin. Synaptophysin (Milipore Mab38 anti-rabbit, 1:500) was applied for presynaptic terminals and developed using the ABC system (Vectastain ABC Kit, Vector
Laboratories). Both VGlut1 (pre-synaptic vesicular glutamate transporter protein, Synaptic
Systems, Catalog #135304, anti-guinea pig, 1:5000) and NeuN (neuronal cells, Millipore
NeuN21, anti-goat, 1:100) received microwave pre-treatment for 15 minutes at 100°C in
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citrate buffer (Vector Antigen Unmasking Solution, Vector Laboratories) and were
developed using the ABC system. To quantify glial cell proliferation, antibody to GFAP
(glial fibrillary acidic protein, generated at the CNDR, 1:2000) was applied, developed
using the ABC system, and counterstained with hemetoxylin. An antibody for NMDA
glutamate receptor sub-unit 1 (NR1, Abcam, 1:5000, with citrate pre-treatment) was
applied, developed using the BioGenex system, and counterstained with hemetoxylin.
The following antibodies were quantified in the mid-hippocampus: synaptophysin,
VGlut1, NeuN, and GFAP. Four successive slides were chosen per mouse, one for each
antibody, in the mid-hippocampus based on a visual match to Bregma -2.18 anatomy (see
Figure 32vi, middle atlas section). Sections were discarded if damaged or incorrect
anatomy was determined after immunostaining. Stained slides were scanned using an
automatic slide scanner (Lamina Scanner, PerkinElmer). Scanned slides were viewed
using CaseViewer (freeware, v1.3.0.41885), and snapshots were taken at 10x
magnification. ROIs were segmented by hand in the dentate gyrus polymorph and granule
cell layer, and all laminae of the CA1 and CA2,3 (see Figure 37a for example ROIs).
Images were thresholded to the same level for all mice (ImageJ, NIH). The amount of
immunostaining was measured as the percentage of area occupied (% AOC) by positive
staining within the ROI. GFAP immunostaining was distinguished from hemetoxylin by the
color deconvolution plug-in (Ruifrok et al., 2001) for ImageJ using the hemetoxylin and
DAB optical densities (ODs) provided; the hemetoxylin image was used for ROI
identification, and the chromagen image was thresholded before measuring the %AOC.
Slides immunostained with NR1 were quantified in the caudal-hippocampus due to a
greater amount of NR1 positive cells present compared to the mid-hippocampus sections.
The caudal-hippocampus was chosen based on anatomical features of Bregma -3.18 (see
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Figure 32vi third atlas section). ROIs were outlined in the DG, CA1, and CA2,3. Positive
chromagen signal was measured in the NR1 stain by identification and averaging of red,
blue, green (RGB) OD values from five random NR1 positive neurons for color
deconvolution of signal from background and counterstain. A minimum OD threshold was
applied to measure the area occupied by NR1 positive neurons and was confirmed for
accuracy by visual inspection.
d. Statistical analyses
To determine the effects of time and group (genotype) on GluCEST and volume
results, a linear mixed effect model (LMM) for repeated measures was applied to data
from each cluster. First-order auto regressive analysis was used as covariance structure
based on Bayesian Information Criterion (IBM SPSS version 22). The linear mixed effect
model with time and genotype was fitted for each of the outcome measures with Time,
Group (genotype) and Time*Group as fixed effects and intercepts as random effects. A
significance level of p≤0.05 was considered statistically significant and F-values are
reported wherever necessary. GluCEST data from Cohort 1 acquired at 7 months and
Cohort 2 at 9 months were combined to gain statistical power. Data from Cohort 2 at 3
months was not acquired; however, LMM was chosen for its flexibility in handling missing
data.
Student’s one-tailed t-test was also performed to determine significant differences
between group averages of various data, assuming unequal variance. Error bars express
the standard error of the mean (SEM).
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III.

Results

a. Longitudinal glutamate imaging in sub-regions of the hippocampus
Glutamate levels were measured in vivo using GluCEST imaging from three slices
spanning the hippocampus. Representative GluCEST maps from the hippocampus of a
WT and PS19 mouse are shown at each age in Figure 33. GluCEST contrast is clearly
not homogeneous within the hippocampus. Several obvious features can be observed.
The caudal slice generally has higher GluCEST than the rostral slice, and a region of high
GluCEST is longitudinally maintained in the dorsal hippocampus. The ventral
hippocampus region has reduced GluCEST contrast and is enlarged in the PS19 mouse.
GluCEST also appears to increase in various regions as both the WT and PS19 mice age.

Figure 33. Representative GluCEST maps in the hippocampus.
Examples are shown here from a congenic BL6-PS19 mouse and a healthy WT
mouse as they age from 3-13 months. All three slices are also from the same mice.
The exception is at 9 months, where maps from different mice are shown because
only Cohort 2 was imaged at this time point.
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For a more detailed analysis, GluCEST maps in the hippocampus were segmented
into three clusters for each slice. The average GluCEST value in each cluster was
averaged across the group of WT and PS19 mice at each age. Group averages from the
nine clusters were arranged in a grid and are referenced according to slice position
(rostral-R, middle-M, caudal-C) and cluster location (dorsal-D, intermediate-I, ventral-V,
see Figure 32vii). Figure 34 illustrates that a spatial gradient is observed in glutamate
levels. GluCEST values are highest in the most caudal-dorsal region and are lowest in the
more rostral-ventral regions. For instance, the caudal-dorsal (C-D) cluster has the highest
GluCEST values, and the rostral-ventral (R-V) cluster has the lowest GluCEST values.
At 3 months of age, the average GluCEST asymmetry is slightly elevated in PS19 mice
over WT levels (Figure 34a-b). In all regions of PS19 mice, GluCEST decreases from 37 months. In WT mice, however, GluCEST increases in all regions from 3-7 months. The
combination of these effects produces the earliest significant differences at 7 months
between WT and PS19 mice (Figure 34c). The M-D region at 7 months is the location and
age of the greatest measured difference in GluCEST between PS19 and WT mice (30%
reduction, p≤0.001, Figure 34c).
After 7 months, GluCEST in WT mice progressively diminishes but remains higher
than PS19 mice in all regions except the M-D. At 13 months GluCEST in the PS19 M-D is
significantly elevated over WT levels (p≤0.05, Figure 34c). Several other dorsal regions
of the PS19 hippocampus show increases in GluCEST compared to earlier time-points:
the M-D and R-D regions increase from 7-9 months and 9-13 months, the C-D and M-I
region from 9-13 months.
By contrast, the intermediate and ventral regions of the hippocampus progressively
decrease from 7-13 months and are significantly reduced from WT in the middle and
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caudal slices at each age (Figure 34c). By 13 months, GluCEST is significantly reduced
in all ventral regions of PS19 mice compared to WT. The LMM analysis confirms the
significant effect of time on GluCEST in the ventral regions and the C-I region (Table 2a).
There is also a significant interaction between group*time in the C-I, C-V, and M-V regions.
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Figure 34. Glutamate gradient in the hippocampus measured in vivo by
GluCEST MRI
a-b) Group average GluCEST asymmetry values from clusters in the
hippocampus arranged on an anatomical grid. A gradient in glutamate levels is
clearly observed along the rostral-caudal and dorsal-ventral axes of the
hippocampus. In WT mice there is a ubiquitous increase in GluCEST levels as
mice age to 7 months; glutamate levels decline back to baseline by 13 months.
PS19 mice have progressively decreased GluCEST levels throughout lifetime in
most regions. An increase in GluCEST is measured among the dorsal regions of
the PS19 cohort from 9-13 months.
c) GluCEST asymmetry values were compared for each cluster between WT
and PS19 mice using a Student’s t-test. The earliest significant differences
between PS19 and WT mice are measured at 7 months in the more caudal, dorsal
regions. In later stages of tauopathy, GluCEST values become significantly
reduced in ventral regions as hippocampal tissue is lost.
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b. Volume changes in sub-regions of the hippocampus
Longitudinal volume changes are represented in bar graphs for each cluster and are
arranged in a grid (Figure 35). Interestingly there is an increasing trend in volume of the
dorsal PS19 hippocampus until 9 months; the volume is abruptly decreased between 913 months (Figure 35a). The volume of the PS19 M-D region becomes significantly
reduced compared to WT at 13 months (p≤0.01), while C-D volume remains significantly
increased over WT (p≤0.001). Volume is relatively maintained in the dorsal regions of WT
mice.
The volume of the C-I cluster decreases at 9 months below WT volume, and reaches
significance by 13 months (p≤0.001, Figure 35b). Volume of the M-I cluster shows a more
progressive decrease from 3-13 months and is significantly lower than WT at 13 months
(p≤0.001). WT mice also show some reduction in M-I volume during the course of the
study. The LMM analysis reveals a significant effect of time and group*time interaction on
the volume of the C-I, and M-I clusters (Table 2b). The volume of the R-I region is
significantly affected by time in the LMM analysis.
C-V volume in PS19 mice follows that of WT mice until 13 months when volume is
significantly enlarged (p≤0.01, Figure 35c). There is a significant effect of time on C-V
volume by LMM analysis (Table 2b). The greatest change in volume is measured in the
M-V cluster at 13 months (58% increase compared to WT, p≤0.001). This region is
significantly affected by time and group*time interaction (Table 2b). The volume of the RV is slightly increased with age in both WT and PS19 mice (Figure 35c), and indeed there
is a significant effect of time based on the LMM analysis (Table 2b).
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Figure 35. Longitudinal volume changes in sub-regions of the hippocampus
Bar graphs represent the volume of each cluster normalized with the total
volume of the hippocampus. Graphs are arranged according to their cluster
position (see Figure 32vii).
a) The volume (or proportion of the hippocampus) of dorsal clusters for each
slice. Interestingly there is an increasing trend in volume of the dorsal PS19
hippocampus until 9mo.
b) In contrast, the volume of intermediate clusters in the mid and caudal slices
progressively decrease in PS19 mice with age, which reaches significance at 13
months compared to WT.
c) The ventricle volume is depicted in the volumes of the ventral clusters. A
severe increase in ventricle volume was measured in all 3 slices from 9-13 months
in PS19 mice. Ventricle volume is significantly larger than WT at 13 months (also
shown in histology sections in Figure 36d).
Significance is reported between WT and PS19 group averages at each age
using the Student’s t-test. *p≤0.05; ** p≤0.01; ***p≤0.001
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Table 2. Effects of group, time, and group*time were fit for GluCEST and
volume results using a linear mixed effect model (LMM) for repeated measures.
a) GluCEST in the ventral clusters of all three slices, corresponding primarily
to CSF, is significantly affected by time. An interaction between group*time also
contributes to ventral GluCEST in the caudal and middle slices. The caudalintermediate cluster, corresponding to the CA23, is significantly affected by time
and the interaction between group*time.
b) Volume of the intermediate and ventral clusters of all three slices is
primarily modeled by the effect of time. A group*time interaction exists in the
caudal-intermediate, mid-intermediate, and mid-ventral clusters.

c. Longitudinal pathology in the congenic BL6-PS19 mouse model of tauopathy
At 3 months of age, mild pathology has already begun to appear in PS19 mice (Figure
36a). Hyper-phosphorylated tau (by AT8 immunostaining) is present in the first layer of
the caudal cortex and mossy fibers of the caudal CA3. As PS19 mice age to 6 months,
pathology is present in all layers of the rostral-caudal hippocampus and has infiltrated
deeper layers of the cortex, the entorhinal cortex, and amygdala. At 9 months tau
pathology proliferates through the entire hippocampus, and tissue degeneration is
observed (Figure 36c). By 13 months AT8 pathology is present in the thalamus and the
frontal cortex in addition to the hippocampus (Figure 36d).
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Figure 36. Tau pathology by AT8 IHC in congenic BL6-PS19 mice as disease
progresses.
a) AT8 immunostaining in the hippocampus of a 3 month PS19 mouse, from
rostral to caudal, shows early pathologic tau in the first layer of the caudal cortex
and mossy fibers in the CA3.
b) Pathology spreads by 6 months from the entorhinal cortex and amygdala
through all layers of the rostral to caudal hippocampus.
c) Tissue degeneration is apparent in the hippocampus by 9 months and
further by 13 months.
d) Pathology is present throughout the thalamus and frontal cortex by 13
months. WT mouse brain shows little degeneration of the hippocampus with age.
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Synapse density by synaptophysin immunostaining was quantified in histological
sections corresponding to the regions of mid-hippocampus imaged in vivo. The earliest
significant difference in synapse density was measured at 6 months in PS19 mice
compared to WT mice at 3 months in all sub-regions of the hippocampus (p≤0.01, Figure
37a, Table 3a). Synapse density continues to decrease in all sub-regions of the
hippocampus of PS19 mice out to 9 months.
VGlut1, a marker of glutamatergic pre-synapses, reveals interesting dynamics as
PS19 mice age (Figure 37b, Table 3b). At 3 months VGlut1 is significantly different than
WT in the DG of PS19 mice (p≤0.01). By 6 months VGlut1 immunostaining is increased
from that observed at 3-6 months in all sub-regions of PS19 mice. By 9 months VGlut1
presence is significantly reduced from WT in all sub-regions (p≤0.01 in CA2,3). There is a
significant reduction in VGlut1 immunostaining in the CA1 and CA2,3 of WT mice by 13
months (Table 3b).
In PS19 mice, both GFAP (Figure 37c) and NeuN (Figure 37d), markers of glial cells
and neurons, were significantly different from WT by 9 months NeuN was significantly
reduced in all sub-regions (p≤0.05, Table 3d) while GFAP was significantly increased in
all sub-regions (p≤0.001, Table 3c). Increased GFAP throughout the hippocampus was
the most severe change measured by histology with more than 20x greater presence of
glial cells at 9 months throughout the hippocampus.
Positive immunostaining of glutamate receptor NR1 was quantified intracelluarly in the
caudal hippocampus (Figure 38a). The average %AOC was reduced in all sub-regions of
3 months PS19 mice compared to WT. Significant reductions were measured by 6-9
months in the CA1 and CA2,3 (p≤0.05, Figure 38b-d, Table 3e).
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Figure 37. Synaptic and cell-type specific IHC markers in the hippocampus.
IHC was performed on sections through the hippocampus corresponding to the
mid-slice using various antibodies: a) Synaptophysin for pre-synapse density, b)
VGlut for glutamatergic pre-synapse density, c) NeuN for neuronal cells, and d)
GFAP for glial cells. ROIs including the dentate gyrus (DG), CA1, and CA23 were
segmented from 10x images, and percent area occupied (%AOC) was quantified.
All images are displayed at 5x magnification. Graphs report group averages in the
CA23. Student’s t-tests were performed between each group average against the
WT 3 month average (*p≤0.05; ** p≤0.01; ***p≤0.001). The earliest significant
difference was measured at 6mo. in PS19 synaptophysin density compared to WT
levels at 3 months in all ROIs (p≤0.001). Glutamatergic synapses by VGlut tend to
increase at 6 months throughout the hippocampus, followed by a significant
reduction at 9 months compared to WT levels at 3 months (p≤0.01). NeuN is
significantly reduced in all ROIs by 9 months (p≤0.05), while GFAP is significantly
increased by 9 months (p≤0.001).
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Figure 38. Immunostaining of NMDA glutamate receptor NR1 in the caudal
CA23.
a) ROIs were manually drawn in the CA1, CA23, and DG.
b-c) Representative bands through the CA23 from a WT mouse at 3 months
and a PS19 mouse at 6 months. Positive NR1 immunostaining was considered
intracellular. Fewer NR1-positive cells appear in PS19 mice at 3 and 6-9 months
in all ROIs.
d) Significantly lower NR1 levels are measured at 6-9 months in PS19 mice
(p≤0.05).

Table 3. Quantification of IHC for various antibodies
Trends from all sub-regions follow that of the CA23, which are graphed in
Figure 37 and Figure 38. Student’s t-tests were performed between each group
average against the WT 3 month average.
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IV.

Discussion

a. Reduced GluCEST and synaptic density are measured before volume loss in the PS19
mouse model of tauopathy
The earliest significant differences in GluCEST between PS19 and WT mice were
measured at 7 months of age, at which point GluCEST was significantly decreased
throughout the entire middle and caudal hippocampus slices. The largest difference was
measured in the middle-dorsal region (30% reduced from WT). Synapse density was also
significantly reduced in every sub-region of the hippocampus in PS19 mice at 6 months.
Volume loss was not significantly different until 13 months between PS19 and WT mice.
Reduced GluCEST occurred not only earlier than volume loss but also in a different
location than volume changes within the hippocampus. A shift in location of GluCEST
deficits is observed in Figure 34c, where significance shifts are observed from the dorsalcaudal region of the grid at 7 months to the ventral-caudal region by 13 months. Early
differences at 7 months seem to be a metabolic deficit in glutamate levels, which is
concurrent with reduced synapse density. This is in contrast to lower GluCEST in the
ventral regions by 13 months, which is a result of hippocampal volume loss and ventricle
volume increase.
b. Interpretation of cluster analysis and glutamate gradient measured in vivo by GluCEST
MRI
GluCEST contrast follows a gradient along the dorsal-ventral and caudal-rostral axes
of the hippocampus. GluCEST values are highest in the most caudal-dorsal region and
decrease towards the rostral-ventral regions. Numerous studies have reported gradients
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within the hippocampus in terms of gene expression (Fanselow and Dong, 2010;
Thompson et al., 2008), connectivity (Risold and Swanson, 1996), electrophysiology
(Staresina et al., 2012), and spatial processing functions (Kjelstrup et al., 2008). These
gradients also exist along the dorsal-ventral axis of the hippocampus, and may be better
understood in terms of the functional “long” axis (Strange et al., 2014). To facilitate
interpretation of our cluster-based analysis in terms of hippocampal sub-regions, an
anatomical model is provided in Figure 32vii. According to this model, the dorsal regions
correspond anatomically to the DG and may include contributions from CA1, although they
remain more dorsal than CA2,3. The intermediate clusters therefore include the
hippocampal sub-region CA2,3. In the caudal slice, the CA1 extends from the dorsal to
ventral hippocampus in young mice, and may therefore contribute to the GluCEST signal
in all caudal clusters. The ventral clusters contain sub-fields of the CA in younger mice,
and transition to CSF as tissue is lost. These regions are subject to partial-volume effects
between adjacent anatomies.
Gradients in neuron activation and neurogenesis have also been observed within the
hippocampus. Neurons in the most dorsal hippocampus are highly active even without a
stimulating memory task (Snyder et al., 2011). Additionally, there is a greater density of
newborn neurons in the dorsal-DG compared to ventral regions of the DG in young
(Snyder et al., 2009) and old rats (Snyder et al., 2011). These findings are consistent with
our observations that the highest glutamate levels measured by GluCEST imaging were
observed in dorsal regions (rostral to caudal) corresponding to the DG (Figure 34). We
also found that neurons, by NeuN immunostaining, appear to be more densely populated
in the DG compared to CA1 and CA2,3 (Table 3d). Additionally, NR1 immunostaining
increased in WT mice in the DG from 3-13 months (Table 3e).
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c. MRI measures increased glutamate levels in vivo during mouse lifetime
Early signs of tau pathology were observed in both the GluCEST measurement and
synaptophysin immunostaining. At 3 months there was a trend of higher glutamate levels
in every sub-region of the PS19 hippocampus compared to WT (Figure 34a-b). At this
age hyper-phosphorylated tau pathology was only present in select layers of the caudal
hippocampus, whereas the trend in synapse density was lower in all sub-regions
analyzed. A potential explanation for this early state of elevated glutamate, which causes
synapse deficits in the absence of phosphorylated tau, would be excitotoxicity. A higher
GluCEST signal of 1-2% measured here in the 3 months PS19 hippocampus corresponds
to an elevation of glutamate by approximately 2-3 mM/L (Cai et al., 2012), which is more
than sufficient to induce excitotoxicity (Nicholls and Budd, 1998). Additional experiments
are needed to prove this relationship; however, this demonstrates the potential for
GluCEST imaging to measure excitotoxicity in vivo.
Throughout the hippocampus, increased GluCEST levels at 3 months preceded an
increase in VGlut1 levels at 6 months in PS19 mice. Another recently published study
found a similar trend in VGlut1 at 5 months in a P301L mouse model by immunoblotting
of hippocampus tissue (Hunsberger et al., 2015). That finding coincided with decreased
expression of GLT-1, a transporter involved in clearing glutamate from the extracellular
space. We have also shown a progressive decrease in NR1, an NMDA receptor, which
resides on the post-synapse. Together, these effects produce excess glutamate in the
extracellular space, which leads to excitotoxicity (Hunsberger et al., 2015). This may be a
translatable effect to early stages of neurodegeneration. VGlut was shown to be elevated
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in the mid-frontal gyrus of patients with early stages of mild-cognitive impairment (Bell et
al., 2007).
Another unexpected finding of this study was a ubiquitous increase in hippocampal
GluCEST levels from 3-7mo in WT mice. 7 month old PS19 mice, however, do not show
this effect. Instead, the rise in GluCEST levels in PS19 mice occurs at 9 months in the
dorsal clusters rostral-mid, and further at 13 months in all dorsal clusters and the midintermediate cluster (Figure 34b). These clusters correspond to the DG and CA1 from
rostral-caudal, and mid-CA2,3 sub-regions. Indeed the LMM analysis confirms that
GluCEST and volume measures in the dorsal regions could not be modeled by time or
genotype, but rather show more complex dynamics throughout lifetime.
We suspect there are both developmental effects and pathologic effects creating these
dynamics. We propose two potential causes for increased glutamate during lifetime. One
process that may elevate glutamate levels is the increased concentration of glial cells
throughout lifetime. It is known that GFAP immunostaining increases during healthy aging
in mice (Kohama et al., 1995), rhesus macaques (Haley et al., 2010), and humans (David
et al., 1997). While the greatest concentration of glutamate occurs in neurons (10-15mM,
7x greater than that of other metabolites), there is a substantial contribution from glial cells
(6-10mM) (McKenna, 2007). A proliferation of glial cells around 7 months of age in WT
mice could contribute to an increase in GluCEST, given that the GluCEST signal is directly
proportional to the amount of total free glutamate in the brain.
The delayed increase in GluCEST measured at 9 months in PS19 mice appears to be
correlated with a 20-fold increase in GFAP presence at this age (Figure 37c). Increased
GluCEST was only measured in the clusters containing the DG likely due to the greater
density of neurons and glial cells here. In contrast, this effect was likely counterbalanced
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in the CA1 and CA2,3 regions by a decrease in synapse density (both general and
glutamatergic). GluCEST appears to be most closely associated with the combined effects
of synaptophysin and GFAP immunostaining.
A second process that could increase the glutamate in dorsal regions of the
hippocampus is the phenomenon of neurogenesis. In AD patients (Jin et al., 2004b) and
in a mouse model of AD (Jin et al., 2004a), there is evidence that neurogenesis is
increased in the DG. In this study, as well as our previous work (Crescenzi et al., 2014),
glutamate is elevated in PS19 mice over WT in the DG of the middle slice (cluster M-D
here) by 13 months (equivalent to late stage pathology studied previously). While
histological confirmation of neurogenesis as the cause for increased GluCEST contrast in
the DG requires further investigation, GluCEST is the only technique with potential to show
this effect in vivo. This provides an important opportunity for future studies to use GluCEST
technology as neurogenic therapies are developed (Chadwick et al., 2011; Chohan et al.,
2011; Wang et al., 2010).
d. Considerations for future studies in congenic BL6-PS19 mice with tauopathy
Future studies in this mouse model should consider the time course of disease
presented here, and the relevant regions of pathologic symptoms. Immunostaining for tau
pathology was indistinguishable between 9 and 13 months in the PS19 hippocampus
(Figure 36c-d). By 13 months, immunostaining is difficult to quantify in the hippocampus
due to severe tissue loss. Furthermore the greatest significant difference in GluCEST
levels between WT and PS19 mice occurred at 7 months, at the same age that significant
differences were measurable in synapse density. Therefore, 9 months is a sufficient
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endpoint where pathologic events including the formation of pathologic tau, synapse loss,
volume loss, and even metabolic dynamics have already occurred.
In this work, mice were studied every 3 months. The interval between 6-9 months
appears to be the period of greatest change in pathology including gross morphologic
changes of the hippocampus (Figure 36b-c), a sharp reduction in synapse density (Figure
37a), and a shift in location of GluCEST deficits from dorsal to ventral (Figure 34c). It
would be interesting to study PS19 mice during this time period more closely. Several
remaining questions could be investigated: How sharply does hippocampal volume
diminish, and is there a breaking-point of cellular stress which triggers neuronal death? If
elevated GluCEST in young PS19 mice is indeed a measure of excitotoxicity, how is
glutamate metabolism affected during the 6 month delay before neuronal death? For
instance, calpain I is a calcium-dependent protease whose reaction yields reactive oxygen
species (McCord, 1985). Calpain I was discovered to be a necessary mechanistic link
between NMDA-excitotoxicity and pathologic tau degradation leading to cell death
(Amadoro et al., 2006). Subsequently, is the increase in dorsal-hippocampal glutamate
protective? GluCEST imaging could aid in in vivo detection of excitotoxicity, and the time
course of neuronal death or therapeutic rescue.
V.

Summary
The goals of this longitudinal study were to determine the earliest stage at which PS19

mice can be distinguished from WT by GluCEST MRI, and whether GluCEST changes
are associated with synapse loss before volume loss occurs in the PS19 hippocampus.
Additionally, histological evidence from age-matched littermates supporting MRI-observed
changes in glutamate levels was explored using a variety of cell-type specific antibodies
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(NeuN and GFAP), and glutamate transporter (VGlut1) and receptor (NMDA-NR1)
antibodies. Sub-regions of the hippocampus were analyzed in order to associate locationspecific changes in MRI and histological measures. The most significant difference in
GluCEST between WT and PS19 mice was measured at 7 months of age in the CA1 and
DG sub-regions (30% reduced from WT, p≤0.001). Synapse density was also significantly
reduced in every sub-region of the hippocampus in PS19 mice by 6 months. Volume loss
was not significantly different until 13 months between PS19 and WT mice. Further, a
gradient in glutamate levels was observed along the dorsal-ventral and rostral-caudal axes
within the hippocampus, where the highest GluCEST values were measured in the caudaldorsal hippocampus. Dynamics in glutamate levels of the WT and PS19 hippocampus
were most closely correlated with the combined changes in synapse density by
synaptophysin and glial cell reactivity by GFAP IHC. The following are highlights of these
results:
•

Hippocampal glutamate levels are significantly decreased in early stages of PS19
tauopathy compared to WT, which is concurrent with synapse loss before
structural volume loss.

•

Glutamate levels increase from 3-7 months in the BL6-WT mouse hippocampus.

•

Glutamate levels increase at 9 months and 13 months in the DG and CA1 of the
PS19 hippocampus, which is associated temporally with increased GFAP
immunostaining.

•

GluCEST MRI measured a gradient in glutamate levels in vivo along the dorsalventral and rostral-caudal axes of the mouse hippocampus.
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CHAPTER 6: Glutamate CEST MRI measures elevated glutamate in vivo in
MPTP Mouse Model of Parkinson’s Disease
I.

Introduction

MPTP toxicity in mice is a well validated model of early glutamatergic excitotoxicity in
PD pathology (Jackson-Lewis and Przedborski, 2007). The aim of the current study was
to use GluCEST MRI to measure regional changes in glutamate levels in the MPTP mouse
model of PD, in order to investigate its potential as a diagnostic tool. MPTP toxicity is
spatially selective to dopaminergic neurons in the SNc, thereby increasing glutamate in
the striatum and not in regions such as the thalamus. Therefore, GluCEST was
hypothesized to be elevated in the striatum and not in an unaffected region such as the
thalamus. GluCEST measurements in the striatum were compared with glutamate
concentration changes measured by 1H MRS in this region. In addition, GluCEST contrast
was correlated with two previously established measures of disease in the MPTP model:
neurobehavioral measures of motor dysfunction and immunohistochemical markers.
GluCEST imaging is the first technique with potential to show the spatial selectivity of
MPTP toxicity which previously has not been reported at high-resolution in vivo. This study
is also the first to apply GluCEST to a disease that is marked by increased glutamate
levels without the confounding effects of pH changes.
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II.

Methods

a. MPTP administration and animal care
The IACUC of the University of Pennsylvania approved all the experimental protocols
in this study. C57BL6 mice were procured from the Charles River Laboratory, Horsham,
PA, USA and kept at the ULAR animal housing facility at the University of Pennsylvania.
Mice were housed in a humidity controlled room ~22°C under a 12 hour light/ dark cycle
with ad libitum access to food and water. Mice aged 3 months old were divided into two
groups: control (n = 11) and MPTP (n = 13). Mice in the MPTP group received MPTP (25
mg/kg, via intraperitoneal injection, Sigma/Aldrich, St. Louis, MO, USA) dissolved in
normal saline once a day for 7 days, while the control mice received the same volume of
normal saline for the same period.
b. Neurobehavioral testing
Forepaw grip strength test was performed on both groups of mice on the 0th and 8th
days of treatment using a device described previously (Bagga et al., 2013). Briefly, an
apparatus consisting of a steel rod of 1.5 mm diameter and 30 cm long positioned
horizontally between two vertical columns 30 cm high. Mice were made to hold the rod
using fore limbs and their tail was restrained to prohibit the use of hind limbs. The duration
of hanging on the rod was monitored for both groups of animals. The forepaw grip strength
was measured as the holding impulse (weight × duration of holding) in order to normalize
the effect of different mass of the mice.
The four limb hanging test was performed on both groups of mice on the 8th day of
treatment. The testing procedure implemented here was modified from a protocol
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previously described (Anandhan et al., 2012). The mice were placed on the top of a
standard wire cage lid and were made to hold for a few seconds before turning the lid
upside down. The latency of mice to fall off the wire lid was measured. The trial was
repeated 3 times (5 minutes apart) and the average value was computed. The four limb
endurance was reported as holding impulse (holding impulse = weight × duration).
c. Acquisition and processing of anatomic MRI, GluCEST MRI, and 1H MRS
Mouse husbandry and handling during imaging was identical to that stated in
Chapter 2, section II.a. “Mouse preparation and monitoring during MRI” on page 26.
Axial T2-weighted (TR/TE = 3000/36 ms, matrix = 128 × 128, FOV = 2 cm, NEX = 2,
no. of slices = 16, slice thickness = 1 mm) brain images were acquired. Quantification of
brain ventricle volume was performed using a homemade script in MATLAB (v2009b). The
regions of interest were manually delineated for the third and fourth ventricles and the
cerebral aqueduct combined over the left and right hemispheres. The ventricle volume
was measured as the summed volumes (in voxel units) of the ventricle from multiple slices.
The whole brain volume was also measured as a reference, covering 8 slices from the
rostral end of the forebrain to the caudal end of the cerebellum; the voxel volume of all
slices was summed in order to obtain the whole brain volume. The ventricle volume was
calculated as the ratio of the number of voxels in the ventricles to that in the whole brain.
1

H MRS was performed on control (n = 10) and MPTP treated (n = 14) mice using the

PRESS pulse sequence (TR/TE = 3000/28 ms, spectral width = 4 kHz, number of points
= 4006). The WET water suppression technique was used to acquire a water-suppressed
spectrum (averages = 512), and another spectrum was acquired without water
suppression to obtain the water reference signal for normalization (averages = 16).
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Unsuppressed water spectra had a line width of 20 Hz or less after localized shimming.
Spectra were acquired from a voxel localized in the striatum (2.25 × 2.25 × 2.25 mm3). All
spectra were acquired while gating to respiration. Total acquisition time for spectroscopy
was about 20 min.
Metabolite concentrations measured by in vivo 1H MRS were quantified using the
LCModel software (Provencher, 2001). A spectral range of 0-4.2 ppm was used for
analysis. The following metabolites were included in the basis set: alanine, Asp, Cr, GABA,
glucose, Glu, Gln, glycerophosphocholine, phosphocholine, MI, Lac, NAA, Nacetylaspartylglutamate, phosphocreatine, scyllo-inositol, and taurine. In addition, 9 presimulated macromolecule signals were incorporated in the basis set. The concentration of
metabolites was measured using the unsuppressed water peak as a concentration
standard. Water content in the brain was assumed to be approximately 80%. Metabolites
having a CRLB <20% were considered for further analysis (Srinivasan et al., 2004).
A custom-programmed RF spoiled GRE readout with a frequency selective saturation
preparation pulse sequence was used as described previously in Chapter 2, section II.c.
“GluCEST MRI protocol in mice” on page 30. The following sequence parameters were
used in this study: saturation preparation pulse power (B1rms = 6uT and duration of 1s as
four pulses of 250 ms duration each), GRE readout (effective TR/TE = 6.2/2.9 ms, number
of averages = 4). The entire preparation/acquisition combination was repeated every 8s.
GluCEST images were collected with saturation frequencies from ± 2.5 – 3.5 ppm offset
from water with a step size of 0.25 ppm.
GluCEST, B0, and B1 maps were acquired from 2 slices (2mm thick each). One slice
included the striatum where elevated Glu is specifically hypothesized to occur in the MPTP
model of PD. The second slice included the thalamus region as a control. Segmentation
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of the striatum and thalamus was performed manually on the T2-weighted anatomical
MRI, and ROIs were overlaid on the GluCEST maps.
d. IHC protocols for tyrosine hydroxylase and GFAP
Mice from the first cohort were utilized for IHC: control (n=5) and MPTP treated (n=7).
Mouse brain tissue was prepared for histology following the methods outlined in Chapter
3, section II.d. “General tissue preparation and methods of immunohistochemistry” on
page 46.
The primary antibodies used in this study include tyrosine hydroxylase (TH, RbTH
UPN88, Millipore, 1:1k dilution, †) which is specific for dopaminergic neurons, and glial
fibrillary acidic protein (GFAP, stock prepared at the CNDR, 1:2k dilution, ‡) to monitor the
glial cell response. GFAP immunostained slides were counterstained with hemetoxylin.
Stained slides were scanned using an automatic slide scanner (Lamina Scanner,
PerkinElmer). Scanned slides were viewed using CaseViewer (freeware, v1.3.0.41885).
Quantification methods were performed in Image J (NIH) and averaged over the left and
right hemispheres for all antibodies. The mean intensity of TH immunostaining in the
striatum was quantified from square ROIs segmented from 3.5x images (Figure 43A).
ROIs from the color image (without counterstain) were converted to gray-level intensity for
quantification. In the SNc, the punctate dark-brown stain was selected using a fixed
threshold for all mice (Figure 43F), and the percent area occupied (%AOC) was calculated
over a square ROI cropped from 10x images.
In order to quantify GFAP immunostaining, 3.5x images from the striatum and
thalamus were analyzed by the color deconvolution plug-in (Ruifrok et al., 2001) using the
“H DAB” color optical densities provided. ROIs were selected over the entire striatum and
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thalamus from the counter-stained image and applied to the brown image. A consistent
threshold was applied, and the %AOC by GFAP immunostaining was calculated.
e. Statistical analyses
For all results, a two-tailed non-equal variance Student’s t-test was used to compare
results from MPTP treated with control mice. A significance level of at least p≤0.05 was
determined using the Bonferroni correction. Mean values are reported and graphed, where
error bars represent the standard deviation.
III.

Results

a. Neurobehavioral observations
Treatment with MPTP did not cause any alteration in the weight of mice (p > 0.61).
Sub-acute administration of MPTP to mice led to a significant reduction in the fore paw
grip strength (Day 0: 1331 ± 167 g.sec, Day 8: 856 ± 211 g.sec; p≤0.001) while it was
unchanged in the control mice (Day 0: 1336 ± 237 g.sec, Day 8: 1313 ± 234 g.sec; p =
0.80, Figure 39A). Additionally, four paw hanging test results were found to be significantly
reduced in mice treated with MPTP on Day 8 (32.1 ± 11.3 N.sec) compared to control
mice on Day 8 (55.8 ± 11.9 N.sec, p≤0.001, Figure 39B).
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Figure 39. Motor function in control and MPTP mice.
A. Fore paw grip strength test shows a significant reduction after MPTP treatment
(p≤0.001, percent difference: -35.7%). B. Four limb hanging test shows a
significant reduction with administration of MPTP (p≤0.001, percent difference: 42.4%).

b. Ventricle volume
The ventricles are enlarged in MPTP treated mice which is qualitatively apparent from
T2-weight images (Figure 40A). It was found that sub-acute exposure to MPTP leads to
a significant increase of 30.8% in the volume fraction of ventricles in the brain (Control
3.38 ± 0.43 %, MPTP 4.42 ± 0.52 %; p≤0.001, Figure 40B).
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Figure 40. Ventricle volume in control vs. MPTP mice.
A. Ventricle volume is increased in MPTP mice which can be seen from a T2weighted MRI. B. Significantly larger percent ventricle volume of the whole brain
was measured in MPTP 4.42 ± 0.52 % mice versus control 3.38 ± 0.43 %, p≤0.001.

c. Neurometabolite levels measured by 1H MRS in the striatum
Qualitative comparison of the localized 1H MRS of the striatum showed elevated levels
of Glu following treatment with MPTP (Figure 41). LCModel analysis was performed to
measure changes in the concentration of metabolites (mmol/g). MPTP treatment led to a
significant increase in the concentration of Glu (Control: 12.8 ± 1.9; MPTP: 14.8 ± 2.6 mM,
p<0.01), GABA (Control: 2.8 ± 0.5; MPTP: 3.6 ± 0.7 mM, p<0.001), Gln (Control: 5.5 ± 1.4;
MPTP: 7.0 ± 2.9 mM, p<0.05), and MI (Control: 5.9 ± 0.9; MPTP: 6.7 ± 1.1 mM, p<0.01,
Figure 41B).
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Figure 41. Neurometabolite levels measured by 1H MRS in the striatum.
A. Spectra from example control and MPTP treated mice. Red horizontal lines
mark notable trends of elevated Glu (2.35 ppm) and Glx (3.75 ppm), while NAA
levels do not differ. B. Significantly increased concentrations of Glu (Control: 12.8
± 1.9; MPTP: 14.8 ± 2.6 mM, p<0.01), GABA (Control: 2.8 ± 0.5; MPTP: 3.6 ± 0.7 mM,
p<0.001), Gln (Control: 5.5 ± 1.4; MPTP: 7.0 ± 2.9 mM, p<0.05), and MI (Control: 5.9
± 0.9; MPTP: 6.7 ± 1.1 mM, p<0.01) were measured.

d. GluCEST MRI in the striatum and thalamus
Glutamate CEST (GluCEST) images clearly show the result of elevated glutamate in
the striatum following MPTP treatment (Figure 42A). This effect is specific to the slice
containing the striatum, whereas the GluCEST contrast in the thalamus is
indistinguishable between MPTP and control mice (Figure 42A-C). Indeed the average
GluCEST asymmetry (%) in the striatum was significantly elevated in the right (MPTP:
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26.1 ± 2.9, Control: 22.9 ± 2.5, p≤0.01), left (MPTP: 25.8 ± 2.8, Control: 22.9 ± 2.6, p≤0.01),
and average of both hemispheres (MPTP: 25.9 ± 2.8, Control: 22.9 ± 2.5, p≤0.01, Figure
42B). The average GluCEST asymmetry in the thalamus remained equal in MPTP and
control mice (MPTP: 25.8 ± 3.4, Control: 24.8 ± 3.3, p=0.46, Figure 42D).

Figure 42. GluCEST asymmetry in the striatum and thalamus of control and
MPTP treated mice.
(A, C) GluCEST maps from control and MPTP treated mice and corresponding
ROIs segmented in the striatum and thalamus. (B) Average GluCEST asymmetry
(%) in the striatum, including right, left, and combined hemispheres, was
significantly elevated in MPTP mice (**p≤0.01). (D) Average GluCEST asymmetry
in the thalamus was not significantly different between control and MPTP mice.
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e. IHC for dopaminergic neurons and GFAP
In the striatum, the intensity of TH immunostaining was reduced by 22.4% in MPTP
treated mice (Control: 106.9 ± 11.8 mean intensity, MPTP: 82.9 ± 11.7, p≤0.001, Figure
43C). The area occupied by TH immunostaining (%AOC) was further reduced by 32.4%
in the SNc (Control: 4.39 ± 0.91, MPTP: 2.96 ± 0.99, p≤0.01, Figure 43G). These results
indicate a loss of dopaminergic innervations in the striatum due to a loss of dopaminergic
neurons in the SNc.
The %AOC by GFAP immunostaining in the striatum was significantly increased in
MPTP treated mice (Control: 1.53 ± 2.49, MPTP: 7.75 ± 1.79, p≤0.001, Figure 44C). In
the thalamus the %AOC by GFAP was not significantly different between MPTP and
control mice (Control: 1.09 ± 0.29, MPTP: 0.87 ± 0.37, p=0.76, Figure 44F). These results
indicate the presence of astrogliosis in the striatum and not the thalamus following MPTP
treatment.
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Figure 43. IHC for tyrosine hydroxylase (TH) reveals a loss of dopaminergic
neurons in the striatum and SNc.
A. Images of the striatum where ROIs were selected in the right and left
hemispheres. B. The mean intensity was measured over the ROI after conversion
to a gray-level image. C. TH was significantly reduced in the MPTP striatum
(***p≤0.001). D. The SNc was located from a 2x image of the thalamus (E.) and a
snap-shot was taken at 10x. F. A threshold was set to segment the dark-brown
punctate stain, and reported as the %AOC. G. A significant reduction in TH was
also measured in MPTP mice (**p≤0.01).

117

Figure 44. IHC for GFAP reveals astrogliosis in the striatum but not in the
thalamus.
A, D. 3.5x images were taken in the striatum and thalamus. B, E. The DAB image
was extracted from the counterstained image using ImageJ color deconvolution.
ROIs were drawn around each hemisphere of the striatum and thalamus. C, F. The
amount of GFAP positive stain was quantified as the %AOC. A significant
elevation was measured in the MPTP striatum (***p≤0.001), while GFAP did not
differ in the thalamus.
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IV.

Discussion

a. GluCEST as a potential biomarker of elevated glutamate in PD
The clinical diagnosis of PD usually occurs after a substantial number of neurons in
the SNc have degenerated. A suitable biomarker would allow treatment with putative
neuroprotective agents to begin long before the significant and irreversible loss of neurons
and would enable the assessment of disease modification. There is a need for PD
biomarkers which include (1) prodromal or premotor stage biomarkers, (2) biomarkers of
risk or susceptibility, and (3) motor stage biomarkers.
The findings presented in this study provide the first application of GluCEST as a
potential biomarker for the early detection of PD in a preclinical model. GluCEST, a novel
MRI technique, has been reported to provide high spatial resolution imaging of small
decreases in the levels of Glu in the brain (Crescenzi et al., 2014; Haris et al., 2013a).
Here we have demonstrated the ability for GluCEST imaging to measure increases in Glu
in a location-specific manner in the MPTP mouse model of PD. GluCEST measured in
vivo was 13% higher in the MPTP striatum while no difference was measured in the
thalamus. This trend corroborates the increased Glu measured by MR spectroscopy in
vivo in the striatum.
Increased Glu in the striatum of MPTP mice is associated with two physiologic effects:
elevated extracellular Glu and the reactivity of glial cells. First, GluCEST contrast and the
Glu signal measured by 1H MRS are sensitive to the total concentration of Glu. However,
under normal physiologic conditions, the intracellular concentration of Glu (1-10 mmol/L)
far exceeds that of the extracellular concentration (up to 100 µmol/L during
neurotransmission). The contribution of extracellular Glu to the GluCEST signal is
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negligible in healthy mice. Anatomical studies in a rat model of PD and in Parkinson’s
patients reveals adaptive changes in striatal glutamatergic synapses suggestive of
increased synaptic activity (Anglade, 1996; Ingham et al., 1998; Meshul et al., 1999). This
change in glutamatergic synaptic function following DA denervation is confirmed by an
increase in the basal extracellular level of striatal Glu as determined by in vivo
microdialysis in a rat model of PD (Jonkers et al., 2002; Lindefors and Ungerstedt, 1990;
Meshul et al., 1999).
The elevation in GluCEST in the striatum of MPTP mice was found to be associated
with elevated GFAP immunostaining in this region; neither marker was increased in the
thalamus as a control region. The presence of GFAP indicates the activation or reactivity
of glial cells. Glial cells contain 6-10 mmol/L of Glu in healthy brain tissue (McKenna,
2007). Glial cells function in part to clear high concentrations of Glu from the extracellular
space in PD (Vila et al., 2001). As glial cells remove Glu from the extracellular space, the
glial contribution to total Glu levels would increase. Increased glial Glu concentration in
the striatum would be reflected in higher GluCEST values. Glial cells with GFAP reactivity
were previously reported to increase in number and size in response to MPTP toxicity
(Dervan et al., 2004). Although the glutamatergic transporter function may be
compromised in this model (Dervan et al., 2004), the effect of gliosis in the striatum as a
response to dopaminergic neuron loss in the SNc would also increase total Glu levels and
thereby GluCEST in the striatum.
V.

Summary
The goal of this study was to determine the potential for GluCEST MRI as a biomarker

of PD in a preclinical mouse model. A PD mouse model was created using the neurotoxin
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MPTP. MPTP causes specific loss of dopaminergic neurons in the substantia niagra pars
compacta which leads to decreased inhibitory signaling to the striatum and severe
increases in the primary excitatory neurotransmitter, glutamate. Motor function is severely
impaired in this model after the loss of dopaminergic neurons which was confirmed in this
study by the forepaw grip strength test and the four limb hanging test. GluCEST imaging
and 1H MRS were carried out in vivo in order to measure glutamate levels in the striatum
and thalamus. Immunostaining for tyrosine hydroxylase as a marker of dopaminergic
neurons and GFAP as a marker of glial cell reactivity was performed in the striatum and
thalamus. GluCEST was 13% higher in the MPTP striatum while no difference was
measured in the thalamus. This trend corroborates increased Glu measured by MR
spectroscopy in vivo in the striatum. GFAP immunostaining in the striatum was also
significantly increased in MPTP treated mice. The following are highlights from these
results:
•

GluCEST is capable of noninvasively measuring elevated glutamate levels in the
MPTP neurotoxin model of PD.

•

The high spatial resolution of GluCEST is advantageous as a potential biomarker
of PD whereas elevated glutamate levels are specific to the striatum.

•

Histological quantification of GFAP correlates with elevated glutamate measured
by GluCEST in the striatum and not in the thalamus of MPTP mice.
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Concluding statement: GluCEST is a promising biomarker of
neurodegeneration
This thesis focused on application of the GluCEST MRI method to preclinical models
of neurodegeneration. The first study presented in Chapter 2 utilized a well-characterized
mouse model of the amyloid-beta plaque pathology of Alzheimer’s disease in order to
highlight several advantages of GluCEST over 1H MRS. While the measurements of
glutamate levels by the two modalities were shown to correlate, the enhanced sensitivity
of GluCEST to glutamate changes as well as its ability to map glutamate levels throughout
the brain was exploited. Chapters 3-5 discuss a mouse model of tau pathology, and
investigate the underlying biochemical correlates to GluCEST contrast. Beginning in a
late-stage preliminary study, and continuing in a longitudinal study, synaptophysin
immunostaining was found to correlate spatially and temporally with the GluCEST
contrast. Before pathologic tau protein can be detected, GluCEST deficits and synapse
loss are measurable. This provides a promising early biomarker of tauopathies. Finally,
glial cell reactivity (by GFAP immunostaining) may indicate elevated glial glutamate, as
detected in vivo by GluCEST. This association was found to be true of later stages of
pathology in tauopathy mice and in the MPTP mouse model of Parkinson’s disease. These
findings exploit the ability of GluCEST to measure elevated glutamate in vivo, and provide
a basis for the hypothesis of alterations in the glutamate-glutamine cycle function in
astrocytes.
Results of this work demonstrate the utility of GluCEST imaging to study regional and
temporal

variations

in

glutamate

in

different

pathologies

associated

with

neurodegeneration. Translating the GluCEST technique to 7T human brain imaging is
already viable.
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ABREVIATIONS
1

H MRS
AD
ADNI
a-KG
AMPA
APP-PS1
ATP
CBD
Cho
CNS
Cr, Cre, tCr
CSF
CTE
DLB
DS
FDA
FDG-PET
FTD
FTDP-17
GABA
GDH
Gln
GLT-1/EAAT2,
EAAT1
Glu
GluR1
GRE
GS
IACUC
IHC
L-DOPA
MAO-B
MAPT
MCI
mGluR5
MI
MPP+
MPTP

Proton magnetic resonance spectroscopy
Alzheimer’s Disease
Alzheimer's Disease Neuroimaging Initiative
alpha-ketogluterate
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
amyloid precursor protein, presinilin-1; genes mutated in AD mouse
model
adenosine triphosphate
Corticobasal Degeneration
choline
central nervous system
total creatine
cerebral spinal fluid
Chronic Traumatic Encephalopathy
Dementia with Lewey bodies
direct saturation
Federal drug administration
fludeoxyglucose contrasst age for positron emission tomography
Frontotemporal dementia
Frontotemporal dementia with Parkinsonism linked to chromosome
17
gamma-aminobutyric acid
glutamate dehydrogenase
glutamine
glutamate transporter, excitatory amino acid
glutamate
glutamate receptor
gradient echo
glutamine synthetase
Institutional Animal Care and Use Committee
immunohistochemistry
L-3,4-dihydroxyphenylalanine
monoamine oxidase B enzyme
microtubule-associated protein
mild-cognitive impairment
metabotropic Glu receptor subtype 5
myo-inositol
methyl-4-phenylpyridinium
1-methyl-4-phenyl1,2,3,6-tetrahydropyridin
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MT
MTR
NAA
NFT(s)
NINCDS-NRDA
NMDA
NMR
PAG
PBS
PD
PET
PHF(s)
PiD
PSP
ROI(s)
SNc
SNR
TCA
TE
TR
VGlut
VTA
WT

magnetization transfer
magnetization transfer ratio
N-acetylaspartate
neurofibrillary tangles
National Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer's Disease and Related Disorders
Association
N-methyl D-aspartate glutamate receptor
nuclear magnetic resonance
phosphate-activated glutaminase
phosphate buffered saline
Parkinson's Disease
positron-emission tomography
paired helical filaments
Pick's disease
Progressive supranuclear palsy
region of interest
substantia nigra pars compacta
signal-to-noise ratio
tricarboxylic acid cycle
echo time
repetition time
vesicular glutamate transporter
ventral tegmental area
wild-type

124

BIBLIOGRAPHY

Adler, D.H., Pluta, J., Kadivar, S., Craige, C., Gee, J.C., Avants, B.B., Yushkevich, P. a.,
2014. Histology-derived volumetric annotation of the human hippocampal subfields
in postmortem MRI. Neuroimage 84, 505–523.
doi:10.1016/j.neuroimage.2013.08.067
Agdeppa, E.D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N., Petric, A., Cole,
G.M., Small, G.W., Huang, S.C., Barrio, J.R., 2001. Binding characteristics of
radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron
emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s
disease. J. Neurosci. 21, RC189.
Aguirre, J.A., Kehr, J., Yoshitake, T., Liu, F.-L., Rivera, A., Fernandez-Espinola, S.,
Andbjer, B., Leo, G., Medhurst, A.D., Agnati, L.F., Fuxe, K., 2005. Protection but
maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal
dopaminergic terminals in MPTP-lesioned mice after acute treatment with the
mGluR5 antagonist MPEP. Brain Res. 1033, 216–20.
doi:10.1016/j.brainres.2004.11.040
Alexander, G.E., 1994. Basal ganglia-thalamocortical circuits: their role in control of
movements. J. Clinical Neurophysiology. 11(4) 420-431.
Alonso, A.D., Zaidi, T., Novak, M., Grundke-Iqbal, I., Iqbal, K., 2001.
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical
filaments/straight filaments. Proc. Natl. Acad. Sci. U. S. A. 98, 6923–6928 ST.
Amadoro, G., Ciotti, M.T., Costanzi, M., Cestari, V., Calissano, P., Canu, N., 2006.
NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK
activation. Proc. Natl. Acad. Sci. U. S. A. 103, 2892–2897.
doi:10.1073/pnas.0511065103
Ambrosi, G., Cerri, S., Blandini, F., 2013. A further update on the role of excitotoxicity in
the pathogenesis of Parkinson’s disease. J. Neural Transm. 1–11.
doi:10.1007/s00702-013-1149-z
Anandhan, a., Janakiraman, U., Manivasagam, T., 2012. Theaflavin ameliorates
behavioral deficits, biochemical indices and monoamine transporters expression
against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
mouse model of Parkinson’s disease. Neuroscience 218, 257–267.
doi:10.1016/j.neuroscience.2012.05.039
Anglade, P., 1996. Synaptic Plasticity in the Caudate Nucleus of Patients with
Parkinson’s Disease. Neurodegeneration 5, 121–128. doi:10.1006/neur.1996.0018
125

Aronica, E., Dickson, D.W., Kress, Y., Morrison, J.H., Zukin, R.S., 1997. Non-plaque
dystrophic dendrites in Alzheimer hippocampus: A new pathological structure
revealed by glutamate receptor immunocytochemistry. Neuroscience 82, 979–991.
doi:10.1016/S0306-4522(97)00260-1
Bai, Y., Milne, J.S., Maybe, L., Englander, S.W., 1993. Primary Structure Effects on
Peptide Group Hydrogen Exchange. Proteins. 17, 75-86.
Bagga, P., Chugani, A.N., Varadarajan, K.S., Patel, A.B., 2013. In vivo NMR studies of
regional cerebral energetics in MPTP model of Parkinson’s disease: Recovery of
cerebral metabolism with acute levodopa treatment. J. Neurochem. 127, 365–377.
doi:10.1111/jnc.12407
Ballatore, C., Lee, V.M.-Y., Trojanowski, J.Q., 2007. Tau-mediated neurodegeneration in
Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. 8, 663–72.
doi:10.1038/nrn2194
Barger, S.W., Goodwin, M.E., Porter, M.M., Beggs, M.L., 2007. Glutamate release from
activated microglia requires the oxidative burst and lipid peroxidation. J.
Neurochem. 101, 1205–13. doi:10.1111/j.1471-4159.2007.04487.x
Battaglia, G., Busceti, C.L., Molinaro, G., Biagioni, F., Storto, M., Fornai, F., Nicoletti, F.,
Bruno, V., 2004. Endogenous activation of mGlu5 metabotropic glutamate
receptors contributes to the development of nigro-striatal damage induced by 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Neurosci. 24, 828–835.
doi:10.1523/JNEUROSCI.3831-03.2004
Beal, M.F., 2000. Energetics in the pathogenesis of neurodegenerative diseases. Trends
Neurosci. 23, 298–304.
Beal, M.F., 1998. Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis.
Ann. Neurol. 44, S110–S114.
Bell, K.F.S., Bennett, D. a, Cuello, a C., 2007. Paradoxical upregulation of glutamatergic
presynaptic boutons during mild cognitive impairment. J. Neurosci. 27, 10810–
10817. doi:10.1523/JNEUROSCI.3269-07.2007
Bellocchio, E.E., 2000. Uptake of Glutamate into Synaptic Vesicles by an Inorganic
Phosphate Transporter. Science. 289, 957–960. doi:10.1126/science.289.5481.957
Benjamin, A.M., Quastel, J.H., 1975. METABOLISM OF AMINO ACIDS AND AMMONIA
IN RAT BRAIN CORTEX SLICES IN VITRO: A POSSIBLE ROLE OF AMMONIA IN
BRAIN FUNCTION. J. Neurochem. 25, 197–206. doi:10.1111/j.14714159.1975.tb06953.x

126

Black, Y.D., Xiao, D., Pellegrino, D., Kachroo, A., Brownell, A.L., Schwarzschild, M. a.,
2010. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a
6-hydroxydopamine model of Parkinson’s disease. Neurosci. Lett. 486, 161–165.
doi:10.1016/j.neulet.2010.09.043
Blesa, J., Phani, S., Jackson-Lewis, V., Przedborski, S., 2012. Classic and new animal
models of Parkinson’s disease. J. Biomed. Biotechnol. 2012.
doi:10.1155/2012/845618
Boekhoorn, K., Terwel, D., Biemans, B., Borghgraef, P., Wiegert, O., Ramakers, G.J.A.,
de Vos, K., Krugers, H., Tomiyama, T., Mori, H., Joels, M., van Leuven, F.,
Lucassen, P.J., 2006. Improved long-term potentiation and memory in young tauP301L transgenic mice before onset of hyperphosphorylation and tauopathy. J.
Neurosci. 26, 3514–23. doi:10.1523/JNEUROSCI.5425-05.2006
Bottomley, P. a, 1987. Spatial localization in NMR spectroscopy in vivo. Ann. N. Y. Acad.
Sci. 508, 333–348. doi:10.1111/j.1749-6632.1987.tb32915.x
Braak, H., Braak, E., 1991. Neuropathological stageing of Alzheimer-related changes.
Acta Neuropathol. 82, 239–259. doi:10.1007/BF00308809
Cai, K., Haris, M., Singh, A., Kogan, F., Greenberg, J.H., Hariharan, H., Detre, J. a,
Reddy, R., 2012. Magnetic resonance imaging of glutamate. Nat. Med. 18, 302–6.
doi:10.1038/nm.2615
Chadwick, W., Mitchell, N., Caroll, J., Zhou, Y., Park, S.S., Wang, L., Becker, K.G.,
Zhang, Y., Lehrmann, E., Wood, W.H., Martin, B., Maudsley, S., 2011.
Amitriptyline-mediated cognitive enhancement in aged 3Tg Alzheimer’s disease
mice is associated with neurogenesis and neurotrophic activity. PLoS One 6.
doi:10.1371/journal.pone.0021660
Chan, K.W.Y., McMahon, M.T., Kato, Y., Liu, G., Bulte, J.W.M., Bhujwalla, Z.M.,
Artemov, D., Van Zijl, P.C.M., 2012. Natural D -glucose as a biodegradable MRI
contrast agent for detecting cancer. Magn. Reson. Med. 68, 1764–1773.
doi:10.1002/mrm.24520
Chan, P., DeLanney, L.E., Irwin, I., Langston, J.W., Di Monte, D., 1991. Rapid ATP loss
caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J.
Neurochem. 57, 348–51.
Chassain, C., Bielicki, G., Carcenac, C., Ronsin, A.C., Renou, J.P., Savasta, M., Durif,
F., 2013. Does MPTP intoxication in mice induce metabolite changes in the nucleus
accumbens? A 1H nuclear MRS study. NMR Biomed. 26, 336–347.
doi:10.1002/nbm.2853

127

Chassain, C., Bielicki, G., Durand, E., Lolignier, S., Essafi, F., Traoré, A., Durif, F., 2008.
Metabolic changes detected by proton magnetic resonance spectroscopy in vivo
and in vitro in a murin model of Parkinson’s disease, the MPTP-intoxicated mouse.
J. Neurochem. 105, 874–82. doi:10.1111/j.1471-4159.2007.05185.x
Chassain, C., Bielicki, G., Keller, C., Renou, J.-P., Durif, F., 2010. Metabolic changes
detected in vivo by 1H MRS in the MPTP-intoxicated mouse. NMR Biomed. 23,
547–53. doi:10.1002/nbm.1504
Chohan, M.O., Li, B., Blanchard, J., Tung, Y.C., Heaney, A.T., Rabe, A., Iqbal, K.,
Grundke-Iqbal, I., 2011. Enhancement of dentate gyrus neurogenesis, dendritic and
synaptic plasticity and memory by a neurotrophic peptide. Neurobiol. Aging 32,
1420–1434. doi:10.1016/j.neurobiolaging.2009.08.008
Chong, S.-A., Benilova, I., Shaban, H., De Strooper, B., Devijver, H., Moechars, D.,
Eberle, W., Bartic, C., Van Leuven, F., Callewaert, G., 2011. Synaptic dysfunction
in hippocampus of transgenic mouse models of Alzheimer’s disease: a multielectrode array study. Neurobiol. Dis. 44, 284–91. doi:10.1016/j.nbd.2011.07.006
Clare, R., King, V.G., Wirenfeldt, M., Vinters, H. V, 2011. NIH Public Access 88, 2083–
2090. doi:10.1002/jnr.22392.Synapse
Cleveland, D.W., Hwo, S.-Y., Kirschner, M.W., 1977. Purification of tau, a microtubuleassociated protein that induces assembly of microtubules from purified tubulin. J.
Mol. Biol. 116, 207–225. doi:10.1016/0022-2836(77)90213-3
Coyle, J.T., Puttfarcken, P., 2014. and Stress , Oxidative Disorders Neurodegenerative
262, 689–695.
Crescenzi, R., DeBrosse, C., Nanga, R.P.R., Reddy, S., Haris, M., Hariharan, H., Iba,
M., Lee, V.M.Y., Detre, J. a, Borthakur, A., Reddy, R., 2014. In vivo measurement
of glutamate loss is associated with synapse loss in a mouse model of tauopathy.
Neuroimage 101, 185–92. doi:10.1016/j.neuroimage.2014.06.067
D’Amelio, F., Eng, L.F., Gibbs, M.A., 1990. Glutamine synthetase immunoreactivity is
present in oligodendroglia of various regions of the central nervous system. Glia 3,
335–41. doi:10.1002/glia.440030504
Dagher, A.P., Aletras, A., Choyke, P., Balaban, R.S., 2000. Imaging of urea using
chemical exchange-dependent saturation transfer at 1.5 T. J. Magn. Reson.
Imaging 12, 745–748. doi:10.1002/1522-2586(200011)12:5<745::AIDJMRI12>3.0.CO;2-H
Danbolt, N.C., 2001. Glutamate uptake. Prog. Neurobiol. 65, 1–105. doi:10.1016/S03010082(00)00067-8
128

David, J.P., Ghozali, F., Fallet-Bianco, C., Wattez, a, Delaine, S., Boniface, B., Di
Menza, C., Delacourte, a, 1997. Glial reaction in the hippocampal formation is
highly correlated with aging in human brain. Neurosci. Lett. 235, 53–56.
De Lau, L.M.L., Breteler, M.M.B., 2006. Epidemiology of Parkinson’s disease. Lancet.
Neurol. 5, 525–35. doi:10.1016/S1474-4422(06)70471-9
DeKosky, S.T., Scheff, S.W., 1990. Synapse loss in frontal cortex biopsies in
Alzheimer’s disease: correlation with cognitive severity. Ann. Neurol. 27, 457–464.
doi:10.1002/ana.410270502
Dervan, A.G., Meshul, C.K., Beales, M., McBean, G.J., Moore, C., Totterdell, S., Snyder,
A.K., Meredith, G.E., 2004. Astroglial plasticity and glutamate function in a chronic
mouse model of Parkinson’s disease. Exp. Neurol. 190, 145–156.
doi:10.1016/j.expneurol.2004.07.004
Dewar, D., Chalmers, D.T., Graham, D.I., McCulloch, J., 1991. Glutamate metabotropic
and AMPA binding sites are reduced in Alzheimer’s disease: An autoradiographic
study of the hippocampus. Brain Res. 553, 58–64. doi:10.1016/00068993(91)90230-S
Dolphin A. C. and Archer E. R. (1983) An adenosine agonist inhibits and a cyclic GMP
analogue
enhances the release of glutamate but not GABA from slices of rat dentate gyrus.
Neurosci. Let. 43, 49-54.
Dong, H.-W., Swanson, L.W., Chen, L., Fanselow, M.S., Toga, A.W., 2009. Genomicanatomic evidence for distinct functional domains in hippocampal field CA1. Proc.
Natl. Acad. Sci. U. S. A. 106, 11794–11799. doi:10.1073/pnas.0812608106
Drechsel, D.N., Hyman, A.A., Cobb, M.H., Kirschner, M.W., 1992. Modulation of the
dynamic instability of tubulin assembly by the microtubule-associated protein tau.
Mol. Biol. Cell 3, 1141–54.
Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P.,
Cummings, J., Delocourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K.,
O’Brien, J., Pasquier, F., Robert, P., Rossor, M., Solloway, S., Stern, Y., Visser,
P.J., Scheltens, P., 2007. Research criteria for the diagnosis of Alzheimer"s
disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734–746 ST –
Research criteria for the diagnosis . doi:10.1016/s1474-4422(07)70178-3
Englander SW, Kallenbach NR. Hydrogen exchange and structural dynamics of proteins
and
nucleic acids. Q Rev Biophys 1984;16: 521–655.

129

Eriksson, P.S., Perfilieva, E., Björk-Eriksson, T., Alborn, a M., Nordborg, C., Peterson, D.
a, Gage, F.H., 1998. Neurogenesis in the adult human hippocampus. Nat. Med. 4,
1313–1317. doi:10.1038/3305
Fanselow, M.S., Dong, H.-W., 2010. Are the dorsal and ventral hippocampus functionally
distinct structures? Neuron 65, 7–19. doi:10.1016/j.neuron.2009.11.031
Fodero-Tavoletti, M.T., Furumoto, S., Taylor, L., McLean, C. a, Mulligan, R.S., Birchall,
I., Harada, R., Masters, C.L., Yanai, K., Kudo, Y., Rowe, C.C., Okamura, N.,
Villemagne, V.L., 2014. Assessing THK523 selectivity for tau deposits in
Alzheimer’s disease and non-Alzheimer's disease tauopathies. Alzheimers. Res.
Ther. 6, 11. doi:10.1186/alzrt240
Gazewood, J.D., Health, V., Clebak, K., Monticello, L., Care, P., 2013. Parkinson
Disease : An Update. Am. Fam. Physician 87, 267–273.
Gong, Y., Lippa, C.F., 2010. Review: disruption of the postsynaptic density in
Alzheimer’s disease and other neurodegenerative dementias. Am. J. Alzheimers.
Dis. Other Demen. 25, 547–555. doi:10.1177/1533317510382893
Greenamyre, J., Young, A., 1989. Excitatory amino acids and Alzheimer’s disease.
Neurobiol. Aging 10, 593–602.
Griffith, H.R., den Hollander, J. a, Okonkwo, O.C., O’Brien, T., Watts, R.L., Marson,
D.C., 2008. Brain metabolism differs in Alzheimer’s disease and Parkinson's
disease dementia. Alzheimers. Dement. 4, 421–427. doi:10.1016/j.jalz.2008.04.008
Gruetter, R., Seaquist, E.R., Kim, S., Uǧurbil, K., 1998. Localized in vivo 13C-NMR of
glutamate metabolism in the human brain: Initial results at 4 Tesla. Dev. Neurosci.
20, 380–388. doi:10.1159/000017334
Guevara, C. a., Blain, C.R., Stahl, D., Lythgoe, D.J., Leigh, P.N., Barker, G.J., 2010.
Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease,
progressive supranuclear palsy and multiple system atrophy. Eur. J. Neurol. 17,
1193–1202. doi:10.1111/j.1468-1331.2010.03010.x
Guivel-Scharen, V., Sinnwell, T., Wolff, S.D., Balaban, R.S., 1998. Detection of proton
chemical exchange between metabolites and water in biological tissues. J. Magn.
Reson. 133, 36–45. doi:10.1006/jmre.1998.1440
Hagberg, H., Lehmann, A., Sandberg, M., Nyström, B., Jacobson, I., Hamberger, A.,
1985. Ischemia-induced shift of inhibitory and excitatory amino acids from intra- to
extracellular compartments. J. Cereb. Blood Flow Metab. 5, 413–9.
doi:10.1038/jcbfm.1985.56

130

Haley, G.E., Kohama, S.G., Urbanski, H.F., Raber, J., 2010. Age-related decreases in
SYN levels associated with increases in MAP-2, apoE, and GFAP levels in the
rhesus macaque prefrontal cortex and hippocampus. Age (Omaha). 32, 283–296.
doi:10.1007/s11357-010-9137-9
Hamberger, A., Nyström, B., 1984. Extra- and intracellular amino acids in the
hippocampus during development of hepatic encephalopathy. Neurochem. Res. 9,
1181–92.
Haris, M., Cai, K., Singh, A., Hariharan, H., Reddy, R., 2011. In vivo mapping of brain
myo-inositol. Neuroimage 54, 2079–85. doi:10.1016/j.neuroimage.2010.10.017
Haris, M., Nath, K., Cai, K., Singh, A., Crescenzi, R., Kogan, F., Verma, G., Reddy, S.,
Hariharan, H., Melhem, E.R., Reddy, R., 2013a. Imaging of glutamate
neurotransmitter alterations in Alzheimer’s disease. NMR Biomed. 26, 386–91.
doi:10.1002/nbm.2875
Haris, M., Singh, A., Cai, K., Kogan, F., McGarvey, J., Debrosse, C., Zsido, G. a,
Witschey, W.R.T., Koomalsingh, K., Pilla, J.J., Chirinos, J. a, Ferrari, V. a, Gorman,
J.H., Hariharan, H., Gorman, R.C., Reddy, R., 2014a. A technique for in vivo
mapping of myocardial creatine kinase metabolism. Nat. Med. 20, 209–215.
doi:10.1038/nm.3436
Haris, M., Singh, A., Cai, K., Nath, K., Crescenzi, R., Kogan, F., Hariharan, H., Reddy,
R., 2013b. MICEST: a potential tool for non-invasive detection of molecular
changes in Alzheimer’s disease. J. Neurosci. Methods 212, 87–93.
doi:10.1016/j.jneumeth.2012.09.025
Haris, M., Singh, A., Mohammed, I., Ittyerah, R., Nath, K., Nanga, R.P.R., Debrosse, C.,
Kogan, F., Cai, K., Poptani, H., Reddy, D., Hariharan, H., Reddy, R., 2014b. In vivo
magnetic resonance imaging of tumor protease activity. Sci. Rep. 4, 6081.
doi:10.1038/srep06081
Hattori, N., Abe, C.A.K., Sakoda, S., Sawada, T., 2002. Proton MR spectroscopic study
at 3 T esla on glutamate / glutamine in Alzheimer ’ s disease. Rev. Lit. Arts Am. 13,
7–10.
Hertz, L., Dringen, R., Schousboe, A., Robinson, S.R., 1999. Mini-Review Astrocytes :
Glutamate Producers for Neurons 428, 417–428.
Hogstad, S., Svenneby, G., Torgner, I.A., Kvamme, E., Hertz, L., Schousboe, A., 1988.
Glutaminase in neurons and astrocytes cultured from mouse brain: kinetic
properties and effects of phosphate, glutamate, and ammonia. Neurochem. Res.
13, 383–8.

131

Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L. a., Grant, M.K., Pitstick, R.,
Carlson, G. a., Lanier, L.M., Yuan, L.L., Ashe, K.H., Liao, D., 2010. Tau
Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of
Neurodegeneration. Neuron 68, 1067–1081. doi:10.1016/j.neuron.2010.11.030
Hunsberger, H.C., Rudy, C.C., Batten, S.R., Gerhardt, G. a., Reed, M.N., 2015. P301L
tau expression affects glutamate release and clearance in the hippocampal
trisynaptic pathway. J. Neurochem. 132, 169–182. doi:10.1111/jnc.12967
Hurtado, D.E., Molina-Porcel, L., Iba, M., Aboagye, A.K., Paul, S.M., Trojanowski, J.Q.,
Lee, V.M.-Y., 2010. A{beta} accelerates the spatiotemporal progression of tau
pathology and augments tau amyloidosis in an Alzheimer mouse model. Am. J.
Pathol. 177, 1977–88. doi:10.2353/ajpath.2010.100346
Ingham, C. a, Hood, S.H., Taggart, P., Arbuthnott, G.W., 1998. Plasticity of synapses in
the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway.
J. Neurosci. 18, 4732–43.
Jackson-Lewis, V., Przedborski, S., 2007. Protocol for the MPTP mouse model of
Parkinson’s disease. Nat. Protoc. 2, 141–51. doi:10.1038/nprot.2006.342
Jacob, C.P., Koutsilieri, E., Bartl, J., Neuen-Jacob, E., Arzberger, T., Zander, N., Ravid,
R., Roggendorf, W., Riederer, P., Grünblatt, E., 2007. Alterations in expression of
glutamatergic transporters and receptors in sporadic Alzheimer’s disease. J.
Alzheimers. Dis. 11, 97–116.
James, B.D., Leurgans, S.E., Hebert, L.E., Scherr, P. a, Yaffe, K., Bennett, D. a, 2014.
Contribution of Alzheimer disease to mortality in the United States. Neurology 82,
1045–1050. doi:10.1212/WNL.0000000000000240
Jansen, K.L.R. et al., 1990. Autoradiographic k. l. r. Neuroscience 39, 613–627.
Jicha, G.A., Nelson, P.T., 2011. Management of frontotemporal dementia: targeting
symptom management in such a heterogeneous disease requires a wide range of
therapeutic options. Neurodegener. Dis. Manag. doi:10.2217/nmt.11.9
Jin, K., Galvan, V., Xie, L., Mao, X.O., Gorostiza, O.F., Bredesen, D.E., Greenberg, D. a,
2004a. Enhanced neurogenesis in Alzheimer’s disease transgenic (PDGFAPPSw,Ind) mice. Proc. Natl. Acad. Sci. U. S. A. 101, 13363–13367.
doi:10.1073/pnas.0403678101
Jin, K., Peel, A.L., Mao, X.O., Xie, L., Cottrell, B. a, Henshall, D.C., Greenberg, D. a,
2004b. Increased hippocampal neurogenesis in Alzheimer’s disease. Proc. Natl.
Acad. Sci. U. S. A. 101, 343–347. doi:10.1073/pnas.2634794100

132

Jin, T., Wang, P., Zong, X., Kim, S.G., 2013. MR imaging of the amide-proton transfer
effect and the pH-insensitive nuclear overhauser effect at 9.4 T. Magn. Reson.
Med. 69, 760–770. doi:10.1002/mrm.24315
Johnson, G.A., Ali-Sharief, A., Badea, A., Brandenburg, J., Cofer, G., Fubara, B.,
Gewalt, S., Hedlund, L.W., Upchurch, L., 2007. High-throughput morphologic
phenotyping of the mouse brain with magnetic resonance histology. Neuroimage
37, 82–9. doi:10.1016/j.neuroimage.2007.05.013
Johnson, G.A., Badea, A., Brandenburg, J., Cofer, G., Fubara, B., Liu, S., Nissanov, J.,
2010. Waxholm space: an image-based reference for coordinating mouse brain
research. Neuroimage 53, 365–72. doi:10.1016/j.neuroimage.2010.06.067
Jones, C.K., Schlosser, M.J., van Zijl, P.C.M., Pomper, M.G., Golay, X., Zhou, J., 2006.
Amide proton transfer imaging of human brain tumors at 3T. Magn. Reson. Med.
56, 585–92.
Jonkers, N., Sarre, S., Ebinger, G., Michotte, Y., 2002. MK801 suppresses the L-DOPAinduced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res. 926,
149–155. doi:10.1016/S0006-8993(01)03147-X
Kantarci, K., Boeve, B.F., Wszolek, Z.K., Rademakers, R., Whitwell, J.L., Baker, M.C.,
Senjem, M.L., Samikoglu, a R., Knopman, D.S., Petersen, R.C., Jack, C.R., 2010.
MRS in presymptomatic MAPT mutation carriers: a potential biomarker for taumediated pathology. Neurology 75, 771–8. doi:10.1212/WNL.0b013e3181f073c7
Kantarci, K., Jack Jr., C.R., 2003. Neuroimaging in Alzheimer disease: an evidencebased review. Neuroimaging Clin N Am 13, 197–209.
Kantarci, K., Petersen, R.C., Boeve, B.F., Knopman, D.S., Tang-Wai, D.F., O’Brien,
P.C., Weigand, S.D., Edland, S.D., Smith, G.E., Ivnik, R.J., Ferman, T.J., Tangalos,
E.G., Jack, C.R., 2004. H-1 MR spectroscopy in common dementias. Neurology 63,
1393–1398.
Kantarci, K., Weigand, S.D., Petersen, R.C., Boeve, B.F., Knopman, D.S., Gunter, J.,
Reyes, D., Shiung, M., O’Brien, P.C., Smith, G.E., Ivnik, R.J., Tangalos, E.G., Jack,
C.R., 2007. Longitudinal H-1 MRS changes in mild cognitive impairment and
Alzheimer’s disease. Neurobiol. Aging 28, 1330–1339.
doi:10.1016/j.neurobiolaging.2006.06.018
Kashani, A., Lepicard, È., Poirel, O., Videau, C., David, J.P., Fallet-Bianco, C., Simon,
A., Delacourte, A., Giros, B., Epelbaum, J., Betancur, C., El Mestikawy, S., 2008.
Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive
decline in Alzheimer disease. Neurobiol. Aging 29, 1619–1630.
doi:10.1016/j.neurobiolaging.2007.04.010
133

Kirvell, S.L., Esiri, M., Francis, P.T., 2006. Down-regulation of vesicular glutamate
transporters precedes cell loss and pathology in Alzheimer’s disease. J.
Neurochem. 98, 939–950. doi:10.1111/j.1471-4159.2006.03935.x
Kjelstrup, K.B., Solstad, T., Brun, V.H., Hafting, T., Witter, M.P., Moser, E.I., Moser, M.,
Kjelstrup, K.B., Solstad, T., Brun, V.H., Hafting, T., 2008. Finite Scale of Spatial
Representation in the Hippocampus. Science (80-. ). 321, 140–143.
Kogan, F., Haris, M., Debrosse, C., Singh, A., Nanga, R.P., Cai, K., Hariharan, H.,
Reddy, R., 2014. In vivo chemical exchange saturation transfer imaging of creatine
(CrCEST) in skeletal muscle at 3T. J. Magn. Reson. Imaging 40, 596–602.
doi:10.1002/jmri.24412
Kohama, S.G., Goss, J.R., Finch, C.E., McNeill, T.H., 1995. Increases of glial fibrillary
acidic protein in the aging female mouse brain. Neurobiol. Aging 16, 59–67.
Komori, T., 1999. Tau-positive dial Inclusions in Progressive Supranuclear Palsy,
Corticobasal Degeneration and Pick’s Disease. Brain Pathol. 9, 663–679.
doi:10.1111/j.1750-3639.1999.tb00549.x
Kulak, A., Duarte, J.M.N., Do, K.Q., Gruetter, R., 2010. Neurochemical profile of the
developing mouse cortex determined by in vivo1H NMR spectroscopy at 14.1 T and
the effect of recurrent anaesthesia. J. Neurochem. 115, 1466–1477.
doi:10.1111/j.1471-4159.2010.07051.x
Kvamme, E., Svenneby, G., Hertz, L., Schousboe, A., 1982. Properties of phosphate
activated glutaminase in astrocytes cultured from mouse brain. Neurochem. Res. 7,
761–70.
Lakis, N., Corona, R.J., Toshkezi, G., Chin, L.S., 2013. Chronic traumatic
encephalopathy - neuropathology in athletes and war veterans. Neurol. Res. 35,
290–9. doi:10.1179/1743132813Y.0000000177
Lange, K.W., Löschmann, P.A., Sofic, E., Burg, M., Horowski, R., Kalveram, K.T.,
Wachtel, H., Riederer, P., 1993. The competitive NMDA antagonist CPP protects
substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn.
Schmiedebergs. Arch. Pharmacol. 348, 586–92.
Lee, V.M.Y., Goedert, M., Trojanowski, J.Q., 2001. Neurodegenerative tauopathies.
Annu. Rev. Neurosci. 24, 1121–1159.
Lee, Y.B., Du, S., Rhim, H., Lee, E.B., Markelonis, G.J., Oh, T.H., 2000. Rapid increase
in immunoreactivity to GFAP in astrocytes in vitro induced by acidic pH is mediated
by calcium influx and calpain I. Brain Res. 864, 220–229. doi:10.1016/S00068993(00)02180-6
134

Lehmann, A., Isacsson, H., Hamberger, A., 1983. Effects of In Vivo Administration of
Kainic Acid on the Extracellular Amino Acid Pool in the Rabbit Hippocampus. J.
Neurochem. 40, 1314–1320. doi:10.1111/j.1471-4159.1983.tb13572.x
Leung, K.K., Malone, I.M., Ourselin, S., Gunter, J.L., Bernstein, M. a., Thompson, P.M.,
Jack, C.R., Weiner, M.W., Fox, N.C., 2015. Effects of changing from nonaccelerated to accelerated MRI for follow-up in brain atrophy measurement.
Neuroimage 107, 46–53. doi:10.1016/j.neuroimage.2014.11.049
Lindefors, N., Ungerstedt, U., 1990. Bilateral regulation of glutamate tissue and
extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci.
Lett. 115, 248–252. doi:10.1016/0304-3940(90)90463-J
Ling, W., Regatte, R.R., Navon, G., Jerschow, A., 2008. Assessment of
glycosaminoglycan concentration in vivo by chemical exchange-dependent
saturation transfer (gagCEST). Proc. Natl. Acad. Sci. U. S. A. 105, 2266–70.
doi:10.1073/pnas.0707666105
Liu, G., Gilad, A. a, Bulte, J.W.M., Zijl, P.C.M. Van, Mcmahon, M.T., 2010. NIH Public
Access. Media 5, 162–170. doi:10.1002/cmmi.383.
Lynch, M.A., Introduction, I., Erk, B., Potentiation, L., Age, D., Cognition, E., Potentiation,
L., 2004. Long-Term Potentiation and Memory 87–136.
Mandal, P.K., Akolkar, H., Tripathi, M., 2012, Mapping of Hippocampal pH and
Neurochemicals from in vivo Multi-Voxel 31P Study in Healthy Normal Young
Male/Female, Mild Cognitive Impairment, and Alzheimer's Disease. J. Alzheimer's
Disease. 29, 1-12. doi: 10.3233/JAD-2012-120166.
Marini, A.M., Lipsky, R.H., Schwartz, J.P., Kopin, I.J., 1992. Accumulation of 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine in cultured cerebellar astrocytes. J. Neurochem.
58, 1250–8.
Marjanska, M., Curran, G.L., Wengenack, T.M., Henry, P.G., Bliss, R.L., Poduslo, J.F.,
Jack Jr., C.R., Ugurbil, K., Garwood, M., 2005. Monitoring disease progression in
transgenic mouse models of Alzheimer’s disease with proton magnetic resonance
spectroscopy. Proc Natl Acad Sci U S A 102, 11906–10.
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R.,
Trojanowski, J.Q., Lee, V.M.-Y., Ono, M., Masamoto, K., Takano, H., Sahara, N.,
Iwata, N., Okamura, N., Furumoto, S., Kudo, Y., Chang, Q., Saido, T.C.,
Takashima, A., Lewis, J., Jang, M.-K., Aoki, I., Ito, H., Higuchi, M., 2013. Imaging of
tau pathology in a tauopathy mouse model and in Alzheimer patients compared to
normal controls. Neuron 79, 1094–108. doi:10.1016/j.neuron.2013.07.037

135

McConnell HM. Reaction rates by nuclear magnetic resonance. J Chem Phys
1958;28:430–
431.18.
McCord, J.M., 1985. Oxygen-derived Free Radicals in Postischemic Tissue Injury. N.
Engl. J. Med. 312, 159–163.
McKee, A.C., Cantu, R.C., Nowinski, C.J., Hedley-Whyte, E.T., Gavett, B.E., Budson,
A.E., Santini, V.E., Lee, H.-S., Kubilus, C.A., Stern, R.A., 2009. Chronic traumatic
encephalopathy in athletes: progressive tauopathy after repetitive head injury. J.
Neuropathol. Exp. Neurol. 68, 709–35. doi:10.1097/NEN.0b013e3181a9d503
McKenna, M.C., 2007. The glutamate-glutamine cycle is not stoichiometric: fates of
glutamate in brain. J. Neurosci. Res. 85, 3347–58. doi:10.1002/jnr.21444
McNaught, K.S.., Jenner, P., 2000. Extracellular accumulation of nitric oxide, hydrogen
peroxide, and glutamate in astrocytic cultures following glutathione depletion,
complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem.
Pharmacol. 60, 979–988. doi:10.1016/S0006-2952(00)00415-9
Meredith, G.E., Rademacher, D.J., 2011. MPTP mouse models of Parkinson’s disease:
an update. J. Parkinsons. Dis. 1, 19–33. doi:10.3233/JPD-2011-11023
Meredith, G.E., Totterdell, S., Beales, M., Meshul, C.K., 2009. Impaired glutamate
homeostasis and programmed cell death in a chronic MPTP mouse model of
Parkinson’s disease. Exp. Neurol. 219, 334–40.
doi:10.1016/j.expneurol.2009.06.005
Meshul, C.K., Emre, N., Nakamura, C.M., Allen, C., Donohue, M.K., Buckman, J.F.,
1999. Time-dependent changes in striatal glutamate synapses following a 6hydroxydopamine lesion. Neuroscience 88, 1–16. doi:10.1016/S03064522(98)00189-4
Mlynárik, V., Cacquevel, M., Sun-Reimer, L., Janssens, S., Cudalbu, C., Lei, H.,
Schneider, B.L., Aebischer, P., Gruetter, R., 2012. Proton and phosphorus
magnetic resonance spectroscopy of a mouse model of Alzheimer’s disease. J.
Alzheimers. Dis. 31 Suppl 3, S87–99. doi:10.3233/JAD-2012-112072
Morales, I., Rodriguez, M., 2012. Self-induced accumulation of glutamate in striatal
astrocytes and basal ganglia excitotoxicity. Glia 60, 1481–94.
doi:10.1002/glia.22368
Mu, L., Schubiger, P.A., Ametamey, S.M., 2010. Radioligands for the PET Imaging of
Metabotropic Glutamate Receptor Subtype 5 (mGluR5). Curr. Top. Med. Chem. 10,
1558–1568.
136

Mu, Y., Gage, F.H., 2011. Adult hippocampal neurogenesis and its role in Alzheimer’s
disease. Mol. Neurodegener. 6, 85. doi:10.1186/1750-1326-6-85
Murphy, S.L., Xu, J., Kochanek, K.D., 2013. Deaths: final data for 2010. Natl. Vital Stat.
Rep. 61, 1–117. doi:May 8, 2013
Nicholls, D.G., Budd, S.L., 1998. Mitochondria and neuronal glutamate excitotoxicity.
Biochim. Biophys. Acta - Bioenerg. 1366, 97–112. doi:10.1016/S00052728(98)00123-6
Nicoll, R. a, Schmitz, D., 2005. Synaptic plasticity at hippocampal mossy fibre synapses.
Nat. Rev. Neurosci. 6, 863–876. doi:10.1038/nrn1786
Norenberg, M.D., Martinez-Hernandez, A., 1979. Fine structural localization of glutamine
synthetase in astrocytes of rat brain. Brain Res. 161, 303–310. doi:10.1016/00068993(79)90071-4
Novelli, A., Reilly, J.A., Lysko, P.G., Henneberry, R.C., 1988. Glutamate becomes
neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels
are reduced. Brain Res. 451, 205–12.
Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., Lanciego, J.L., Artieda, J., Gonzalo,
N., Olanow, C.W., 2000. Pathophysiology of the basal ganglia in Parkinson’s
disease. Trends Neurosci. 23, S8–S19. doi:10.1016/S1471-1931(00)00028-8
Öz, G., Terpstra, M., Tkáč, I., Aia, P., Lowary, J., Tuite, P.J., Gruetter, R., 2006. Proton
MRS of the unilateral substantia nigra in the human brain at 4 tesla: Detection of
high GABA concentrations. Magn. Reson. Med. 55, 296–301.
doi:10.1002/mrm.20761
Pellegrino, D., Cicchetti, F., Wang, X., Zhu, A., Yu, M., Saint-Pierre, M., Brownell, A.-L.,
2007. Modulation of dopaminergic and glutamatergic brain function: PET studies on
parkinsonian rats. J. Nucl. Med. 48, 1147–53. doi:10.2967/jnumed.106.037796
Pennanen, L., Wolfer, D.P., Nitsch, R.M., Götz, J., 2006. Impaired spatial reference
memory and increased exploratory behavior in P301L tau transgenic mice. Genes,
Brain Behav. 5, 369–379. doi:10.1111/j.1601-183X.2005.00165.x
Penney, J.B., Maragos, W.F., Greenamyre, J.T., Debowey, D.L., Hollingsworth, Z.,
Young, a B., 1990. Excitatory amino acid binding sites in the hippocampal region of
Alzheimer’s disease and other dementias. J. Neurol. Neurosurg. Psychiatry 53,
314–320.
Pfeuffer, J., Tkác, I., Provencher, S.W., Gruetter, R., 1999. Toward an in vivo
neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR
spectra of the rat brain. J. Magn. Reson. 141, 104–20. doi:10.1006/jmre.1999.1895
137

Provencher, S.W., 2001. Automatic quantitation of localized in vivo 1 H spectra with
LCModel. NMR Biomed. 260–264. doi:10.1002/nbm.698
Puoliväli, J., Wang, J., Heikkinen, T., Heikkilä, M., Tapiola, T., van Groen, T., Tanila, H.,
2002. Hippocampal A beta 42 levels correlate with spatial memory deficit in APP
and PS1 double transgenic mice. Neurobiol. Dis. 9, 339–347.
doi:10.1006/nbdi.2002.0481
Ramsay, R.R., Dadgar, J., Trevor, A., Singer, T.P., 1986. Energy-driven uptake of Nmethyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP.
Life Sci. 39, 581–8.
Ratnavalli, E., Brayne, C., Dawson, K., Hodges, J.R., 2002. The prevalence of
frontotemporal 184–188.
Risold, P.Y., Swanson, L.W., 1996. Structural evidence for functional domains in the rat
hippocampus. Science 272, 1484–1486. doi:10.1126/science.272.5267.1484
Robinson, J.L., Molina-Porcel, L., Corrada, M.M., Raible, K., Lee, E.B., Lee, V.M.-Y.,
Kawas, C.H., Trojanowski, J.Q., 2014. Perforant path synaptic loss correlates with
cognitive impairment and Alzheimer’s disease in the oldest-old. Brain 137, 2578–
87. doi:10.1093/brain/awu190
Rosness, T.A., Haugen, P.K., Passant, U., Engedal, K., 2008. Frontotemporal dementia
–– a clinically complex diagnosis 837–842. doi:10.1002/gps
Ruifrok AC, Johnston DA. Quantification of histochemical staining by color
deconvolution.
Analytical & Quantitative Cytology & Histology 2001; 23: 291-299.
Rupsingh, R., Borrie, M., Smith, M., Wells, J.L., Bartha, R., 2011. Reduced hippocampal
glutamate in Alzheimer disease. Neurobiol. Aging 32, 802–10.
doi:10.1016/j.neurobiolaging.2009.05.002
Sanchez-Pernaute, R., Wang, J.-Q., Kuruppu, D., Cao, L., Tueckmantel, W., Kozikowski,
A., Isacson, O., Brownell, A.-L., 2008. Enhanced binding of metabotropic glutamate
receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates.
Neuroimage 42, 248–51. doi:10.1016/j.neuroimage.2008.04.170
Sasaki, K., Shimura, H., Itaya, M., Tanaka, R., Mori, H., Mizuno, Y., Kosik, K.S., Tanaka,
S., Hattori, N., 2009. Excitatory amino acid transporter 2 associates with
phosphorylated tau and is localized in neurofibrillary tangles of tauopathic brains.
FEBS Lett. 583, 2194–200. doi:10.1016/j.febslet.2009.06.015
Schousboe, a, 1981. Transport and metabolism of glutamate and GABA in neurons are
glial cells., International review of neurobiology.
138

Schousboe, A., Hertz, L., Svenneby, G., Kvamme, E., 1979. PHOSPHATE ACTIVATED
GLUTAMINASE ACTIVITY AND GLUTAMINE UPTAKE IN PRIMARY CULTURES
OF ASTROCYTES. J. Neurochem. 32, 943–950. doi:10.1111/j.14714159.1979.tb04579.x
Sherry, a D., Woods, M., 2008. Chemical exchange saturation transfer contrast agents
for magnetic resonance imaging. Annu. Rev. Biomed. Eng. 10, 391–411.
doi:10.1146/annurev.bioeng.9.060906.151929
Singh, A., Cai, K., Haris, M., Hariharan, H., Reddy, R., 2013. On B1 inhomogeneity
correction of in vivo human brain glutamate chemical exchange saturation transfer
contrast at 7T. Magn. Reson. Med. 69, 818–824. doi:10.1002/mrm.24290
Singh, A., Haris, M., Cai, K., Kassey, V.B., Kogan, F., Reddy, D., Hariharan, H., Reddy,
R., 2012. Chemical exchange saturation transfer magnetic resonance imaging of
human knee cartilage at 3 T and 7 T. Magn. Reson. Med. 68, 588–94.
doi:10.1002/mrm.23250
Snyder, J.S., Radik, R., Wojtowicz, J.M., Cameron, H. a., 2009. Anatomical gradients of
adult neurogenesis and activity: Young neurons in the ventral dentate gyrus are
activated by water maze training. Hippocampus 19, 360–370.
doi:10.1002/hipo.20525
Snyder, J.S., Ramchand, P., Rabbett, S., Radik, R., Wojtowicz, J.M., Cameron, H. a,
2011. Septo-temporal gradients of neurogenesis and activity in 13-month-old rats.
Neurobiol. Aging 32, 1149–56. doi:10.1016/j.neurobiolaging.2009.05.022
Spampanato, J., Sullivan, R.K., Turpin, F.R., Bartlett, P.F., Sah, P., 2012. Properties of
doublecortin expressing neurons in the adult mouse dentate gyrus. PLoS One 7,
e41029. doi:10.1371/journal.pone.0041029
Srinivasan, R., Vigneron, D., Sailasuta, N., Hurd, R., Nelson, S., 2004. A comparative
study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H
proton spectroscopic imaging of the human brain. Magn. Reson. Imaging 22, 523–
528. doi:10.1016/j.mri.2004.01.028
Staresina, B.P., Fell, J., Do Lam, A.T. a, Axmacher, N., Henson, R.N., 2012. Memory
signals are temporally dissociated in and across human hippocampus and
perirhinal cortex. Nat. Neurosci. 15, 1167–1173. doi:10.1038/nn.3154
Stayte, S., Vissel, B., 2014. Advances in non-dopaminergic treatments for Parkinson’s
disease. Front. Neurosci. 8, 113. doi:10.3389/fnins.2014.00113
Strange, B. a., Witter, M.P., Lein, E.S., Moser, E.I., 2014. Functional organization of the
hippocampal longitudinal axis. Nat. Rev. Neurosci. 15, 655–669.
doi:10.1038/nrn3785
139

Sun, P.Z., Farrar, C.T., Sorensen, a G., 2007. Correction for artifacts induced by B(0)
and B(1) field inhomogeneities in pH-sensitive chemical exchange saturation
transfer (CEST) imaging. Magn. Reson. Med. 58, 1207–15. doi:10.1002/mrm.21398
Tansey, F.A., Farooq, M., Cammer, W., 1991. Glutamine Synthetase in
Oligodendrocytes and Astrocytes: New Biochemical and Immunocytochemical
Evidence. J. Neurochem. 56, 266–272. doi:10.1111/j.1471-4159.1991.tb02591.x
Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A.,
Katzman, R., 1991. Physical basis of cognitive alterations in Alzheimer’s disease:
synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572–
80. doi:10.1002/ana.410300410
Thibodeau, B.M., Rajaram, B.R.D., Lanctôt, K.L., 2009. An Evolution of the Diagnostic
Criteria for Tauopathies Behavioral and Psychological Symptoms of Frontotemporal
Dementia : A Review of People with Frontotemporal The Impact of a Community
Day Program on the Lives of Patients with Frontotemporal Dementia On the Cover
… 12.
Thompson, C.L., Pathak, S.D., Jeromin, A., Ng, L.L., MacPherson, C.R., Mortrud, M.T.,
Cusick, A., Riley, Z.L., Sunkin, S.M., Bernard, A., Puchalski, R.B., Gage, F.H.,
Jones, A.R., Bajic, V.B., Hawrylycz, M.J., Lein, E.S., 2008. Genomic Anatomy of
the Hippocampus. Neuron 60, 1010–1021. doi:10.1016/j.neuron.2008.12.008
Turski, L., Bressler, K., Rettig, K.J., Löschmann, P.A., Wachtel, H., 1991. Protection of
substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
Nature 349, 414–8. doi:10.1038/349414a0
Van Zijl, P.C.M., Jones, C.K., Ren, J., Malloy, C.R., Sherry, a D., 2007. MRI detection of
glycogen in vivo by using chemical exchange saturation transfer imaging
(glycoCEST). Proc. Natl. Acad. Sci. U. S. A. 104, 4359–64.
doi:10.1073/pnas.0700281104
Van Zijl, P.C.M., Yadav, N.N., 2011. Chemical exchange saturation transfer (CEST):
What is in a name and what isn’t? Magn. Reson. Med. 65, 927–948.
doi:10.1002/mrm.22761
Van Zijl, P.C.M., Zhou, J., Mori, N., Payen, J.F., Wilson, D., Mori, S., 2003. Mechanism
of magnetization transfer during on-resonance water saturation. A new approach to
detect mobile proteins, peptides, and lipids. Magn. Reson. Med. 49, 440–449.
doi:10.1002/mrm.10398
Vemuri, P., Whitwell, J.L., Kantarci, K., Josephs, K.A., Parisi, J.E., Shiung, M.S.,
Knopman, D.S., Boeve, B.F., Petersen, R.C., Dickson, D.W., Jack, C.R., 2008.
Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate
140

with postmortem Braak neurofibrillary tangle stage. Neuroimage 42, 559–567 ST –
Antemortem MRI based STructural Abno. doi:10.1016/j.neuroimage.2008.05.012
Vercruysse, S., Gilat, M., Shine, J.M., Heremans, E., Lewis, S., Nieuwboer, A., 2014.
Freezing beyond gait in Parkinson’s disease: a review of current neurobehavioral
evidence. Neurosci. Biobehav. Rev. 43, 213–27.
doi:10.1016/j.neubiorev.2014.04.010
Vila, M., Jackson-Lewis, V., Guégan, C., Wu, D.C., Teismann, P., Choi, D.K., Tieu, K.,
Przedborski, S., 2001. The role of glial cells in Parkinson’s disease. Curr. Opin.
Neurol. 14, 483–489. doi:10.1097/00019052-200108000-00009
Villemagne, V.L., Pike, K.E., Darby, D., Maruff, P., Savage, G., Ng, S., Ackermann, U.,
Cowie, T.F., Currie, J., Chan, S.G., Jones, G., Tochon-Danguy, H., O’Keefe, G.,
Masters, C.L., Rowe, C.C., 2008. Abeta deposits in older non-demented individuals
with cognitive decline are indicative of preclinical Alzheimer’s disease.
Neuropsychologia 46, 1688–97. doi:10.1016/j.neuropsychologia.2008.02.008
Vion-Dury, J., Rochefort, N., Michotey, P., Planche, D., Ceccaldi, M., 2004. Proton
magnetic resonance neurospectroscopy and EEG cartography in corticobasal
degeneration: correlations with neuropsychological signs. J. Neurol. Neurosurg.
Psychiatry 75, 1352–1355. doi:10.1136/jnnp.2003.018903
Walker-Samuel, S., Ramasawmy, R., Torrealdea, F., Rega, M., Rajkumar, V., Johnson,
S.P., Richardson, S., Gonçalves, M., Parkes, H.G., Årstad, E., Thomas, D.L.,
Pedley, R.B., Lythgoe, M.F., Golay, X., Arstad, E., 2013. In vivo imaging of glucose
uptake and metabolism in tumors. Nat. Med. 19, 1067–72. doi:10.1038/nm.3252
Wang, M., Singh, C., Liu, L., Irwin, R.W., Chen, S., Chung, E.J., Thompson, R.F., Ming,
J., Singh, C., Liu, L., Irwin, R.W., Chen, S., Ji, E., 2010. Correction for Wang et al.,
Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of
Alzheimer’s disease 107, 11145. doi:10.1073/pnas.1006236107
Ward, K.M., Aletras, a H., Balaban, R.S., 2000. A new class of contrast agents for MRI
based on proton chemical exchange dependent saturation transfer (CEST). J.
Magn. Reson. 143, 79–87. doi:10.1006/jmre.1999.1956
Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Green, R.C.,
Harvey, D., Jack, C.R., Jagust, W., Liu, E., Morris, J.C., Petersen, R.C., Saykin,
A.J., Schmidt, M.E., Shaw, L., Siuciak, J.A., Soares, H., Toga, A.W., Trojanowski,
J.Q., 2012. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers
published since its inception. Alzheimers. Dement. 8, S1–68.
doi:10.1016/j.jalz.2011.09.172

141

Wen, Z., Hu, S., Huang, F., Wang, X., Guo, L., Quan, X., Wang, S., Zhou, J., 2010. MR
imaging of high-grade brain tumors using endogenous protein and peptide-based
contrast. Neuroimage 51, 616–622. doi:10.1016/j.neuroimage.2010.02.050
Westergaard, N., Sonnewald, U., Schousboe, A., 1995. Metabolic Trafficking between
Neurons and Astrocytes: The Glutamate/Glutamine Cycle Revisited. Dev. Neurosci.
17, 203–211. doi:10.1159/000111288
Winter, P.M., Cai, K., Chen, J., Adair, C.R., Kiefer, G.E., Athey, P.S., Gaffney, P.J., Buff,
C.E., Robertson, J.D., Caruthers, S.D., Wickline, S. a., Lanza, G.M., 2006.
Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn.
Reson. Med. 56, 1384–1388. doi:10.1002/mrm.21093
Yang, D.W., Xie, Z.Y., Stephenson, D., Morton, D., Hicks, C.D., Brown, T.M., Sriram, R.,
O’Neill, S., Raunig, D., Bocan, T., 2011. Volumetric MRI and MRS provide sensitive
measures of Alzheimer’s disease neuropathology in inducible Tau transgenic mice
(rTg4510). Neuroimage 54, 2652–2658 ST – Volumetric MRI and MRS provide
sen. doi:10.1016/j.neuroimage.2010.10.067
Yasuda, R.P., Ikonomovic, M.D., Sheffield, R., Rubin, R.T., Wolfe, B.B., Armstrong,
D.M., 1995. Reduction of AMPA-selective glutamate receptor subunits in the
entorhinal cortex of patients with Alzheimer’s disease pathology: a biochemical
study. Brain Res. 678, 161–167. doi:10.1016/0006-8993(95)00178-S
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.M., Iwata, N., Saido, T.C., Maeda, J.,
Suhara, T., Trojanowski, J.Q., Lee, V.M.Y., 2007. Synapse loss and microglial
activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–
351 ST – Synapse loss and microglial activati. doi:10.1016/j.neuron.2007.01.010
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T.C., Maeda, J.,
Suhara, T., Trojanowski, J.Q., Lee, V.M.-Y., 2007. Synapse loss and microglial
activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–
51. doi:10.1016/j.neuron.2007.01.010
Zhou, J., Blakeley, J.O., Hua, J., Kim, M., Laterra, J., Pomper, M.G., van Zijl, P.C.M.,
2008. Practical data acquisition method for human brain tumor amide proton
transfer (APT) imaging. Magn. Reson. Med. 60, 842–9.
Zhou, J., Lal, B., Wilson, D. a, Laterra, J., van Zijl, P.C.M., 2003a. Amide proton transfer
(APT) contrast for imaging of brain tumors. Magn. Reson. Med. 50, 1120–6.
Zhou, J., Payen, J.-F., Wilson, D. a, Traystman, R.J., van Zijl, P.C.M., 2003b. Using the
amide proton signals of intracellular proteins and peptides to detect pH effects in
MRI. Nat. Med. 9, 1085–90. doi:10.1038/nm907

142

Zuddas, A., Oberto, G., Vaglini, F., Fascetti, F., Fornai, F., Corsini, G.U., 1992. MK-801
prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in
primates. J. Neurochem. 59, 733–9.

143

